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Visualizing cell surface interactions using cryogenic electron microscopy
Micah Allen Rapp
The study of the three-dimensional structures of biological macromolecules has given us
significant insight into life and its mechanisms. Understanding these structures in their native
contexts, a challenging but important goal, came closer to reality with the development of
electron microscopy. After many years of technological development, we are now starting to
understand previously intractable biological phenomena at an unprecedented resolution. One such
phenomenon is how neighboring cells interact, both to communicate and send signals, and to
adhere and form complex tissue structures. While the molecules that mediate such processes have
long been studied in isolation, electron microscopy allows us to examine them in a more native
biophysical environment; as hydrated, dynamic molecules tethered to opposed cellular
membranes.
Imaging unadulterated biological material using electron microscopy requires that the
sample be embedded in a thin layer of vitreous ice to immobilize the molecules and protect them
from the vacuum of the microscope, and thus is generally referred to as cryogenic electron
microscopy (cryo-EM). Samples can be imaged using two common cryo-EM modalities: single
particle analysis (SPA), where many two-dimensional projection images of molecules in solution
are collected, and cryo-electron tomography (cryo-ET), where the sample is tilted as it is imaged
at multiple angles to reconstruct a three-dimensional volume. In this work, I will describe how I
have used both SPA and cryo-ET to understand cell surface interactions involving a variety of
proteins.
The first chapter will look at the cell surface molecules known as the Toll receptors, a
family of molecules found in Drosophila melanogaster, with orthologs in mammals known as the
Toll-like receptors (TLRs). I will focus on their role in the development of the Drosophila embryo
during germ band extension, a kind of convergent extension that is a conserved process through
all metazoans. Biophysical assays of the three implicated Toll receptors, Toll-2, -6, and -8,
revealed both homophilic and heterophilic interactions. SPA was used to determine the structure
of monomeric Toll-2 which closely resembles the overall fold of Toll, whose structure was
previously solved by x-ray crystallography. Surface plasmon resonance (SPR) spectroscopy and
analytical ultracentrifugation (AUC) showed Toll-6 is a dimer in solution, which I visualized
using cryo-EM. The Toll-6 homodimer is a novel dimer interface for Tolls and TLRs, where
molecules on the same cell surface have been shown to dimerize in the presence of a wide variety
of ligands. In contrast, the Toll-6 dimer is formed in the absence of any ligand and exists in an
antiparallel arrangement that could be formed by molecules on opposing cell surfaces. Together,
these results provide a biochemical basis for germ band extension which may be further explored
through the study of structure-based mutations.
While cryo-EM SPA is a powerful tool, cryo-ET allows one to reconstruct three
dimensional volumes of highly heterogeneous samples, such as the interior of cells, where
molecules of interest may not exist in enough copies to facilitate averaging. This technique,
where the sample is imaged multiple times as it is tilted to obtain three-dimensional information
of a region of interest, was used to study cell adhesion of a different type: that mediated by the
classical cadherins. These calcium-dependent adhesion molecules cluster into adherens junctions,
spot-like protein densities found in a wide variety of tissues. In the second chapter, these
junctions are recapitulated between synthetic liposome membranes by tethering the adherent
cadherin molecules to chemically functionalized lipids. They are then imaged using cryo-ET to
reveal higher-order structural details. First, this method is applied to the clustered protocadherins,
a family of cadherins that mediate neuronal self-avoidance in mammals. Cryo-ET in combination
with x-ray crystallography revealed that clustered protocadherins form extended one-dimensional
zippers between membranes, which are a combination of strictly homophilic trans interactions
coupled with promiscuous cis interactions. Neurons express unique subsets of the 50-60 possible
isoforms, and when two neuronal processes express identical subsets, which happens only when
those processes are a part of the same cell, these linear chains grow and initiate a repulsive signal.
If the subsets are different, the chains terminate and no repulsive signal is generated. The same
technique has been used previously to study the type I classical cadherins, perhaps the most
well-studied members of the cadherin superfamily. In the second half of this chapter, we extend
our analysis to include the type II classical cadherins, which possess more complex expression
patterns and binding specificities. Cryo-ET of type II cadherin ectodomains tethered to synthetic
liposomes revealed that several representative members of this family form only moderately
ordered arrays between liposomes, a finding in agreement with their role in cell sorting and
migration. However, VE-cadherin, an outlier type II expressed in vascular endothelial cells where
it withstands blood pressure, forms extraordinarily ordered junctions. Subtomogram averaging
reveals the regularity of this two-dimensional array.
In the final chapter, I describe my work on a membrane surface molecule of a different kind,
one not involved in cell adhesion but viral infection. The global COVID-19 pandemic gave me
the opportunity to contribute to our understanding of SARS-CoV-2 by studying the structure of
neutralizing antibodies bound to the viral spike protein, perhaps the most infamous membrane
surface protein. The first subchapter describes the initial isolation, neutralization, and structural
analysis of antibodies isolated from convalescent COVID-19 patients. This work revealed that
patients with severe COVID-19 produce potently neutralizing antibodies that target two spike
protein domains: the receptor binding domain (RBD) and the N-terminal domain (NTD).
RBD-directed antibodies occlude binding to ACE2, the human receptor that mediates viral fusion,
but the neutralization mechanism of NTD-directed antibodies is unknown. The following two
subchapters are more detailed structural studies of two specific types of antibodies. The first looks
at a class of RBD-directed antibodies derived from the VH1-2 gene, which are some of the most
potent and common antibodies against SARS-CoV-2. The heavy chains of these antibodies
recognize almost identical epitopes, but the antibodies employ a modular approach to recognize
the RBD in either of its possible conformations. The second class are antibodies that target the
NTD, which our work revealed all bind to a single antigenic supersite. The final subchapter
focuses on emerging SARS-CoV-2 variants and includes the structures of two antibodies that are
still capable of neutralizing these new variants. They are also infrequent in the human antibody
response to SARS-CoV-2, meaning they put little selective pressure on the virus to produce
escape mutations, making them good candidates for monoclonal antibody therapies.
Though Drosophila embryogenesis, adherens junction formation, and SARS-CoV-2
neutralization are seemingly unrelated systems, they are united by the incredible flexibility of
cryo-EM to visualize biological molecules in more native environments. Whether it is the ability
to study multiprotein complexes or assemblies formed between membranes, cryo-EM is a
powerful technique that promises to help bridge the divide between structure and function.
Table of Contents
Acknowledgments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . viii
Dedication . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . viii
Preface . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
Chapter 1: Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2
1.1 Cryogenic electron microscopy of biological macromolecules . . . . . . . . . . . . 2
1.2 Single particle analysis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3
1.3 Cryogenic electron tomography . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10
1.4 Structural studies of cell surface proteins . . . . . . . . . . . . . . . . . . . . . . . 14
Chapter 2: Single particle analysis of the Drosophila melanogaster Toll receptors . . . . . 16
2.1 Abstract . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16
2.2 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16
2.3 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18
2.4 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23
2.5 Materials and Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27
2.6 Supplemental Data . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32
2.7 Future perspectives . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 34
i
Chapter 3: Visualizing cadherin intermembrane recognition and adhesion assemblies . . . . 37
3.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37
3.2 Visualization of clustered prodocadherin neuronal self-recognition complexes . . . 39
3.2.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 39
3.3 Visualization of classical cadherin assemblies by cryo-electron tomography . . . . 62
3.3.1 Abstract . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 62
3.3.2 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 62
3.3.3 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 64
3.3.4 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 71
3.3.5 Materials and Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . 74
3.3.6 Future perspectives . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 76
Chapter 4: Structures of multiple neutralizing antibodies that target the SARS-CoV-2 spike
glycoprotein . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 80
4.1 Preface . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 80
4.2 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 81
4.3 Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike . 83
4.4 Modular basis for potent SARS-CoV-2 neutralization by a prevalent VH1-2-derived
antibody class . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 112
4.5 Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal do-
main target a single supersite . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 135
4.6 Structural basis for accommodation of emerging B.1.351 and B.1.1.7 variants by
two potent SARS-CoV-2 neutralizing antibodies . . . . . . . . . . . . . . . . . . . 160
4.7 Future Perspectives . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 176
Concluding Remarks . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 179
ii
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 206
Appendix A: Other collaborative projects . . . . . . . . . . . . . . . . . . . . . . . . . . 207
Appendix B: Curriculum Vitae . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 216
iii
Acknowledgements
This dissertation would not have been possible without the work and support of many
people. I will try, and ultimately fail, to properly express my gratitude to those who have been
with me throughout this process.
I am immensely fortunate to have been mentored by Larry Shapiro, Clint Potter, and
Bridget Carragher, and owe much of my success to them. Larry, an incredible biochemist and
structural biologist, has an amazing ability to use these disciplines to gain insight into function. It
is a scientific mentality that was evident from our first meeting and is largely what compelled me
to work with him. His approach to science and enthusiasm for discovery have been inspiring.
Clint and Bridget have been extraordinarily supportive and patient with me as I entered cryo-EM
as a complete novice. They have not only taught me a great deal, but have also been there for me
during the most challenging moments of my graduate career. Working with all of them, I always
felt like I had the intellectual freedom to indulge my curiosity and forge my own path while still
being pushed and guided to success. I could not have asked for better mentors, advisors, and role
models. Thank you Clint, Bridget, and Larry.
Next I would like to thank all of the members of the Shapiro lab and the Simons Electron
Microscopy Center. From the Shapiro lab, thank you to Gil Dionne, Jared Sampson, Fabiana
Bahna, Seetha Mannepalli, Göran Ahlsén, Phini Katsamba, Kerry Goodman, Julia Brasch, Oliver
Harrison, Filip Cosmanescu, Jude Bimela, Seniha Ipekci, Saurabh Patel, Gabrielle Cerutti, Ryan
Casner, Yicheng Guo, Zizhang Sheng, Eswar Reddem, and Natalie McArthur. From SEMC,
thank you to Priyamvada Acharya, Michael Alink , Mahira Aragon, Tristan Bepler, Swapnil
iv
Bhaktar, Daija Bobe, Chase Budell, Cathleen Castello, Anchi Cheng, Eugene Chua, Sargis
Dallakyan, Venkat Dandey, Charlie Dubbeldam, Ed Eng, Robert Gheorghita, Jason Gorman,
Carolina Hernandez, Serban Ilca, Kelsey Jordan, Elina Kopylov, Misha Kopylov, Shaker Krit,
Huihui Kuang, Kashyap Maruthi, Joshua Mendez, Alex Noble, Carl Negro, Reza Paraan, Daniel
Podolsky, Ashleigh Raczkowski, Bill Rice, Anjelique Sawh, Bruno Scap, Giovanna Scapin,
Dennish Shushunov, Yong Zi Tan, Hui Wei, Laura Yaunhee Yen, Zhening Zhang, and Christina
Zimanyi. You all have been not only colleagues and teachers, but also friends. I am better off
having known each of you.
I want to specifically acknowledge several colleagues with whom I have worked particularly
close. Thank you to Gil Dionne for work on mechanotransduction and introducing me to one of
the most interesting biological systems I’ve ever worked on. Thank you to Jared Sampson for
work on the Drosophila Toll receptor project. Working with you on that project has been some of
the most pure and fun science I’ve done. Thank you to Alex Noble and Julia Brasch for their work
on the cadherin project and teaching me so much about cadherins and cryo-ET. It was a true
pleasure working with and learning from you. Thank you to Phini Katsamba and Göran Ahlsén
for their work on biophysical assays done for so many projects. I can’t imagine the Shapiro lab
without you. Thank you to Fabiana Bahna and Seetha Mannepalli for their tireless cloning and
protein expression work. Thank you to Gabrielle Cerutti, Ryan Casner, Eswar Reddem, Jude
Bimela, Yicheng Guo, and Zizhang Sheng for your work on SARS-CoV-2. I am immensely proud
of everything you all have done and it was an honor to do such important work with you.
Thank you to the members of my thesis committee, Joachim Frank, Filippo Mancia, and
Oliver Clarke. Your feedback and advice has been invaluable, as was the push you gave me to pull
together my diverse body of work into something coherent. Thank you to David Ho for joining
the dissertation defense committee and for giving me the opportunity to work on SARS-CoV-2.
Thank you to the Columbia University Integrated Program in Cellular, Molecular and
Biomedical Studies for all of the support over the years. Ron Liem and Dona Farber, you have
been fantastic program directors and I appreciate the opportunity to do my PhD at Columbia.
v
Thank you to Zaia Sivo for looking out for me and so many other graduate students. I always
knew you were in my corner, and that meant the world.
Columbia is full of so many talented graduate students whom I have been fortunate to know.
Thank you to my friends Patrick Dummer, Davys Vega, Sam Hayward, Dan Cole, Corey Garyn,
Tyler Haplin-Healy, Felix Wu, and many others. I’m proud to be a part of such an impressive
group of scientists and people.
Moving to New York City from the midwest was challenging but made infinitely easier by
my new friends. Thank you to Matt, Nick, Kate, Trevor, Lydia, and Joy for being the best and
coolest.
I would not be where I am without the early mentorship of George Mourad, Neil Schultes,
and Jessica Schein. George (I can’t believe I’m calling you George and not Dr. Mourad), you
have always been an inspiration, not just as a scientist but as a teacher and a person. Thank you
for the support and encouragement during such a tough personal time for me. Neil, thank you for
exemplifying what great scientific collaboration looks like and for the advice during my grad
school interview process. Jess, you demonstrated such enthusiasm and exuberance for science
and I will try to never forget that lesson. Your bright and cheery personality was, well, sometimes
exhausting, but I never would have made it through all-nighters in the lab without it. For some
reason you’ve always believed in me, even when I didn’t believe in myself, and I can’t thank you
enough. I’m lucky to have you as a friend.
Saying ‘thank you’ to my family for their love and support seems woefully insufficient, but
I’m going to try regardless. To my parents Dean and Becky, thank you for continually supporting
me in all the strange things I’ve decided to spend my time on throughout my life, and of course
for the unconditional love you have shown me even when it was hard. Thank you to my siblings,
Mikenna, Morgan, and Dylan. I am so lucky to not only have such loving siblings, but also such
great friends. Thank you for everything. To Sean and Jessie, I feel so lucky to be able to say all of
that about you as well. Our family is better with the two of you in it. And to Roan, Kiernan,
Emmy, and Titus, being your uncle is one of the greatest joys of my life. I can’t wait to talk your
vi
ear off about science, and then try and convince you to do something more lucrative with your
lives. I love all of you.
Finally, thank you to Kaitie. From the moment we met, you have been my companion, my
love, my best friend, and my north star. I would not be here without you, and I am so grateful to
have you in my life. I am wholly unworthy of the grace and patience you have shown me
throughout this process, and I will spend the rest of my life trying to repay you.
vii
Dedication
This work is dedicated to the memory of Kotaro Kelly. Thank you for pushing me to strive
for excellence, and teaching me that we are all more than the work we do. Rest in peace, friend.
viii
Preface
I began my training as a scientist in the lab of Dr. George Mourad, a plant genetics lab
studying nucleobase metabolism, at Purdue University Fort Wayne where I was a biology major. I
had little knowledge of and zero experience in structural biology until my senior year of college
when I began to dabble in homology modeling for my research. I came to structural biology as a
pure biologist who was interested in what it could teach us about life, a mentality that has guided
my research ever since.
Cryo-EM has fascinated me from the moment I learned about it, and I knew I wanted to use
it to understand proteins in more native environments for my graduate research. I was immensely
fortunate, then, to be able to work under the guidance of Larry Shapiro, who constantly supplied
me with fascinating biological systems to study, and Clint Potter and Bridget Carragher, who
encouraged me to indulge that curiosity while teaching me the techniques necessary to do so.
This curiosity led me down many paths, often working on several projects simultaneously.
Some of those were completed, or nearly completed, and are described here. Others,
unfortunately, were not. Almost ironically, my background and interest in biology led me to focus
more on the technique I was using and less on any one specific system. This was undoubtedly
challenging, and often felt foolhardy, but it has given me an appreciation for the flexibility and
power of cryo-EM. Though my graduate research could most politely be described as “diverse”, I
believe it demonstrates how different cryo-EM imaging modalities can be combined with other
techniques in biophysics to paint a more comprehensive picture of protein structure and function.
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Chapter 1: Introduction
1.1 Cryogenic electron microscopy of biological macromolecules
Over the last several years, the use of cryogenic electron microscopy (cryo-EM) to study the
three-dimensional structure of biological macromolecules has rapidly expanded. Briefly, the pro-
cess involves depositing a sample of biological material, from purified proteins in solution to whole
cells, onto a circular metal mesh, called an EM grid, and rapidly freezing it to embed it in a thin
layer of vitreous ice. This grid is then placed in a transmission electron microscope (TEM) and
imaged. There are two primary imaging modalities used in cryo-EM: single particle analysis (SPA)
and cryo-electron tomography (cryo-ET).
In SPA, two-dimensional projection images of hundreds of thousands to millions of copies of
a macromolecule are collected. This macromolecule is usually purified, as two key assumptions of
this modality are that each copy of the molecule, generally called a "particle", is an exact copy of
all others and all are randomly oriented in the thin layer of vitreous ice. These particles are located,
excised from the image, aligned, and then averaged to produce a three-dimensional reconstruction.
In Cryo-ET, the sample is tilted inside of the microscope as it is imaged, producing a so-called "tilt
series", a collection of two-dimensional projection images at different angles. These can be aligned
and used to reconstruct a three-dimensional volume of a region of interest, providing structural
information on molecules that are particularly unique and do not exist as many copies. This three-
dimensional volume can then be segmented, where voxels are assigned to a specific object, or
if sufficient copies of a molecule exist, sub-volumes can be extracted, aligned and averaged in a
workflow similar to SPA.
This chapter will introduce the general workflows of each technique, which are graphically
depicted in Figures 1.1 and 1.2, and conclude with the rationale behind their use in studying cell
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surface proteins.
1.2 Single particle analysis
SPA is the dominant technique in cryo-EM. Of the all cryo-EM structures deposited to the
Protein Data Bank (PDB) [1], 89% are structures obtained by SPA (www.rcsb.org). It has also
produced the highest resolution structure of a protein in its native-hydrated state to-date [2, 3].
Colloquially, SPA is what most people are referring to when they talk about cryo-EM, and indeed
it is a very powerful technique for studying purified proteins, multi-protein complexes, ribonucleo-
proteins, and perhaps molecules in un-purified cellular lysate, though this is far less common [4].
For many years the primary approach to high-resolution structure determination has been x-ray
crystallography, where purified proteins are coaxed into forming highly-ordered crystals that will
produce diffraction patterns when hit with a beam of x-rays. These diffraction patterns can then be
used to calculate a 3D structure of the protein.
SPA and x-ray crystallography obviously differ in their approaches, but what I wish to high-
light here are not the methodological details but the differences in their applicability. SPA benefits
from not needing to force the protein molecules into a crystal, a process which requires a relatively
large amount of protein and is very difficult for large proteins, intermembrane proteins, and multi-
protein complexes. In addition, molecules in a cryo-EM sample are allowed to diffuse in solution
just before being frozen, better preserving their native dynamics and hydration states. There are of
course instances where x-ray crystallography is preferred. SPA struggles to obtain high resolution
reconstructions of small molecules. Typically, any soluble protein less than 100 kDa or membrane
protein less than 50 kDa will be a significant challenge to study via cryo-EM, though these are
only approximations and the boundaries of what is possible are pushed further every day. Second,
cryo-EM is still unable to reach atomic resolution save for very specific test samples [2, 3]. Ulti-
mately, for the work described here, cryo-EM was particularly well-suited to the systems I wished
to study.
3
Figure 1.1: Cryo-EM single particle analysis workflow
The resolution revolution
Early in its history, the 3D reconstructions obtained by cryo-EM were typically in the nanome-
ter range, offering information about the overall architecture of biological macromolecules, but
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lacking in high-resolution details such as the positions of amino acid side chains or secondary
structure. This changed during a period of technological development known as the “resolution
revolution” [5]. One of the most important advances during this period was the development of
direct electron detectors (DDs) [6, 7, 8, 9, 10], which had fast enough framerates that short movies
could be recorded instead of single images. The frames of these movies could then be shifted and
rotated relative to one another to correct for the movement of the sample during image acquisition
[8]. Another important advance was the automation of the microscopes themselves, allowing re-
searchers to collect thousands of images a day with relatively little user intervention [11, 12, 13,
14, 15]. With the ability to collect massive datasets came the need for sophisticated algorithms
to process them. Though the fundamental mathematics have existed for some time [16, 17], the
resolution revolution saw new Bayesian approaches that could obtain reliable high-resolution re-
constructions [18]. One of the key assumptions of these reconstruction approaches is that each
molecule, of which there can be hundreds of thousands to millions in a dataset, is an exact copy of
all others. Given that the biological molecules are dynamic machines and tumbling in solution the
moment before being frozen, this assumption rarely holds true. Thus, new techniques for separat-
ing particles into more homogeneous classes have been crucial to cryo-EM’s rapid growth [19, 20,
21].
Sample preparation and initial quality assessment
Like in crystallography, the first step in SPA is usually protein expression and purification. Overex-
pression in heterologous systems, such as mammalian HEK293 [22] or Drosophila melanogaster
Schneider 2 (S2) cells [23] used here, followed by purification using various forms of centrifu-
gation and liquid chromatography, produce a sample of protein suspended in aqueous solution.
During and following purification, it is critical to ensure that the sample is properly folded, homo-
geneous, and in the case of multi-protein complexes, intact. Size exclusion chromatography (SEC)
is used to both purify the molecule and ensure it is a homogeneous size, which is evidenced by a
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single, monodispersed peak in the chromatogram. Many other techniques exist to assess sample
quality after purification, such as mass photometry [24] and negative stain electron microscopy.
Such room temperature EM is an optional step that is relatively quick and inexpensive, provid-
ing both information on the quality of the sample and initial, low-resolution information about its
structure. First, the sample is adsorbed to an EM grid with a thin carbon support film, then excess
sample is removed with filter paper. A heavy metal stain such as uranyl acetate or uranyl formate
is then pipetted onto the support film, blotted away, and allowed to dry. The stain outlines the pro-
tein and scatters electrons strongly, allowing one to see low resolution features with high contrast.
Once sample quality is confirmed, the next step is to prepare a sample for cryo-EM.
Macromolecule vitrification by plunge freezing
Flash-freezing the molecule solution into a thin layer of amorphous ice is a technique that is under-
going constant optimization and development. This step protects the molecules from the vacuum
inside of the transmission electron microscope (TEM), while also preserving the molecule in its na-
tive state [25]. First, the sample is applied to an EM grid with a ‘holey’ support, that is a thin sheet
of metal (usually carbon or gold) with small perforations in it. Then excess sample is removed,
typically with filter paper, leaving a very thin layer of molecules in solution suspended across the
small holes in the support film. The grid is then plunged into a suitable cryogen, such as liquid
ethane or an ethane/propane mix, cooled by liquid nitrogen to below -160°C [26]. This freezes
the sample rapidly enough that water molecules are unable to form crystalline ice, which could
damage the biological material and may diffract electrons strongly enough to render the sample
virtually opaque in the microscope, depending on the thickness of the ice. While this process has
been somewhat automated with devices such as the FEI Vitrobot and Leica EM GP, the funda-
mental principles remained unchanged for many years. Recently, additional instruments have been
developed that increase throughput and reduce the amount of sample required, such as the SPT
Labtech Chameleon (originally “Spotiton”) [27, 28, 29, 30] and the CryoSol VitroJet [31].
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Data collection
The electron microscope was invented in 1931 by Ernst Ruska, who would go on to receive the
1986 Nobel Pize in Physics for this work, and Max Knoll [32]. In 1939, just eight years later, Ernst
and his brother Helmut, a physician, published a paper on “Übermikroskopie” of viruses [33, 34],
demonstrating the early importance of imaging biological material by electron microscopy. Per-
haps the main challenege is the sensitivity of biological samples to radiation damage compared to
samples imaged in material science [35]. Modern TEMs used in cryo-EM are operated in a low-
dose mode that preserves high-resolution information but significantly reduces the signal-to-noise
ratio. An electron source, typically a field emission gun (FEG) or a filament made of tungsten or
lanthanum hexaboride (LaB6), generates a beam of electrons that is focused and magnified by a
series of electromagnetic lenses before and after passing through the sample before finally reach-
ing the detector. Modern TEMs operate at a range of accelerating voltages, with lower-energy
microscopes in the 80-200 kV range used for initial sample screening, and more complex 300
kV microscopes used for high resolution data collection. This process is now largely automated
through software such as Leginon [11, 12, 14, 15], Thermo Fisher Scientific’s EPU, Gatan’s Lati-
tude, and SerialEM [13].
Image pre-prossessing
Concurrent with data collection, a series of image pre-processing steps are performed. The first is
known as motion correction, and is one of the most significant methodological advances enabling
the “resolution revolution”, made possible by the development of direct electron detectors. Ex-
posure times typically range between 2-10 seconds, depending on the data collection scheme and
type of detector being used. During this time, it is believed there is a build-up of negative charge
on the surface of the sample, which causes a beam-induced movement of the support film as more
7
electrons pass through the sample for imaging [36, 37, 38, 39]. This movement causes a significant
blurring effect and severely limits resolution. Modern detectors, as mentioned before, have frame
rates in the range of 40-1200 frames per second, which allows us to collect several dozen frames
during the exposure time. These frames can then be “motion corrected” by shifting and rotating
them relative to one another to compensate for the beam-induced movement [8, 40, 37, 41, 42].
These frames can also be “dose weighted”; the later frames are images of the sample after increas-
ing radiation damage, meaning the early frames contain the highest resolution information and
would ideally contribute the most high-resolution information to the 3D reconstruction. Through
dose weighting, the high-resolution information in the later frames is down-weighted to account
for this accumulation of damage [42, 43, 44]. The second pre-processing step is an estimation of
the contrast transfer function (CTF). Aberrations in the TEM, such as astigmatism and defocus,
modify the image recorded by the detector, and these aberrations are described by the CTF. This
function is multiplied with the Fourier transform of the sample, specifically its Coulomb potential.
Taking the inverse Fourier transform of this product produces the projection image. This function
is also modulated by an envelope that increasingly dampens higher spatial frequency information.
Thus, correction of the CTF [45] is essential to obtaining high resolution reconstructions [46].
Particle picking and two-dimensional classification
After pre-processing, the first step in the reconstruction pipeline is to identify the x and y coor-
dinates of each protein within each image. The conceptually simplest approach is to manually pick
each one. However, given that a typical dataset has thousands of micrographs and hundreds of
particles per micrograph, this approach is not practical. Fortunately there are many automated ap-
proaches, including Difference or Laplacian of Gaussians pickers [47, 48], template-based pickers
[49, 50], and deep learning approaches [51, 52, 53]. Once coordinates have been selected, a box
centered on each coordinate is excised from the image to create a particle stack. In order to assess
the quality of the data and accuracy of the particle picks, two-dimensional classification is often
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performed, though is not strictly necessary. An iterative series of two-dimensional alignment, clas-
sification, and re-alignment will ideally produce averages of particles with the same orientation.
If obviously-incorrect particle picks sort into distinct classes, they may be removed from further
processing. Two-dimensional classification also provides an initial look at the quality of the data,
as quality images of homogeneous molecules will produce highly-ordered averages.
Three-dimensional classification and reconstruction
In order to obtain high resolution three-dimensional reconstructions of molecules, a sufficiently ho-
mogeneous stack must be obtained. While two-dimensional classification can identify obviously-
incorrect particle picks, it is not possible to sort particles into different conformational or com-
positional states based on two-dimensional averages. Thus, particles must be classified in three
dimensions. First, an initial three-dimensional starting model must be generated. While this can
now be created ab initio [54, 48], it used to be necessary, and sometimes still is if ab initio re-
construction fails, for the researcher to supply their own starting map. As the initial model can
bias the classification results, it is often best to use a model that is generated from the structurally
heterogeneous data itself. Maximum-liklihood methods are then used to classify the data into a
pre-determined number of classes [18]. As the number of classes is not usually known a priori,
multiple rounds of three-dimensional classification are run, varying the number of classes each
time. Once one or more suitably homogeneous particle stacks are obtained, three-dimensional
refinement with finer angular sampling can be performed to obtain a high resolution reconstruc-
tion [17]. New approaches have also been developed to more directly visualize and study that
heterogeneity [21, 55, 56, 57], or even to allow particles in the stack to contribute to the final
reconstruction regardless of their conformation [58].
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1.3 Cryogenic electron tomography
When dealing with samples that do not exist in sufficient copies for reconstruction by SPA,
cryo-electron tomography (cryo-ET) can be a powerful tool to obtain high resolution structural
information. This imaging modality uses the same microscope as SPA, but instead of collecting
individual 2D projection images of the sample at each imaging region, a single region is imaged
multiple times as the sample is tilted (called a tilt series). These tilt images are then aligned and
used to reconstruct a 3D volume of the region of interest. Though this process benefits from many
of the same advancements described for SPA, such as direct detectors, automation, and certain
image processing steps, the workflow is far less mature and often time-consuming with many steps
applied ad hoc. However, the field is advancing rapidly and recently these data have been used to
obtain near-atomic resolution reconstructions of macromolecules [59, 60, 61].
The primary benefit of cryo-ET is the ability to obtain native structural information of unique
macromolecules, and to-date stands as the highest resolution imaging technique for in situ samples
such as cells and tissue.
Sample preparation for cryo-electron tomography
As cryo-ET is strictly an imaging modality, it is agnostic to sample preparation. Thus, one can
image a sample of vitrified pure protein via either SPA or tomography. However, samples nor-
mally imaged by cryo-ET differ significantly from those usually imaged by SPA. For example,
cryo-ET is often used to image whole cells that have been vitrified on EM grids. These can ei-
ther be plunge-frozen bacterial cells or mammalian cells frozen by high-pressuer freezing [62, 63].
Mammalian cells are too thick to be vitrified by simply plunging them into a cryogen, and so a
high-pressure freezer must be used, a device that can quickly lower the temperature of the cham-
ber while drastically increasing the pressure thereby increasing the cooling effect and vitrifying
very thick samples. Somewhat in between this approach and vitrifying purified proteins is the cre-
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ation of synthetic samples using mimetics such as liposomes [64], a technique discussed in detail
in Chapter 3.
Samples such as mammalian cells that are too thick to vitrify by plunge-freezing are also too
thick to image directly by TEM. At 300 kV, the most common accelerating voltage for high-end
TEMs today, the mean free path of the electron through ice is approximately 300 nm [65, 66, 67].
In order to obtain such a thin sample for cells that are several micrometres thick, after vitrification
the sample is placed in a cryo-Focused Ion Beam-Scanning Electron Microscope (FIB-SEM). The
SEM is used to image the sample so that it can be properly oriented, while the FIB carves a lamella
out of the cell that is ideally 300 nm or less in thickness [63] and still attached to the surround-
ing cell. The lamella can then be transferred to a TEM and imaged by cryo-ET. This technique
is sometimes combined with cryogenic fluorescent light microscopy, an approach known as cryo-
Correlated Light and Electron Microscopy (CLEM), to localize features of interest as the resulting
lamella is more than two orders of magnitude thinner than the cell.
Tomogram collection
A major challenge to obtaining high resolution 3D reconstructions from cryo-ET data is the dam-
age done to the sample by the electron beam. A standard tilt series may be composed of around
40 images (e.g. ±60° tilt with 3° increments), each of which is a short movie with several frames.
Making sure there is enough signal in each frame for frame alignment and averaged tilt image for
successful tilt-series alignment requires a larger amount of total electron dose than is typically used
in SPA. This has led to the testing of multiple collection schemes [68], such as starting at a very
large tilt and moving continuously through to the other high tilt or starting at 0° and alternating
between positive and negative tilt angles. There are benefits to each and the exact tilt collection
scheme is another parameter that is often optimized on a per-sample basis.
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Figure 1.2: Cryo-ET workflow
Pre-processing cryo-electron tomography data
As is true of almost every step of the workflow, pre-processing in cryo-ET is significantly more
complicated than what is routinely done for SPA. The first step is very much the same; each tilt
image is composed of several frames which are translated and rotated relative to one another to
correct for beam-induced motion. Following this, each tilt image must be aligned to the others.
There are many approaches to this, which include the tracking of gold fiducials that are added to
the sample [69, 70, 71, 72] or tracking some signal inherent in the sample itself [73, 74, 75]. This
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step also must be considered on a per-sample basis, as, for example, adding gold fiducials to cells
is very difficult. With the tilt series aligned, it must then be reconstructed into a 3D volume by
weighted back projection [17], simultaneous iterative reconstruction (SIRT) [76, 77, 78], or one of
several other methods. CTF estimation may or may not be performed depending on the resolution
expected, and may be done on the individual tilt series as in SPA, or 3D information can be used
[79], from particle position in the tomogram [59, 80] to advanced models of deformation and local
geometry [60, 81, 75, 61]. Dose-weighting can also be performed by down-weighting later tilt
images to account for accumulated dose during tilt-series collection [44].
Tomogram analysis
Tomograms of cellular samples can be annotated or segmented to assign voxels to different ob-
jects, such as the plasma membrane, vesicles, or various organelles. This may be done manually
or semi-automatically, a process which can be tedious but helps visualize cellular ultrastructure or
serve as a basis for quantification [82]. Deep learning is increasingly being leveraged to perform
this analysis automatically, opening up the possibility of segmenting significantly larger datasets
than would be possible by hand [83, 84].
If at least a part of the sample is homogeneous enough, such as ribosomes in the cytoplasm of
a cell, one can box out sub-tomograms for reconstruction by a workflow analogous to SPA. These
subtomograms can be aligned, classified, and averaged to produce high resolution reconstructions
which now can reach near-atomic resolution [59, 60]. Additional post-processing techniques, such
as sub-tilt series alignment and performing more complex CTF estimation and motion correction,
can push resolutions even further [75, 61], suggesting that with appropriate processing workflows,
subtomogram averaging may be able to reach resolutions comparable to SPA, though routine ap-
plication is still a long ways away [85].
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1.4 Structural studies of cell surface proteins
One great strength of cryo-EM is its ability to provide structural information in a more native
environment. Proteins in SPA samples are allowed to freely diffuse in a hydrated state before
being rapidly frozen. The fact that larger proteins are easier to computationally align than small
ones enables researchers to study large multi-protein complexes at high resolution. Cryo-ET has
the added advantage of providing significant insight into protein structure in situ or in a synthetic
system that recapitulates the native biophysical environment, even if the resolutions of the resulting
reconstructions are usually lower than those obtained by SPA.
These are the features of cryo-EM leveraged here to study cell surface interactions, particularly
cell-cell adhesion molecules and viral surface proteins, using both SPA and cryo-ET. Many cellular
adhesion molecules consist of multiple domains which engage in coordinated interactions key to
their function [86], making them obvious targets for SPA. However, many also possess elongated
and flexible arrangements of extracellular domains, which can pose challenges to reconstruction
by SPA or sub-tomogram averaging. As many particles are averaged together to obtain high reso-
lution, flexibility is detrimental to SPA [20]. In addition, the primary input to data processing is a
stack of particle images within a square box (or cube in the case of subtomogram averaging). The
dimensions of this box will be chiefly determined by the longest dimension of the particle, plus at
least 25% padding. If the particle is roughly spherical, the particle, and thus the signal, will occupy
a significant portion of the box. If, however, one dimension is significantly shorter, as is the case
with members of the cadherin superfamily described in Chapter 3, more of the box will be noise,
which can significantly hinder alignment efforts. In this dissertation, I will begin with a chapter
on the application of SPA to study the Drosophila melanogaster Toll receptors, and conclude with
a chapter on how it was used to visualize neutralizing antibodies bound to the SARS-CoV-2 spike
glycoprotein.
Cell adhesion presents an interesting challenge for structural biology, as the need for opposed
membrane surfaces can be challenging to replicate and directly visualize. Cryo-ET is an ideal
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tool for such a system, particularly when combined with other structural techniques such as SPA
and x-ray crystallography. High resolution details of isolated domains can be obtained via x-ray
crystallography, for example, while higher-order features can be imaged in a native-like environ-
ment with cryo-ET. This approach was used to study various members of the cadherin superfamily,
specifically the clustered protocadherins and the classical cadherins. This integrative approach pro-
vided detailed insight into the intermembrane adhesion assemblies formed by many cadherins and
is described in Chapter 3.
15
Chapter 2: Single particle analysis of the Drosophila melanogaster Toll
receptors
2.1 Abstract
Germ band extension, a developmental process conserved in metazoans, is a tissue remod-
eling event where cell intercalation results in lengthening of the germ band along one axis and
shortening along the perpendicular axis. In Drosophila melanogaster, this contact-dependent cell
rearrangement is driven by the Toll receptors, type 1 transmembrane receptors that engage in trans
adhesive interactions with opposing Tolls. Using solution biophysics combined with cryo-electron
microscopy, we have determined the binding specificities of Toll-2, -6, and -8 and present cryo-EM
reconstructions of a monomeric Toll-2 and dimeric Toll-6 resolved to 3.7Å and 3.8Å, respectively.
Cryo-EM reconstruction of dimerc Toll-6 reveals a novel antiparallel Toll dimer arrangement me-
diated by both membrane-proximal and membrane-distal leucine-rich repeat domains. This study
provides insight into the structural basis for Toll receptor-mediated germ band extension.
2.2 Introduction
Convergent extension of the germ band along the anterior-posterior (AP) axis during embryoge-
nesis is a developmental process conserved in all metazoans, driven by significant cell intercalation
along the dorsoventral (DV) axis [87, 88, 89]. It is best understood in Drosophila melanogaster
where it is initiated by striped expression patterns of the pair-rule transcription factors Eve and
Runt [87, 90, 88]. The force that drives cell intercalation is generated by polar enrichment of
actomyosin that causes a directional contractility of cells at a local scale, which then combine to
induce tissue-level remodeling [88, 91, 92, 93]. Mutations in and overexpression of eve and runt
result in mislocalization of actomyosin and disruption of cell intercalation [87, 90, 89, 94, 95].
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Unfortunately, the connection between polar localization of pair-wise genes and directional cell
rearrangement is unclear.
The Toll receptors were discovered to be a critical component of that connection [96]. These
results fit well with the observation that some members of the Toll family, specifically Toll-2, -6,
-7, and -8, are expressed in stripes reminiscent of pair-rule genes [97, 98]. The founding member,
Toll, is essential for successful DV patterning of the Drosophilaembryo [99] and has been shown
to induce cell adhesion through homotypic interactions [100, 101]. Toll-2 and Toll-8 have been
shown to play various roles in the development of epithelial morphology [102, 103, 104, 105] and
it has recently been shown that asymmetric localization of Toll-8 leads to Myosin-II polarization
through interactions with the adhesion GPCR CIRL [106]. The presence of polarity even in the
absence of the Toll receptors [96] suggests they may interact in concert with other molecules, such
as the leucine-rich-repeat (LRR) receptor Tartan and the teneurin Ten-m [107].
A link between these two interrelated systems may be structural, as the Toll receptors are also
leucine-rich-repeat (LRR) receptors [96]. The structure of the Drosophila Toll receptor has been
solved in complex with its ligand Spätzle [108]. Structures of several dimeric Toll-like receptors
(TLRs), the vertebrate orthologs of the Toll receptors which largely function in innate immune
responses [109, 110, 111], have been solved as complexes with their respective ligands [112, 113,
114]. A similar mechanism for Toll Spätzle-mediated dimerization has also been proposed [115].
However, these dimers are parallel in nature, suggesting the molecules originate from the
same cell surface. Many adhesion molecules, discussed in detail in the next chapter, operate
by binding in an antiparallel trans fashion. Though Toll receptors have long been implicated in
adhesion-mediated tissue rearrangement, little biophysical or structural data regarding these inter-
actions exist. Here, we used solution biophysics of purified Toll receptor ectodomains combined




Toll receptor interaction revealed by surface plasmon resonance
Ectodomains for Toll-2, -6, and -8 were expressed recombinantly in Schneider 2 (S2) cells and
purified. In addition to standard purification tags, ectodomains with a C-terminal AviTag [116]
were also expressed and purified for immobilization during surface plasmon resonance (SPR). All
possible nine combinations of immobilized and free Toll ectodomains were tested for interaction.
Assays with the same protein on the chip and in solution, testing for homotypic interaction, re-
vealed that Toll-6 and Toll-8 self-interact while Toll-2 does not (Fig. 2.1). Heterotypic interactions
between Toll-2 and Toll-6, as well as Toll-8 and Toll-6, were also observed, regardless of which
Toll was immobilized. If these interactions take the same form as the TLRs, SPR suggests the exis-
tence of Toll-6 and Toll-8 homodimers, as well as Toll-2:Toll-6 and Toll-8:Toll-6 heterodimers. To
determine the affinity of the Toll-6 and Toll-8 homodimers, we used analytical ultracentrifugation
(AUC). Surprisingly, AUC data revealed that every Toll receptor was monomeric in solution.
Toll-6 dimerization is pH dependent
We wanted to investigate the effect of pH on Toll receptor oligomerization. Following affin-
ity chromatography, purified ectodomains were dialyzed into buffers with pH values ranging from
5.8 - 7.4. Size-exclusion chromatography coupled with multiangle light scattering (SEC-MALS)
was performed to determine the apparent molecular weight of the sample, which was then com-
pared to mass spectrometry measurements. Toll-2 and -8 showed a gradual increase in apparent
molecular weight with increasing pH, likely due to aggregation which was observed in the size
exclusion chromatogram (Fig. 2.2A, C), with values lower than that measured by mass spectrom-
etry at pH values below 7.4. This is likely due to the additional mass of glycosylations present in
the ectodomain of Toll receptors [108] (Fig. 2.4A) which is more accurately measured by mass
spectrometry than by multi-angle light scattering. Toll-6 showed similar behavior for pHs between
6.25 - 7.4 but showed a sharp increase in apparent molecular weight at pH 6.0, which slightly
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Figure 2.1: Surface plasmon resonance of Toll ectodomains reveals interaction specificities
Biotinylated Toll ectodomains were tethered to a neutravidin-coated sensor chip. Indicated Tolls were then
independently injected and flown over the surface. The traces shown here show a response if binding occurs.
Toll-6 and Toll-8 bind to themselves in a homophilic interaction. Toll-2 and Toll-6 interact heterophilically
regardless of which is tethered to the chip. Toll-6 and Toll-8 also interact heterophilically.
declined at pH 5.8 (Fig. 2.2B). This was accompanied by a shift in the protein peak in SEC, con-
trasted with Toll-2 and Toll-8 where the gradual increase in apparent molecular weight measured
by MALS was accompanied by the appearance of a second aggregate peak instead of a shift of
the main peak. The molecular weight of Toll-6 as measured by mass spec was 136 kDa, and the
apparent molecular weight measured by MALS was 175 kDa, suggesting an equilibrium between
monomeric and dimeric states at the concentration used in this experiment. To further assay the
potential oligomeric state of Toll-6, we repeated AUC at pH 6.0, which confirmed the presence of
a dimer with an affinity of 2.2 ± 0.06 μM.
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Figure 2.2: pH dependence of Toll-6 dimerization measured by size exclusion-multiangle light scat-
tering
Apparent molecular weight of a single peak from size exclusion chromatography, calculated by multian-
gle light scattering (solid blue line) at a range of pHs. Molecular weight calculated by mass spectrometry
(dashed orange line) shown as a benchmark for determining oligomeric state. (A) Toll-2 is monomeric at all
pH values. (B) Toll-6 shows signs of oligomerization at pH 5.8 and 6.0. (C) Toll-8 is monomeric at all pH
values.
Cryo-EM structure of monomeric Toll-2
The general quality and behavior of Toll-2 was first examined using negative stain electron
microscopy. Protein was deposited onto a metal mesh with a continuous carbon film and stained
with uranyl formate (UF). Micrographs showed monodisperse protein with a ‘question mark’ shape
highly similar to Toll (Fig. 2.3). The sample was then vitrified for analysis by cryo-EM. Recon-
struction by SPA produced a cryo-EM map with a resolution of 3.7Å as measured by masked gold
standard Fourier shell correlation (FSC) [117] (Fig. 2.4, 2.7). The main LRR domain is well-
resolved with density characteristic of ß-sheets lining the concave surface typical of LRRs (Fig.
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2.4B). The second, smaller LRR domain is blurred in the reconstruction, suggesting significant
motion between the two domains. Also present is extraneous density likely caused by glycosy-
lation. Due to the preferred orientation of the particle in the very thin (<13nm) layer of vitreous
ice, significant anisotropy somewhat confounds interpretation of the map. Interestingly, there is no
observed density for the extended loop on the convex surface as seen in the Toll crystal structure
between LRRs 14 and 15 [108].
Figure 2.3: Negative stain micrograph of Toll-2 ectodomains
Purified Toll-2 ectodomains were incubated on a EM grid with a continuous carbon support film and stained
with 2% uranyl formate. Monodispersed protein molecules with a curved, “question mark” shape, similar
to Toll, are seen.
Cryo-EM structure of dimeric Toll-6
To solve the structure of a dimeric Toll receptor and obtain insight into their role in adhesion,
we turned to the homodimeric Toll-6. Concentrations of protein samples used in SPA vary widely
but for these samples are approximately 3-4μM. With a KD of 2.2μM, only 55-60% of molecules
are theoretically expected to be in dimeric form, representing only 28-30% of particles in cryo-EM
micrographs. This number may be much lower given the significant denaturation and complex
disassembly that is known to happen at the air-water-interface of many cryo-EM samples between
blotting and vitrification [118, 119]. To overcome this barrier to reconstruction, samples were
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Figure 2.4: Cryo-EM reconstruction of monomeric Toll-2 ectodomain
(A) Single particle reconstruction at 3.7Å of Toll-2 sharped using DeepEMhancer. The primary leucine rich
repeat (LRR) domain is connected to a smaller LRR domain by a flexible linker. This flexibility blurs the
density for the smaller domain in this reconstruction. Extraneous density, likely of N-linked glycans, are
present. (B) ß-sheet density on concave surface of the main leucine-rich repeat domain. (C) Local resolution
of unsharpenedToll-2 map at an FSC threshold of 0.5.
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vitrified using Spotiton [27, 28, 29, 30] which has the dual benefit of reducing adsorption to the air-
water-interface [120] and requiring an approximate 2-3x increase in sample concentration, driving
and preserving dimer formation.
The Toll-6 dimer was reconstructed to 3.8Å (Fig. 2.5, 2.8). However, inspection of the FSC
curve, Euler angle distribution, and density reveal a significant amount of preferred orientation,
confirmed by a sphericity value of 0.764 as calculated by 3DFSC [121] (Fig. 2.8). The dimer
interface is a symmetric interaction between the C-terminus of one protomer with the C-terminal
capping motif of the larger LRR domain of the other, with the C-termini of both protomers oriented
on the same side of the complex (Fig. 2.5B). Unfortunately, this orientation prevents unambiguous
determination of a cis versus trans interaction. The C-terminal capping motif involved in the
dimer interface is the last stretch of amino acids with defined secondary structure, however an
additional 16 unstructured amino acids are present in the construct between the C-terminal cap
and the beginning of the transmembrane α-helix (which itself is not present in the purified protein).
These residues could constitute a flexible tether up to 55Å in length, a distance approximately equal
to the length of the small LRR domain, allowing the observed Toll-6 dimer to potentially orient
from either the same or opposed cell membranes (Fig. 2.6). Determination of the orientation of
the dimer with respect to the membrane(s), and thus its ability to mediate adhesion, is essential to
understanding its role in germ band extension.
2.4 Discussion
Here, purified Toll receptor ectodomains were used to determine binding specificity, solution
biophysical behavior, and structure to help illuminate their role in Drosophila melanogaster germ
band extension. The work in Pare et al. (2014) showed that Toll-2 mutant cells still expressing
Toll-8, most of which also express Toll-6, are still able to maintain planar polarity of myosin-
II and Par-3, the former of which drives cell intercalation by contracting AP edges [90, 88, 89,
92, 93] and the latter of which excludes myosin and stabilizes DV interactions between cells [90,
95]. It is possible that the interaction between Toll-6 and Toll-8 seen in SPR assays (Fig. 2.1)
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Figure 2.5: Cryo-EM reconstruction of dimeric Toll-6 ectodomain
(A) Single particle reconstruction at 3.8Å of Toll-6 sharped using DeepEMhancer with imposed C2 symme-
try. The dimer interface is an interaction between the C-terminal capping motif of the smaller LRR domain
with the C-terminal cap of the larger LRR domain. Both smaller LRR domains are oriented on the same
side. Flexibility in the N-termini of both larger LRR domains blurs the reconstruction. (B) Local refinement
of dimer interface sharpened using DeepEMhancer. One protomer colored purple and the other teal. In
this orientation, both sides of the interface can be observed. Segmentation done using ChimeraX. (C) Local
resolution of unsharpened Toll-6 map at an FSC threshold of 0.5. Notably, the resolution of the interface
appears to be at a higher resolution than the rest of the map.
is sufficient to drive planar polarity, possibly through a cis interaction. Cells expressing Toll-2
showed decreased affinity for a pentamerized Toll-2 ectodomain [96], a result in agreement with
the lack of self-interaction shown by Toll-2 in SPR and its existence as a monomer in solution seen
in AUC and SEC-MALS (Fig. 2.2). However, Toll-2 expressing cells showed an increased affinity
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for pentamerized Toll-8 in the same study. It is possible that the full-length, intermembrane Toll-2
possesses different biophysical properties compared to soluble Toll-2, or the pentamerization of
Toll-8 represents a significant increase in local concentration, revealing an interaction too weak to
be detected by our SPR measurements. Similarly, Toll-2 can mediate polarized adhesion with Toll-
8 positive cells [96], as well as Toll-6. Heterotypic adhesion between Toll-2 and Toll-8 expressing
cells is slightly weaker, however (approximately 35% of Toll-2/Toll-8 expressing cells adhere vs
approximately 45% of Toll-2/Toll-6 cells). Adhesion between Toll-2 and Toll-6 expressing cells is
consistent with the interaction between Toll-2 and Toll-6 observed in SPR (Fig. 2.1).
An interesting result of our biophysical assays was the pH dependence of the Toll-6 dimer (Fig.
2.2). The simplest explanation is that the purified protein is more stable at that particular pH, or
certain residues are in the proper protonation state for dimer formation, likely histidines as the pKa
of the imidazole side chain is approximately six. An atomic structure could provide useful insight
into this question. The other possibility, not mutually exclusive with the first, is that this is a more
physiological pH for the extracellular matrix of the developing Drosophila embryo. While the S2
cells in which these proteins were expressed are grown in media with a pH of 6.7-6.8 [23], which
is lower than mammalian physiological pH, the exact biological role of pH dependence is unclear.
Ultimately, it is likely a side-effect of ectodomain purification.
The Toll-6 dimer described here (Fig. 2.5) represents a novel form of dimerization for Tolls and
TLRs. Given the inability of Tolls to mediate homotypic adhesion between cells [96], it is likely
this constitutes a cis interaction. Ultimately the orientation of the interaction and its physiological
relevance must be tested. The primary goal is to build an atomic model based on the EM map,
identify residues in the interface and mutate them. If they produce the same phenotype as Toll-6
negative cells, the physiological relevance is clear. To understand the potential mechanism through
with this interaction functions, a clear distinction between cis and trans binding must be made. In
this study, liposome aggregation assays were used to confirm or reject the presence of a Toll-6 trans
dimer (data not included). As pH is a critical element of dimer formation (Fig. 2.2), these assays
were performed at pH 6.0. However, tethering of purified ectodomains is done via a C-terminal
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Figure 2.6: Orientation of the Toll-6 dimer makes distinction between cis and trans interaction am-
biguous
Toll-6 dimer is shown with one protomer colored purple and the other teal. Two possible arrangements
with relationship to membranes are shown. Lines attached to the C-termini of each protomer represent
unstructured residues between the C-terminal capping motif and the transmembrane domain.
histidine tag which requires a buffer with an approximate pH of 8.0 to properly deprotonate the
side chains which facilitate binding to Ni-NTA. Thus, no aggregation was observed for either Toll-
6 or the positive control PCDH1 EC1-4 [122]. Additional experiments could be conducted using
the AviTagged Toll ectodomains for testing aggregation of streptavidin-coated beads [123], which
should function well at a range of pH values. Regardless, this is unlike other observed TLR dimers.
All structures of dimeric TLRs solved to date have interfaces mediated by some ligand, though it
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is possible that a member of the Spätzle family, one of which is the ligand for the Toll receptor
[96], could be a ligand for Toll-6 or Toll-7 [124]. Biophysical properties of the Toll receptors in the
presence of Spätzle-2 and Spätzle-5 (a.k.a. DNT1 and DNT2 respectively) should be examined. In
addition to not being ligand-mediated, the dimer is in an altogether different antiparallel orientation
compared to the parallel orientations of other TLR dimers [112, 113, 114]. Even though the
interaction is antiparallel, it may still be a cis interaction (Fig. 2.6). This would be in closer
agreement with the results from Pare et al. (2014), whose assays would only detect trans adhesive
interactions. If this is true, the dimer may function non-adhesively. Conventionally, LRR receptors
like the TLRs dimerize and bring together intracellular domains that initiate signaling cascades
[112, 113, 114]. Such a mechanism may be at play here. Again, conclusively demonstrating
Toll-6’s ability, or lack thereof, to mediate adhesion is crucial.
2.5 Materials and Methods
Expression and purification of recombinant Toll receptor ectodomains
Complementary DNA (cDNA) for full-length Toll-2, -6, and -8 were kindly provided by Jen-
nifer Zallen at the Sloan Kettering Institute. Ectodomains were cloned into pExpreS2-1 vectors
(ExpreS2ion Biotechnologies). Plasmids were sequenced to confirm proper insertion of desired
sequences, then used to insert Avi-tags for SPR by blunt ligation using NEB Quick Ligase (New
England Biolabs, Inc.). Schneider 2 (S2) cells were grown in Excell420 medium (Sigma-Aldrich,
Inc.) supplemented with fetal bovine serum (FBS) and transfected with FuGENE (Promega Cor-
poration). The next day, Zeocin (Thermo Fisher Scientific) was used to select for successful trans-
fection. Cells were grown to confluence for 21 days before being transferred to and expanded in a
baffled Erlenmeyer flask for suspension culture expression. Eight to nine days post-expansion, se-
creted hexahistidine-tagged Toll receptors were collected by nickel-nitrilotriacetic acid (Ni-NTA)
affinity chromatography using a batch procedure (1h, 25°C) followed by size-exclusion chromatog-
raphy using a Superdex 200 Increase 10/300 column (GE Healthcare) on an AKTA pure fast protein
liquid chromatography system (GE Healthcare). Purified proteins were concentrated to between
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2.1 and 12.1mg/ml and frozen in liquid nitrogen for long-term storage.
Surface plasmon resonance
SPR binding experiments were performed using a Biacore T100 biosensor equipped with a
Series S CM4 sensor chip, immobilized with NeutrAvidin over all four flow cells. NeutrAvidin
immobilization was performed in HBS-P buffer, pH 7.4 at 32°C, over all four surfaces using amine-
coupling chemistry as described in Katsamba et al (2009), resulting in approximately 10,000 RU
of NeutrAvidin immobilized. Binding experiments were performed at 25°C in a running buffer
containing 10 mM Tris-Cl pH 7.4, 150 mM NaCl, 0.25 mg/mL BSA and 0.005% (v/v) Tween-20
unless otherwise noted.
Biotinylated Tolls-2, -6 and -8 were tethered over individual NeutrAvidin-immobilized flow
cells at approximately 1000 RU, using a flow rate of 20μL/min. A NeutrAvidin-immobilized flow
cell was used as a reference control. Toll-2 was tested at five concentrations ranging from 27-0.33
μM, prepared in running buffer using a three-fold dilution series. Due to limited sample availabil-
ity, Tolls-6 and -8 were only tested at 27 μM. All analytes were tested over the captured surfaces
at 50μL/min for 30s, followed by 300s of dissociation phase, followed by a buffer injection at
100μL/min for 60s. Protein samples were tested in order of increasing concentration, and each
concentration series was performed in duplicate. Blank buffer cycles were performed by injecting
running buffer as the analyte throughout the experiment to remove systematic noise from the bind-
ing signal. The data was processed using Scrubber 2.0 (BioLogic Software).
Size exclusion chromatography-multiangle light scattering
SEC-MALS analyses were performed using a Superdex 200 Increase 3.2/300 size exclusion
column on an AKTA FPLC system (GE Healthcare) coupled to inline static light scattering (Dawn
Heleos II, Wyatt Technology), differential refractive index (Optilab rEX, Wyatt Technology) and
UV detection. Purified ectodomains were dialyzed into running buffers containing 150 mM NaCl
and 10mM Bis-Tris (pH 5.8, 6.0, 6.25, or 6.5) or 10mM Tris-HCl (pH 7.0 or 7.4) using a 500μL
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Slide-A-Lyzer (Thermo Fisher Scientific) then diluted to 1.0mg/ml. 50ul samples were run at a
flow rate of 0.5ml/min at 25°C. Data were analyzed using ASTRA software (Wyatt Technologies).
Analytical ultracentrifugation
Experiments were performed in a Beckman XL-A/I analytical ultracentrifuge (Beckman-Coulter,
Palo Alto CA, USA), utilizing six-cell centerpieces with straight walls, 12 mm path length and
sapphire windows. All proteins were measured in two different buffers. Protein samples were
dialyzed over-night and then diluted in either TRIS 10 mM, NaCl 150 mM, pH 7.4 or Bis-Tris 10
mM, NaCl 150 mM, pH 6.0. The sample were diluted to an absorbance at 10 mm and 280 nm of
0.65, 0.43 and 0.23 in channels A, B and C, respectively. Dilution buffer were used as blank. The
sample were run at four speeds, 9000 rpm held for 20 h then four scans with 1 h interval, 12000
rpm held for 10 h then four scans with 1h interval, 15000 rpm held for 10 h then four scans with
1h interval, and 18000 rpm held for 10 h then four scans with 1h interval. Measurements were
done at 25°C, and detection was by UV at 280 nm. Solvent density and protein v-bar were de-
termined using the program SednTerp. (Alliance Protein Laboratories, Corte Cancion, Thousand
Oaks, CA, USA) For calculation of dimeric KD and apparent molecular weight, all useful data were
used in a global fit, using the program HeteroAnalysis, obtained from University of Connecticut.
(www.biotech.uconn.edu/auf).
Negative stain electron microscopy
Toll-2 was diluted to a concentration of 50ug/mL. 3μL was pipetted onto a home-made 300-
mesh copper grid with a continuous carbon support film and incubated for 30 seconds. Excess
was removed by side blotting onto Whatman filter paper (SOURCE). 3μL of 2% uranyl formate
was then pipetted onto the grid and immediately removed by side blotting. Another 3μL of uranyl
formate was added and incubated for 45 seconds before being removed and the grid allowed to
dry. Micrographs were collected on a JEOL 1230 TEM at 60,000x magnification, resulting in a
pixel size of 2.0Å with a nominal defocus of -3.0μm, using Leginon [14]. Micrographs with 500ms
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exposures were collected and binned by two, producing a final pixel size of 4.0Å. CTF estimation
and motion correction were not performed.
Cryo-EM sample preparation and data collection
Toll-2 was concentrated to 0.4mg/ml in 10 mM Tris-HCl pH 7.4 and 150 mM NaCl. 3μL of
sample was incubated on C-flat 2/2 carbon grids coated with a gold film for 15 s and vitrified
using a Leica EM GP Plunge Freezer after blotting for 3 s. Data were collected on a Titan Krios
electron microscope (Thermo Fisher Scientific) operating at 300 keV equipped with a Gatan K2
direct electron detector and Gatan Bioquantum image filter (GIF; Gatan, Inc.) using the Leginon
software package [14]. A total electron fluence of 65.45 e-/Å2 was fractionated over 40 frames
with a total exposure time of 6 s. A magnification of 29,000x resulted in a pixel size of 0.832Å
and a defocus range of 1.1-3.2μm was used. A total of 9,324 micrographs were collected.
Toll-6 was concentrated to 1.0mg/ml in 10 mM Bis-Tris pH 6.0 and 150 mM NaCl. 5μL of
sample as aspirated into a Chameleon (STP Labtech) and sprayed onto homemade gold 0.6/1.2
nanowire grids, [28] then vitrified in liquid ethane with a total spray-to-plunge time of 74 ms. Data
were collected on a Titan Krios electron microscope (Thermo Fisher Scientific) operating at 300
keV equipped with a Gatan K2 direct electron detector and Gatan Bioquantum image filter (GIF;
Gatan, Inc.) using the Leginon software package [14]. A total electron fluence of 70.47 e-/Å2 was
fractionated over 40 frames with a total exposure time of 6 s. A magnification of 165,000x resulted
in a pixel size of 0.825Å and a defocus range of 0.5-2.5μm was used. A total of 4,915 micrographs
were collected.
Single particle analysis
Raw movies were aligned and dose-weighted using patch motion correction in MotionCor2
[125]. CTF estimation was performed using CTFFIND4 [126]. Initial particle coordinates were
selected with the Difference of Gaussian (DoG) picker implemented in Appion [47, 127].
For the Toll-2 dataset, 1.6 million particles were initially picked. All subsequent processing
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was done using cryoSPARC [54], except for Topaz particle picking. Iterative 2D classification fol-
lowed by particle curation by removal of classes resembling background noise or poorly-aligned
protein density produced a stack of 770,000 particles. Ab initio model generation followed by
non-uniform refinement [128] produced a 3.9Å reconstruction as measured by masked gold stan-
dard FSC [117]. Forty-four micrographs were manually inspected and obviously incorrect particle
picks were removed leaving a stack of 1,058 accurate particle picks which were used to train a
neural network particle picking model using Topaz [52]. The resulting model, when applied to all
9,324 micrographs produced a stack of 1.01 million particles. A single round of 2D classification
and particle curation produced a stack of 1.00 million particles. Ab initio modeling followed by
non-uniform refinement produced a 3.8Å reconstruction with significantly improved density when
compared to the initial DoG picks.
For the Toll-6 dataset, 767,475 particles were initially picked. Iterative 2D classification fol-
lowed by particle curation produced a stack of 60,350 particles that were refined to 4.3Å. Manual
curation of 120 micrographs produced a set of 1,026 particles for training a Topaz model. A stack
of 585,785 particles were picked with Topaz and further curated using 2D and 3D classification.
The final stack of 79,615 dimerized particles were refined to 3.8Å using non-uniform refinement
with imposed C2 symmetry.




Figure 2.7: Toll-2 cryo-EM data processing
(A) Example micrograph of Toll-2. Scale par = 100nm. (B) FFT of example micrograph. (C) Fourier shell
correlation of final Toll-2 reconstruction. (D) 2D classification of Toll-2 reconstruction particles.
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Figure 2.8: Toll-6 cryo-EM data processing
(A) Example micrograph of Toll-6. Scale bar = 100nm. (B) FFT of example micrograph. (C) Fourier shell
correlation of final Toll-6 reconstruction. (D) 2D classification of Toll-6 reconstruction particles.
Table 2.1: Cryo-EM data collection and processing statistics
Toll-2 Toll-6
Magnification 29,000 165,000
Voltage (keV) 300 300
Electron flux (e-/Å2) 65.45 70.47
Defocus range (μm) -1.1 to -3.2 -0.5 to -2.5
Pixel size (Å) 0.832 0.825
Symmetry imposed C1 C2
Initial particle images (no.) 1.6 million 767,475
Final particle images (no.) 1.01 million 79,615
Map resolution (Å) 3.7 3.8
FSC threshold 0.143 0.143
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2.7 Future perspectives
The next objective is to build atomic models into the Toll-2 monomer and Toll-6 dimer maps
described here. Unfortunately, significant anisotropy caused by preferred orientation in the ice
makes de novo model building difficult. The more reasonable approach is to build homology
models for Toll-2 and Toll-6 and use them as starting models for further refinement into the EM
densities. This approach is not without its own challenges, as the large number of leucine-rich
repeats makes accurate sequence alignment, the key first step in building an accurate homology
model, a challenge. An accurate homology model can be obtained by aligning and modeling
each LRR individually, an approach that was used for modeling numerous TLR ectodomains [131,
132]. Unfortunately, the accompanying web server to this work is no longer functional, however,
it demonstrates that such an approach yields accurate results. With atomic models, mutations in
the Toll-6 dimer interface can be tested experimentally to verify the physiological relevance of the
model. Once mutations are made, Toll-6’s ability to mediate myosin-II polarization can be tested
with mutant Toll-6 cells as described in Pare et al. (2014).
It is also crucial that the distinction between cis and trans binding be made for the Toll-6
homodimer. Initial attempts to make such a distinction using liposome aggregation assays failed,
likely due to 1) the dependence on pH 6.0 buffer for dimer formation (Fig. 2.2) and 2) the need
for a pH 8.0 buffer for sufficient binding of the hexahistidine tag to Ni2+-functionalized liposomes.
This may be overcome by performing bead aggregation assays with AviTagged Toll ectodomains
as described in Harrison et al. (2016). The use of fluorescent beads will enable the study of
both homophilic and heterophilic adhesion, the latter of which is strongly suggested by Pare et al.
(2014).
Being able to identify mutants in heterodimeric interfaces requires structures of heterodimers,
a very feasible goal. First, heterodimer formation should be assayed by SEC-MALS at a vari-
ety of pH values. If confirmed, samples can be prepared for cryo-EM as described here. That
the two heterodimers suggested by SPR (Fig. 2.1) both include Toll-6 may confound analysis of
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cryo-EM data, given the significant increase in compositional heterogeneity. First, there would
be two separate monomer classes, one corresponding to each Toll receptor. Then, in any sample
with Toll-6, there would be a population of Toll-6 homodimers which may be hard to distinguish
from Toll-6-containing heterodimers. While modern classification approaches will likely be able
to separate these populations, especially given the different number of LRRs in the three Toll
receptors involved in germ band extension, they necessarily decrease the number of particles be-
longing to the class of interest, which may significantly hinder reconstruction efforts. The degree
to which this happens is partially dependent on the total protein concentration in the sample and
the relative binding affinities of the two dimer populations, along with the total number of particles
in the dataset. While we have quantified the affinity of the Toll-6 homodimer here using AUC,
heterodimer affinities are still unknown.
Interestingly, this work ultimately suggests Toll receptors are capable of forming both homod-
imers and heterodimers, which may function through distinct effects on planar cell polarity. The
striped nature of Toll expression pattrens in the Drosophila embryo and cell aggregation exper-
iments suggest Toll-mediated cell adhesion is driven by heterophilic interactions between Toll
ectodomains [96], a finding in general agreement with our SPR data. However, homodimer for-
mation as seen by SPR, AUC, and cryo-EM was unexpected. It is possible that these are cis in-
teractions occurring between molecules on the dorsal and ventral edges, that is between molecules
along a particular stripe. These edges are the site of polar Par-3 localization where it strengthens
DV edges and helps drive cell intercalation [95]. Toll cis homodimers may drive Par-3 localization
in a manner similar to TLRs, which initiate signaling cascades through clustering of intracellular
domains by ectodomain cis dimerization.
Clues to the exact function of the Toll-6 homodimer may be found in its role in the central
nervous system, where it is required for locomotion and motor neuron targeting through interac-
tions with a putative ligand Drosophila neurotrophin 1 (DNT1), also known as Spätzle-2 (Spz2)
[124]. Though the Toll-6 homodimer revealed here is not ligand-mediated, and binding to Spz2
may not occur in the developing embryo, the structure of Toll-6 bound to Spz2 could be illu-
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minating, especially considering the role of Toll-Spätzle binding on embryo development [108],
in particular in establishing dorsal-ventral expression patterns [99]. Assuming such a ligand-
mediated dimer remains intact after vitrification, which can be encouraged with the use of the
short wicking-to-vitrification time of Spotition, cryo-EM SPA would likely reveal structures of
both active (dimeric) and inactive (monomeric) Toll-6:Spz2 complexes. Cryo-ET sub-tomogram
averaging of full-length Toll receptors embeded in liposomes may reveal the structural arrange-
ments of intracellular components, perhaps providing insight into their signaling mechanisms.
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Chapter 3: Visualizing cadherin intermembrane recognition and adhesion
assemblies
3.1 Introduction
Cadherins are a superfamily of transmembrane proteins that contain extracellular cadherin (EC)
domains, ß-barrels connected by linker regions that typically bind calcium ions, adding rigidity to
their structure [133]. They are anchored to membranes via a highly conserved single-pass trans-
membrane domain, followed by a cytoplasmic domain that plays a crucial role in their varied
functions. Cadherins are found in a wide range of organisms, from amoebas to primates, where
they often mediate cellular adhesion [134].
The most well-characterized members of the cadherin superfamily are the classical cadherins,
so named in light of their early discovery, which form adherens junctions that are key to the de-
velopment and maintenance of tissue architecture from epithelia [135] to the central nervous sys-
tem [136]. Classical cadherins mediate adhesion by a trans interaction with a cognate cadherin
molecule on an apposing membrane surface, the interface of which involves a conserved strand
swapping mechanism between the membrane distal EC1 domains [133, 137, 138, 139, 140]. The
two subfamilies of vertebrate classical cadherins - type I and type II - both contain five EC do-
mains and a cytoplasmic domain that interacts with the actin cytoskeleton through ß- and α-catenin
[141, 142], but vary in their expression patterns and the exact details of the EC1 strand-swapping
interactions.
The clustered protocadherins, a large family of adhesion molecules clustered closely together
on human chromosome 5 [143], in contrast have six EC domains and identical cytoplasmic do-
mains that are not at all similar to those of the classical cadherins [144]. The adhesive trans
interaction between clustered protocadherins is strictly homophilic, meaning each of the 52 unique
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isoforms found in humans will only bind to another molecule of the same isoform, between the
N-terminal EC domains 1 through 4 [145, 146, 147, 148].
In addition to trans adhesive interactions, both classical cadherins and clustered protocadherins
can engage in cis interactions with molecules on the same cell surface. For the classical cadherins,
the convex surface of the EC2 domain of one protomer binds to the concave surface of the EC1
domain of a partner molecule, opposite the trans interface [133, 137, 149]. The cis interface
between two clustered protocadherins on the same membrane surface is an asymmetric interaction
between EC5 and EC6 from one protomer and only EC6 from the other [147, 150]. Unlike the
strictly homophilic trans interaction, the cis interaction is promiscuous, allowing different isoforms
on the same cell surface to interact. However, the asymmetric nature of the interface does place
some restrictions on possible combinations of cis dimers.
A combination of antiparallel trans interactions and parallel cis interactions have been observed
for other types of adhesion molecules [151], leading to the proposed formation of linear or 2D ar-
rays. Such regular arrays of adhesion molecules were directly observed in vivo when cryo-EM was
used to visualize desmosomes, spot-like cadherin-based adhesive junctions [152, 153, 154, 155].
Crystal structures of full-length cadherin ectodomains revealed similar lattice-like assemblies [149,
137] of alternating cis and trans interactions [156]. As expected, mutations in type 1 cadherins that
disrupt trans interactions were found to completely ablate all adhesion, while mutations targeting
the cis interface prevented the formation of ordered assemblies in crystal structures, on liposomes,
and on the cellular level [149].
The functional relevance of these ordered arrays has long been a topic of discussion [133, 137,
149]. Molecules that mediate adhesion through trans interactions will determine the strength of
that adhesion primarily based on expression levels of the molecules and their binding affinity [157,
140, 86]. Classical cadherin trans interfaces possess a range of binding affinities from approx-
imately 100μM (E-cadherin) [157, 140] to 1μM (VE-cadherin) [139], while cis interactions are
too weak to detect in solution but are observed when constrained to the 2D environment between
opposed membranes [158]. This contrasts with the clustered protocadherins, many of which have
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detectible cis dimerization in solution with dissociation constants ranging from 9 to 80μM [146,
147]. These lateral cis interactions are crucial to the transition from freely diffusing cadherins to
ordered arrays [156]. One possible role of these extended lattices is to increase the overall strength
of the intermolecular bonds formed by trans cadherin binding. Another possibility, discussed in
the first subchapter, is that the formation of extended assemblies can serve as a mechanism to
transduce signals across the plasma membrane, potentially causing a clustering of intracellular
components or through modulation of the cytoskeleton [159]. In either case, understanding the
structure of these assemblies is key to forming and testing mechanistic hypotheses regarding cad-
herin function.
In this chapter, I will describe my efforts to help visualize these assemblies using cryo-ET. In
the first subchapter, segmentation was used to help confirm the correspondence between density in
electron tomograms and the lattice structure obtained through x-ray crystallography of a full-length
protocadherin ectodomain. In the second subchapter, I will describe the approach I used where no
full-length ectodomain crystal structures are available. Cryo-ET and subtomogram averaging were
used to visualize assemblies formed by a number of classical cadherins, offering insight into their
unique functions.
3.2 Visualization of clustered prodocadherin neuronal self-recognition complexes
3.2.1 Introduction
Neuronal self-avoidance is an essential property of all nervous systems; self-avoidance ensures
that neurons do not make stable connections with axons and dendrites from the same neuron, but
are freely able to interact with the cellular processes of non-self neurons. In vertebrates, neuronal
self-avoidance is mediated by the clustered protocadherin (cPcdh) family [160], transmembrane
adhesion molecules with 52 isoforms in the human genome that are expressed stochastically in
individual neurons through alternate promoter choice [161]. Studies of the Drosophila Dscam1
gene [162] ld to the proposal of a model by which a unique combination of 10-50 isoforms imparts
upon a cell a unique identity [163]. Neurites from the same cell that came into contact would then
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engage in a strong adhesive interaction driven by the strictly homophilic trans binding of a common
set of cPcdh isoforms, whereas processes expressing different subsets would fail to adhere. The
Dscams, which are adhesion molecules consisting of eight immunoglobulin (Ig) domains, engage
in strictly homophilic trans binding, similar to the clustered protocadherins [164]. However, while
there are 52 cPcdh isoforms in humans, there are 19,008 possible ectodomain isoforms for Dscams,
chosen by alternative splicing [165]. The probability of two individual neurons expressing the
same subset of Dscam isoforms is thus vanishingly small. However, that probability for clustered
protocadherins is much higher and the margin for error much smaller. How do 52 protocadherins
impart diversity in a manner commensurate with the size and complexity of the mammalian central
nervous system?
An initial hypothesis suggested that a combination of cis and trans interactions would lead
to the formation of cPcdh multimers on cell surfaces that would engage homophilically between
cells and greatly increase the molecular diversity offered by the relatively limited number of cPcdh
isoforms [166, 167]. While numerous cell aggregation experiments reinforced the idea that a com-
bination of cis and trans interactions is at the core of clustered protocadherin-mediated adhesion,
some questions remained [168]. Key to this discussion was the concept of isform tolerance, that
is how many common isoforms could two cells express before they incorrectly identify each other
as self? Given the large number of Dscam isoforms, this tolerance was assumed to be fairly low,
between 10-20% [163]. For example, if a cell expressed 10 Dscam isoforms out of the possi-
ble 19,008 and had 1 to 2 isoforms in common with another cell, they may incorrectly identify
each other as self. Experimental evidence showed this tolerance for the clustered protocadherins
was at least 80% and achieving such a high isoform tolerance is key to obtaining a level of self-
recognition on par with the Dscams [168]. The key feature of the multimer model is its ability to
explain this high tolerance, as two cells would share few multimer ‘recognition units’ even if they
shared a large number of common isoforms. However, estimations of the number of individual
cPcdh isoforms per cell [169] combined with the number of isoforms in a typical neuron led to
an estimation of fewer than 2 copies of each tetrameric recognition unit per cell, a number far too
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small to explain self-recognition.
This led to a model of cPcdh behavior similar to what had been observed for the classical
cadherins, namely the formation of large arrays between opposed membranes. In this ‘chain ter-
mination model,’ the combination of cis and trans interactions between neurites from the same cell
will result in an extended cPcdh zipper whose size is theoretically limited only by the number of
copies of clustered protocadherins within each cell [146]. Introduction of even a single mismatched
isoform terminates the chain, producing a near step-function like effect on the theoretical size of
the zipper and a basis for the binary distinction between self and non-self [146]. This subchapter
will consist of the manuscript describing our lab’s efforts in directly visualizing these zippers using
x-ray crystallography, SPA, and cryo-ET.
Direct visualization utilized a method employed for type I classical cadherins [149] where
purified cadherin ectodomains are tethered to synthetic liposomes, allowed to aggregate, then vit-
rified on EM grids. As in the case of the type I cadherins, we were fortunate to have a full-length
ectodomain crystal structure to compare to our tomograms. Using segmentation, a data analy-
sis technique where voxels in the 3D volume are assigned to different classes, one can use rigid
body fitting, like that implemented in UCSF Chimera [170], to dock atomic structures into those
voxels and compute a correlation coefficient to assess the quality of the fit. Segmentation has of-
ten been done manually using programs like Amira (Thermo Fisher Scientific). This process is
time-consuming to an extent that limits its ability to be applied to large datasets. Like any manual
technique, it is also subject to human error. Recently, convolutional neural networks have been
developed to automate this process [83]. Remarkably, we were able to use this software to an-
notate not only the liposome membranes in our tomograms but also the density for the clustered
protocadherin lattices both accurately and quickly. This allowed us to build a model of neuronal
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Neurite self-recognition and avoidance are fundamental properties 
of all nervous systems1. These processes facilitate dendritic 
arborization2,3, prevent formation of autapses4 and allow free 
interaction among non-self neurons1,2,4,5. Avoidance among 
self neurites is mediated by stochastic cell-surface expression 
of combinations of about 60 isoforms of α-, β- and γ-clustered 
protocadherin that provide mammalian neurons with single-
cell identities1,2,4–13. Avoidance is observed between neurons 
that express identical protocadherin repertoires2,5, and single-
isoform differences are sufficient to prevent self-recognition10. 
Protocadherins form isoform-promiscuous cis dimers and 
isoform-specific homophilic trans dimers10,14–20. Although these 
interactions have previously been characterized in isolation15,17–20, 
structures of full-length protocadherin ectodomains have not been 
determined, and how these two interfaces engage in self-recognition 
between neuronal surfaces remains unknown. Here we determine 
the molecular arrangement of full-length clustered protocadherin 
ectodomains in single-isoform self-recognition complexes, using 
X-ray crystallography and cryo-electron tomography. We determine 
the crystal structure of the clustered protocadherin γB4 ectodomain, 
which reveals a zipper-like lattice that is formed by alternating cis 
and trans interactions. Using cryo-electron tomography, we show 
that clustered protocadherin γB6 ectodomains tethered to liposomes 
spontaneously assemble into linear arrays at membrane contact 
sites, in a configuration that is consistent with the assembly observed 
in the crystal structure. These linear assemblies pack against each 
other as parallel arrays to form larger two-dimensional structures 
between membranes. Our results suggest that the formation of 
ordered linear assemblies by clustered protocadherins represents the 
initial self-recognition step in neuronal avoidance, and thus provide 
support for the isoform-mismatch chain-termination model of 
protocadherin-mediated self-recognition, which depends on these 
linear chains11.
We determined a low-resolution crystal structure of a full-length 
clustered protocadherin (cPCDH) γB4 ectodomain, which comprises 
six extracellular cadherin domains (EC1 to EC6); this revealed an 
extended zipper-like assembly (Fig. 1, Extended Data Fig. 1, Extended 
Data Table 1). The γB4 molecules form cis dimers through an asym-
metric interaction between the EC5 and EC6 of one protomer and the 
EC6 of the other (Fig. 1a); head-to-tail trans interactions—mediated by 
EC1 to EC4—between distinct cis dimers in the crystal generate a one- 
dimensional zipper-like array (Fig. 1b). The cis and trans interactions 
are similar to those that have previously been observed in the crystal 
structures of cPCDH γB fragments15–20. Root mean square deviations 
between aligned Cα atoms are between 2 and 3 Å (Extended Data 
Fig. 2), which suggests that little conformational change is required 
for zipper formation. The cis dimers in the zipper are arranged as if 
they emanate from two apposed membrane surfaces, and the array is 
regular and could theoretically propagate indefinitely.
Whereas the crystal structure of the cPCDH γB4 ectodomain reveals 
a polymeric structure assembled from cis and trans interactions, previ-
ous analytical ultracentrifugation experiments have shown that com-
plete cPCDH γB ectodomains form dimers-of-dimers in solution15,18. 
To understand this difference, we determined the overall architecture 
of these cPCDH γB6EC1–6 ectodomains complexes in solution using 
single-particle cryo-electron tomography (cryo-ET) on purified full-
length cPCDH γB6EC1–6 ectodomains21 preserved in vitreous ice (Fig. 2, 
Extended Data Fig. 3, Supplementary Video 1). Sub-tomogram averag-
ing yielded a 3D map (with a resolution that was calculated to be about 
35 Å by Fourier shell correlation = 0.143), which showed an asymmet-
rical elongated ellipsoidal shape with readily distinguishable character-
istics that closely resemble individual observed particles. In this map, 
extended cPCDH ectodomains appear to wrap around each other in 
the central regions, and to cross at the top and bottom (Fig. 2a). Two-
dimensional class averages obtained from individual images provide 
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Fig. 1 | Crystal structure of the cPCDH γB4 ectodomain reveals a 
zipper-like assembly. a, Asymmetric unit of the γB4 crystal structure, 
which contains two γB4EC1–6 protomers (green and blue) engaged in 
the asymmetrical cis-dimer interaction. b, Zipper-like array of γB4 
through trans interactions mediated by EC1 to EC4, between cis dimers 
related by two-fold symmetry. Three orthogonal views are shown with 
bound calcium ions (violet spheres). γB4 molecules that are interacting 
in trans are shown in identical colours. Top view shows a slice through 
the midsection. c, Schematic of the zipper-like assembly depicted in b, 
arranged as if between two membranes.
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domain-level resolution, and show the solution complex is a dimer of 
two bi-antennary cis dimers joined through trans binding interactions 
in each arm (Fig. 2c, Extended Data Fig. 4). Consistent with this config-
uration, the interacting EC5–6/EC6 regions of the γB7EC3–6 cis-dimer 
structure could readily be docked into the map (Fig. 2b). However, the 
EC3 and EC4 regions from the γB7EC3–6 structure did not fit within 
the map without allowing flexibility at the junction between EC4 and 
EC5, which suggests a conformational change relative to the frag-
ment crystal structure (Extended Data Fig. 5, Extended Data Table 2). 
Similarly, fitting two copies of the trans dimer from the γB2EC1–5 crystal 
structure into the map necessitated bending and rotation of the trans 
dimers about the junction between EC2 and EC3; this was particularly 
pronounced in one of the two trans-dimer arms (Fig. 2b, Extended 
Data Fig. 5). These conformational differences with respect to the frag-
ment crystal structures (Fig. 2e) facilitate the formation of a compact 
dimer-of-dimers in which all four protomers simultaneously engage in 
both cis and trans interactions20 (Fig. 2b). The deformation of cis- and 
trans-dimer crystal structures required to form the dimer-of-dimers 
suggests that it may represent a high-energy conformation.
To determine whether dimer-of-dimers or zipper assemblies form 
between membranes, we tethered cPCDH γB6 ectodomains to lipos-
ome surfaces22 on which ectodomains could freely diffuse, mimicking 
a native membrane environment (Fig. 3a). Wild-type cPCDH γB ecto-
domains mediated robust liposome aggregation, which was dependent 
on trans interactions (Fig. 3b), and mimicked cPCDH behaviour on cell 
surfaces10,14,15 and in solution15. To visualize cPCDHs at membrane 
contact sites, we preserved wild-type γB6EC1–6 aggregates in vitreous 
ice and performed cryo-ET studies (Fig. 3c, Extended Data Fig. 6, 
Supplementary Videos 2, 3). Reconstructed tomograms revealed lipos-
omes in contact with one another, and showed a constant intermem-
brane spacing of about 375 Å between parallel membranes as well as 
ordered protein density between adherent membranes. Different views 
of the cPCDH assembly were identifiable in the tomograms (Fig. 3c–e): 
an ellipsoid ‘front’ view that extended continuously through the volume 
of the tomogram (Extended Data Fig. 7, Supplementary Videos 2, 3); 
a striped, zipper-like ‘side’ view; and a dotted, regular, grid-like ‘top’ 
view that was evident in tomographic slices through cPCDH layers that 
connect vertically stacked liposomes. Visual comparison of γB6EC1–6 
assemblies between membranes (Fig. 3c, e) with the cPCDH zipper 
observed in the crystal structure of γB4EC1–6 (Fig. 1) indicates a high 
level of correspondence; each of the major views that are evident in 
the tomogram are consistent with corresponding views of the zipper 
(Fig. 3c, e). cPCDHs thus form continuous ordered assemblies in a 
native-like membrane environment.
To determine the role of the cis interface we observed in our crystal 
structures, we repeated the cryo-ET experiments with the γB6EC1–6 
cis-mutant V563D18 on liposomes. As expected, because the trans 









































Fig. 2 | cPCDH γB6 ectodomains in solution assemble as a dimer-
of-dimers through cis and trans interfaces. a, Subtomogram-averaged 
density map of γB6EC1–6 particles from reconstructed tomograms reveals 
an asymmetric ellipsoidal complex. b, Fit of cPCDH γB trans- and  
cis-dimer crystal structures into the cryo-ET map. c, Two-dimensional 
class average of γB6EC1–6 particles in ice. Compare to b. d, Schematic of 
γB6EC1–6 ectodomains in the dimer-of-dimers. e, Overlay of γB6EC1–6 
dimer-of-dimers (magenta volume) with γB4EC1–6 zipper from the crystal 
structure (green ribbon). Distance between the EC6 domains of equivalent 
protomers in each model indicated by a bracket.






























cPCDH γB6 wild type 
Fig. 3 | cPCDH γB6 forms continuous ordered assemblies between 
liposome membranes. a, γB6EC1–6 ectodomains tethered to liposomes 
facilitate aggregation. b, Liposome aggregates visualized by fluorescence 
microscopy. Wild-type γB6EC1–6 and cis-mutant (mut) V563D both form 
single large aggregates, whereas the trans-mutant γB7EC3–6 does not 
aggregate liposomes. Negative control shows uncoated liposomes.  
c, Slice of a tomogram that shows aggregates of liposomes coated with 
wild-type γB6EC1–6 ectodomains. Different views of ordered assemblies 
indicated by arrows. d, Schematic of lattice orientations corresponding to 
views in c. e, f, Close-up views of individual slices of tomograms, showing 
front, side and top views of assemblies formed by ectodomains of wild-
type γB6EC1–6 (e) and cis-mutant V563D (f). Note that ordered assemblies 
are absent in the mutant. White arrows indicate lipid bilayers.
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interface is intact, this mutant mediated liposome aggregation in a 
manner similar to wild-type γB6EC1–6 (Fig. 3b). However, the charac-
teristic ordered front, side and top views of the zipper-like arrays from 
wild-type experiments were absent (Fig. 3f, Supplementary Video 4), 
although ectodomains still accumulated at liposome contact sites in 
tomograms and single trans dimers could be observed. This demon-
strates that ordered cPCDH assembly between membranes depends on 
the cis interactions we observed in crystal structures.
We next sought to characterize the correspondence between the 
crystallographic γB4EC1–6 zipper and the intermembrane assembly we 
observed using cryo-ET. We fitted a portion of the γB4EC1–6 zipper from 
the crystal structure into consecutive slices following a front-view array 
through the tomogram volume, which revealed a close correspondence 
between the crystal structure and the assembly from the tomogram 
(Extended Data Fig. 7).
To facilitate the docking of multiple crystallographic cPCDH γB4EC1–6  
zipper arrays into the density, we generated segmented maps for pro-
tein density and lipid bilayers using a convolutional neural network 
(Fig. 4a, b, d, Extended Data Fig. 8, Supplementary Video 5). Thirteen 
distinct zipper arrays—each comprising up to 14 cis dimers—were 
fitted into the protein density (Fig. 4c, f), with good correspondence 
to the segmented protein map (Supplementary Video 5). Top views of 
segmented maps that depict cPCDHs assembled between the apposed 
membranes of vertically stacked liposomes (Fig. 4d) revealed a repeat-
ing pattern in which distances measured between protomers mid-way 
through the zipper (Fig. 4e) alternated between short and long, with a 
notable correspondence to distances measured from the crystal struc-
ture (Fig. 4f). The average distance error between the lattices observed 
in the crystal structure and in the tomogram was < 3 Å (<5%) for the 
three zippers we assessed. Neighbouring zipper assemblies are arranged 
such that they all propagate in parallel, which allows each to extend in 
an unimpeded manner (Fig. 4c, f). This parallel alignment could arise 
owing to packing effects between the matching sawtooth structures of 
neighbouring zippers (Fig. 4e, f, Supplementary Video 5), but no con-
sistent molecular interactions between the protomers of neighbouring 
zippers were observed.
The formation of zipper-like structures by cPCDHs between inter-
acting membranes was previously hypothesized on the basis of cis and 
trans interactions revealed in biophysical studies15,17,18,20. Here we have 
shown that—despite the tendency of cPCDHs to form dimers-of-dimers 
in solution—a zipper-like lattice is the favoured assembly formed by 
cPCDH γB ectodomains between interacting membrane surfaces. 
Because cPCDHs from all subfamilies have similar overall structures 
and use similar cis and trans interfaces15–20, all cPCDHs are likely to 
be able to incorporate into zipper-like arrays15,18. Although dimers-of-
dimers were not observed in the tomographic volumes we analysed, 
we cannot rule out the possibility that this species could form between 
membranes when both arms of the interacting cis dimers are matched.
The assembly of cPCDHs into a zipper-like superstructure—in 
combination with the known homophilic specificity of trans interac-
tions and promiscuity of cis interactions—underpins a chain-termi-
nation model for cPCDH-mediated discrimination between self and 
non-self11,15. In this model, large zipper assemblies can form between 
membrane surfaces that express identical subsets of cPCDH isoforms 
(for example, neurites from the same neuron), which triggers a sig-
nal that leads to avoidance (Fig. 4g). Our tomography results show 
that contiguous zippers extend the entire length of the contact region 
between membrane surfaces, and that neighbouring zippers can form 
in parallel to further increase the size of the assembly. By contrast, 
when isoform repertoires are not identical (for example, neurites from 
different neurons) mismatched isoforms are incorporated, which pre-
vents the further growth of the zipper assemblies and limits their size 
below a presumed signalling threshold (Fig. 4g). Previous computa-






























































Fig. 4 | cPCDH γB6 forms extended parallel zipper arrays on 
membranes, consistent with the chain-termination model. a, Close-up 
view of a single tomographic slice that shows γB6EC1–6 assemblies 
between liposome membranes. Parallel zipper arrays appear as front 
views extending into the plane (orthogonal to the zipper side view shown 
schematically in g). Scale bar, 350 Å. b, Annotated maps of lipid bilayers 
(yellow) and γB6EC1–6 (cyan), overlaid as a slab on a. c, Ten linear arrays 
of cis–trans interactions from the γB4EC1–6 crystal lattice (surfaces) fitted 
into the protein density. Lipid bilayers shown in yellow. See Supplementary 
Video 5. d, Tomogram slice showing annotated top views of parallel 
cPCDH zipper arrays (cyan) formed between membranes of vertically 
stacked liposomes. e, Magnification of the region boxed in d. Distances 
(arrows) between protomers (spheres) in three separate zipper arrays are 
given. f, Distances analogous to those in e, measured from zipper-array 
crystal structures fitted into the protein density. For comparison, distances 
from e are included as grey lines. g, Schematic of the chain-termination 
model of cPCDH function in neuronal self-avoidance. ICD, intracellular 
domain; TM, transmembrane domain.
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discrimination between self and non-self among thousands of inter-
acting neurons11,15,20.
Our results raise the question of whether the specific arrangement of 
cPCDH molecules in the zipper assembly is important for downstream 
signalling—for example, by coupling to structured elements in the 
cytoplasm—or, alternatively, whether the role of the zipper is simply to 
increase the concentration of cPCDHs at cell–cell contacts. Cell-based 
assays show that cPCDHs achieve high concentrations at contacts10, 
but it remains a critical question whether these concentrations are sub-
stantially lowered when mismatched isoforms are present and chains 
are terminated when they are short15. The details of the cPCDH- 
initiated signalling cascade that leads to neuronal avoidance5,23–27 are 
not yet well-defined. Although cPCDH ectodomains are known to be 
cleaved by a metalloproteinase and γ-secretase28, it is unclear whether 
this function is involved in avoidance. Nevertheless, the structures of 
cPCDH recognition complexes reported here provide support for the 
chain-termination model for cPCDH-mediated self-recognition15, and 
a basis for future studies of the molecular mechanisms that underlie 
neuronal avoidance.
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No statistical methods were used to predetermine sample size. The experiments 
were not randomized and investigators were not blinded to allocation during 
experiments and outcome assessment.
Protein production. cDNAs for mouse cPCDH ectodomain regions—excluding 
the predicted signal sequences—were cloned into a pLEXm mammalian expression 
vector (a kind gift from D. J. Leahy, John Hopkins University), modified with the 
BiP signal sequence and a C-terminal octahistidine tag16. The signal sequences 
were predicted using the SignalP 4.0 server29. cPCDH ectodomains consist of six 
extracellular cadherin domains, followed by an unstructured linker of 23–25 amino 
acids before the transmembrane helix21. The γB4EC1–6 and γB6EC1–6 constructs used 
in this study contain coding sequences for the six extracellular cadherin domains 
and five residues from the unstructured linker, followed by the octahistidine tag 
(residues 1–638 for γB4EC1–6, following signal peptide cleavage, and residues 
1–641 for γB6EC1–6). cPCDH γB4 and γB6 share 67.1% sequence identity, and 
display similar cis and trans dimerization behaviour18. The γB6EC1–6 cis-mutant 
construct V563D was generated using the standard Quikchange mutagenesis pro-
tocol (Stratagene).
Suspension-adapted HEK293 Freestyle cells (Invitrogen) in serum-free medium 
(Invitrogen) were used for protein expression. The cell line was not tested for myco-
plasma contamination and has not been authenticated. The plasmid constructs 
were transfected into cells using polyethyleneimine (Polysciences). Medium was 
collected ~6 days after transfection and the secreted proteins were purified by nickel- 
affinity chromatography followed by size-exclusion chromatography in 10 mM 
Tris pH 8.0, 150 mM sodium chloride, 3 mM calcium chloride, and 200–250 mM 
imidazole pH 8.0. Purified proteins were concentrated to >2 mg/ml and used for 
crystallization and/or electron microscopy experiments. Molecular masses deter-
mined by mass spectrometry (Iowa State University Mass Spectrometry Facility) 
for the purified wild-type proteins were 76.6 kDa for γB4EC1–6 and 77.7 kDa for 
γB6EC1–6.
X-ray crystallography. γB4EC1–6 protein crystals were grown using protein in 
size-exclusion buffer (10 mM Tris pH 8.0, 150 mM sodium chloride, 3 mM cal-
cium chloride and 200 mM imidazole), at a concentration of 3 mg/ml and using the 
vapour diffusion method. The crystallization condition was 10% (w/v) PEG8000, 
20% ethylene glycol, 10% Morpheus Amino Acids (Molecular Dimensions) and 
0.1 M Morpheus Buffer System 2 (Hepes/MOPS buffer; Molecular Dimensions), 
pH 7.5. X-ray diffraction data were collected at 100 K from a single crystal at 
Northeastern Collaborative Access Team (NE-CAT) beamline 24ID-C at the 
Advanced Photon Source, Argonne National Laboratory. The dataset was indexed 
using XDS30 and scaled using XSCALE30.
Diffraction anisotropy. The X-ray diffraction data showed strong diffraction ani-
sotropy, with relatively strong diffraction along c* and much weaker diffraction 
along a* and b* (Extended Data Fig. 1, Extended Data Table 1). These data were 
therefore truncated using ellipsoidal limits of 6.0, 6.8 and 4.5 Å along each of the 
three principal crystal axes, as implemented in the UCLA Diffraction Anisotropy 
Server31. The completeness within the applied ellipsoidal resolution limits was 
93.6%.
Crystal-structure phasing and refinement. The γB4EC1–6 crystal structure was 
solved by molecular replacement using Phaser32, implemented in Phenix33, using 
the γB7EC3–6 cis-dimer structure (RCSB Protein Data Bank code (PDB) 5V5X)21 as 
a search model. Following an initial round of rigid-body refinement using Phenix33, 
EC1 to EC2 from the γB2EC1–5 crystal structure (PDB 5T9T)19 were manually 
placed using structural alignment of the EC3 to EC4 regions of the γB2EC1–5 crystal 
structure as a guide to the molecular replacement solution. The resulting model 
was subjected to a further round of rigid-body refinement. At this stage, there was 
clear difference density for the interdomain calcium ions and covalently linked 
glycans that were not present in the models (Extended Data Fig. 1). Iterative model 
building using Coot34 and maximum-likelihood refinement using Phenix33 was 
subsequently conducted, with care taken to maintain the geometry given the low 
resolution of the data; this yielded the final refined structure, the statistics of which 
are reported in Extended Data Table 1.
The electron density maps obtained were of reasonably good quality, given the 
low resolution (Extended Data Fig. 1). However, owing to this low resolution, 
atomic details were not well-defined and side chains were often not resolved. The 
local geometry of the starting models taken from higher-resolution published 
crystal structures of cPCDH γB fragments was therefore maintained as much as 
possible. Given these resolution constraints, we have limited our discussion of the 
crystal structure to the overall architecture and arrangement of the molecules in 
the crystal.
Structure analysis. Interdomain angles were calculated using UCSF Chimera35. 
Root mean square deviations between aligned Cα atoms between structures were 
calculated using PyMol (Schrödinger). Protein structure figures were made using 
PyMol or UCSF Chimera35.
Sample preparation for single-particle cryo-electron microscopy. Single-particle 
grids were prepared using Spotiton v.1.0 robot36–38 to obtain thin vitreous ice, 
aiding contrast during data collection. Lacey carbon or gold nanowire grids were 
prepared in-house as previously described39. Grids were glow-discharged for 10 s 
with O2 and H2, the sample was dispensed onto the grid in 50-pl drops as one single 
stripe and incubated for ~500 ms as determined by the calibrated self-wicking time 
per grid, followed by plunging into liquid ethane.
Liposome aggregation assay and sample preparation for cryo-ET experiments. 
Liposomes were prepared by a hydration and extrusion method from an 8:2 
molar ratio of 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) and the nickel 
salt of 1,2-dioleoyl-sn- glycero-3-([N(5-amino-1-carboxypentyl)iminodiaceti-
cacid]-succinyl) (DOGS-NTA) according to the manufacturer’s protocol (Avanti 
Lipids). Lipids were hydrated with assay buffer (25 mM HEPES pH 7.4, 0.1 M KCl, 
10% (v/v) glycerol and 3 mM CaCl2) and resuspended liposomes were extruded 
using membranes with a pore size of 100 nm. Liposome aggregation assays were 
adapted from previously described experiments22: liposomes and purified octa-
histidine-tagged cPCDH ectodomains were mixed at final concentrations of 
10 mM liposomes and 7 μM protein, in assay buffer, to a total volume of 20 μl, and 
incubated at 37 °C for eight hours. When cells that express cPCDHs come into 
contact with one another, all detectable cPCDH from the cell surface localizes to 
the site of cell–cell contact10; we see a similar effect with liposomes, and cPCDH 
zippers are observed even for low protein-coating densities (for example, Fig. 3c).
For electron microscopy experiments, large aggregates were gently resuspended 
by trituration with a 10-μl pipette tip, and 3 μl of each suspension were incubated 
on home-made, glow-discharged lacey carbon grids for 10 s at 85% relative humid-
ity, blotted for 2.5 s and flash-frozen in liquid ethane using a semi-automated 
approach by using either a Gatan CP3 or FEI Vitrobot.
For fluorescence microscopy, liposomes were prepared with rhodamine lipids 
(Sigma) in addition to the standard composition of DOPC and DOGS-NTA. 
Assays were performed as described for electron microscopy, and 5 μl of each 
experiment was imaged with a Nikon eclipse E800 microscope using QCapture.
Tilt-series data collection. Tilt-series were collected using a Titan Krios (FEI/
Thermo Fisher) outfitted with a direct detector Gatan K2 (Gatan) at 300 keV. 
Some wild-type (Supplementary Video 3), and all cis-mutant, γB6EC1–6 tilt-series 
were collected using a Gatan Bioquantum energy filter (Gatan). In addition, two 
of nine single-particle tilt-series were collected using a Volta phase plate (FEI/
Thermo Fisher). Data were collected bi-directionally with a tilt-range of −54° to 
54° in 2° increments using Leginon40,41 with 100-ms frames for each tilt image at a 
nominal defocus range of 0 and 2 (phase plate collections) or 6 micrometres. Total 
dose per tilt-series collected was between 50 and 150 e− per Å2 with dose rates of 
approximately 8 e− per pixel per s. Incident dose for the 0° tilt image was between 
1.5 and 3.0 e− per Å2, and increased for higher tilt angles according to the cosine 
of the tilt angle. Single-particle tilt-series were collected at a pixel size of 1.76 Å 
and tilt-series of cPCDH-coated liposomes at 1.84 Å. Full-frame alignment was 
performed using MotionCor242.
Tilt-series alignment. Tilt-series were aligned using Appion-Protomo43–45. Tilt-
series were coarsely aligned, manually aligned and then refined using a set of align-
ment thicknesses. The best-aligned iteration was reconstructed for visual analysis 
using Tomo3D SIRT46,47 after dose compensation using a previously described 
relation48. CTF correction was not performed.
Sub-tomogram averaging of the dimers-of-dimers. Particle picking was per-
formed using the dipole set model in Dynamo49,50. Each particle of a dimer-of- 
dimers was annotated at the termini with ‘north’ and ‘south’ to pre-define the 
long axis and aid sub-tomogram alignment (Extended Data Fig. 3). In 7 tomo-
grams, 506 particles were annotated, sub-volumes extracted and processed through 
sub-tomogram alignment and refinement using Dynamo49,50. An initial model 
was created from 86 randomly chosen particles and an ellipsoid mask was applied 
during refinement. Azimuth and cone flip were both enabled to allow particles to 
flip 180° during refinement to permit correction of inverted dipole annotation. No 
symmetry was applied because tests using two-fold symmetry resulted in feature-
less maps, which is consistent with the non-identical bend and rotation apparent 
in the two trans-dimer regions of the final map (Fig. 1).
Single-particle 2D data collection and processing. Data were collected at 300 kV 
on a Titan Krios (FEI/Thermo Fisher) equipped with a Gatan K2 Counting camera. 
The pixel size was 1.1 Å and defocus ranged from 1–4 micrometres. Exposures were 
set to 10 s (40 frames per image) for a total dose of ~68 e− per Å2. Frames were 
aligned using MotionCor242. One thousand, five hundred and forty particles were 
picked manually from 87 micrographs using Appion Manual Picker44 to serve as 
a training set for a positive-unlabelled convoluted neural-network particle picker, 
Topaz51. Fourteen thousand, five hundred and sixty-nine particles were selected 
and 2D classification was performed in Relion252, which provided domain-level 
resolution. Strong preferred orientation was shown in the 2D-class averages, and 
single-particle tomograms revealed that cPCDH γB6EC1–6 was predominantly 
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localized to the air–water interface23. As a result, we pursued further 3D recon-
struction using cryo-ET.
Neural-network tomogram annotation. Semi-automated segmentation of 
the tomograms was performed using the TomoSeg protocol in EMAN2.253. 
Tomograms were imported into the EMAN2.2 workflow, and binned for a final 
pixel size of 7.36 Å. For annotation of cPCDH density, thirteen 64 × 64 pixel 
regions of interest were selected from the reconstructed tomogram and manually 
annotated as positive training references, and 123 regions of interest were selected 
as negative training references. For annotation of liposome membrane density, 
10 regions of interest were selected and manually annotated as positive training 
references, and 100 regions of interest were selected as negative training references. 
Convolutional neural-network training was performed with the default parameters 
of EMAN2.2 for lipid bilayers, and the cPCDH convolutional neural network was 
trained over 40 iterations.
Fitting of continuous γB4EC1–6 arrays into annotated tomogram maps. Atomic 
models were fit into the annotated tomogram using the FitMap command in UCSF 
Chimera35. The tomogram was examined by eye to determine the length of the 
lattices that formed between liposome membranes and the lattice assembly of 
the crystal structure of γB4EC1–6 was extended to match the continuous density. 
The structural assembly was placed in the intermembrane space, and fit globally 
within a 50-nm radius of the initial placement. The average correlation coefficient 
at 20 Å was 0.735 ± 0.0305.
Statistics and reproducibility. The crystal structure was determined from diffrac-
tion data obtained from one crystal (n = 1; Extended Data Fig. 1a, c). Multiplicity and 
final refinement statistics are reported in Extended Data Table 1. The single-particle 
cryo-EM map of the dimer-of-dimers was determined using sub-tomogram 
averaging of volumes extracted from n = 7 independent experiments (Fig. 2c, 
Extended Data Fig. 3). The single-particle averages shown in Fig. 2c and Extended 
Data Fig. 4 were highly reproducible from three independent experiments (n = 3). 
Liposome aggregation assays for wild-type and mutant cPCDH were replicated in 
n = 3 independent experiments, with highly consistent results (Figs. 3, 4, Extended 
Data Figs. 6–8). Reconstructed tomograms of wild-type and mutant proteins 
coated onto liposomes—of which representative images and regions of interest are 
shown in Figs. 2, 4, Extended Data Figs. 6–8—are derived from n > 4 independent 
experiments. Ordered assemblies (Fig. 3c, e, 4a, d, Extended Data Figs. 6–8) were 
consistently observed in all wild-type cPCDH experiments (n > 11), whereas the 
ordered assemblies were consistently absent in all cis-mutant cPCDH tilt series 
(n > 4, Fig. 3f). The neural-network segmentation of protein density and lipid 
bilayers was trained on the full tomogram shown (Extended Data Fig. 8a), and 
could reliably be applied to other tomograms (n = 2, Fig. 4a, b, d, e, Extended 
Data Fig. 8b).
Reporting summary. Further information on research design is available in 
the Nature Research Reporting Summary linked to this paper.
Data availability
Crystallographic atomic coordinates and structure factors have been deposited in 
the Protein Data Bank with accession code PDB 6E6B. Single-particle and cPCDH–
liposome (binned by four or two tomograms) datasets were deposited in the 
Electron Microscopy Data Bank (EMDB) with accession codes EMD-9197, EMD-
9198, EMD-9199 and EMD-9200. Single particle data, unaligned tilt-series images, 
Appion–Protomo tilt-series alignment runs and aligned tilt-series stacks were 
deposited in the Electron Microscopy Pilot Image Archive (EMPIAR) with acces-
sion codes EMPIAR-10234, EMPIAR-10235, EMPIAR-10236, EMPIAR-10237 
and EMPIAR-10238. Any other relevant data are available from the corresponding 
authors upon reasonable request.
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Extended Data Fig. 1 | X-ray diffraction anisotropy and electron density 
map quality for the low-resolution γB4EC1–6 crystal structure.  
a, UCLA Diffraction Anisotropy Server31 output showing the data strength 
as measured by F/σ along the a*, b* and c* axes. b, The diffraction 
limits along the a*, b* and c* axes determined by three different 
methods: F/σ from (a), and the correlation coefficient (CC) and I/σ 
limits calculated by Aimless54,55. c, Synthetic precession photographs of 
the X-ray diffraction in the k = 0 plane (left) and the l = 0 plane (right), 
showing the comparatively stronger or weaker diffraction. d, Examples 
of electron density images of the γB4EC1–6 crystal structure, highlighting 
the difference density observed for ligand molecules after placement 
of all protein domains and one round of rigid-body refinement. Left, 
difference density for a glycosylated asparagine residue (Asn513, chain B). 
Right, difference density for the three calcium ions coordinated between 
extracellular cadherin domains (EC2–EC3 chain B). 2Fo − Fc (blue) and 
Fo − Fc maps (green and red) are shown contoured at 1.0 and ± 3.0σ, 
respectively. e, Example of electron density image of the γB4EC1–6 crystal 
structure after refinement, showing the cis interface. The EC5–EC6 
protomer is coloured pink, and the EC6-only protomer is coloured yellow. 
2Fo − Fc (blue) and Fo − Fc maps (green and red) are shown contoured at 
1.0 and ± 3.0σ, respectively.
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Extended Data Fig. 2 | Comparison between the γB4EC1–6 crystal 
structure and cPCDH γB fragment structures reveals that the 
formation of the zipper assembly does not require large conformational 
changes. a, Structural superposition of the γB4EC1–6 cis dimer from the 
crystal structure (one protomer in slate ribbon, the other in green) with 
the γB7EC3–6 fragment cis-dimer structure (PDB 5V5X; pink ribbon), 
showing the overall similarity between the two structures (particularly in 
the EC5–6/EC6 cis-interacting regions). b, Structural superposition of the 
γB4EC1–6 trans dimer from the crystal structure (slate and green ribbon) 
with the γB2EC1–5 fragment trans-dimer structure (PDB 5T9T; gold 
ribbon), showing the overall similarity between the trans dimers.
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Extended Data Fig. 3 | Particle selection and subtomogram averaging 
of cPCDH γB6 complexes in solution. a, Representative tomographic 
slice that shows the orientation of γB6EC1–6 complexes in vitreous ice. Note 
that front views are predominant, and represent a preferred orientation. 
Axis scale is in pixels. b, Complexes in the ice are selected as dipole 
sets (blue sticks). For each particle ‘north’, ‘centre’ and ‘south’ points are 
marked as blue, cyan and red spheres, respectively. Axis scale is in pixels. 
c, Sub-volumes of pre-oriented particles were extracted from tomograms, 
and sub-tomogram averaged; projections of the final iteration after 
convergence are shown on the right.
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Extended Data Fig. 4 | Two-dimensional cryo-electron microscopy 
of γB6EC1–6 in solution. a, Representative grid atlas of a grid prepared 
using Spotiton. Orange box highlights the path of sample deposition. 
b, Representative micrograph of γB6EC1–6 in vitreous ice. Individual 
extracellular cadherin domains are distinguishable within the ellipsoid 
particles. Orange boxes indicate representative particles. c, Two-
dimensional class averages, calculated using Relion, show highly preferred 
orientation of γB6EC1–6 in the ice. Five separate class averages are shown.
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Extended Data Fig. 5 | Structural comparisons of the dimer-of-dimers 
model from single-particle cryo-EM with crystallographic cis and trans 
dimers. a, Crystallographic cis dimers of γB7EC3–6 (blue ribbon) were 
aligned with the dimer-of-dimers model (space fill, colours as shown 
in Fig. 1) over the EC5–EC6 cis-dimer regions derived from γB7EC3–6 
(black bars). The EC4–EC5 linker region appears to accommodate a high 
degree of structural variation. b, Crystallographic γB2EC1–5 trans dimers 
(blue ribbon) were aligned with the manually positioned EC1–EC2 and 
EC3–EC4 dimer fragments (black bars) in the dimer-of-dimers density. 
Deviations derive from differences in rotation and bend at the EC2–EC3 
and EC3–EC4 linker regions within the antiparallel EC1–EC4 trans 
dimers. c, Comparison of the EC4–EC5 interdomain deflection angles 
between the dimer-of-dimers model (left) and the crystallographic 
γB7EC3–6 cis dimer (right), highlighting the variations between them. 
Individual extracellular cadherin domains were defined as axes in UCSF 
Chimera and are shown as cylinders. All interdomain deflection angles 
are listed in Extended Data Table 2. d, The dimer-of-dimers model was 
assembled by rigid-body-fitting into the cryo-ET density of four-domain 
trans (EC1–EC2 and EC3–EC4) and cis (EC5–EC6 and EC5–EC6) units 
from the γB2EC1–5 and γB7EC3–6 crystal structures, respectively. Deflection 
and rotational angles between these docked units in the final dimer-of-
dimers model (left) compared with those in the γB2EC1–5 trans dimer 
(right), highlighting the conformational change required within the 
EC1–EC4 trans interaction to facilitate formation of the dimer-of-dimers. 
e, Deflection and rotational angles between EC5–EC6 and EC5–EC6 
cis-interaction and the EC3–EC4 and EC1–EC2 trans-interaction units 
in the repeating unit of the crystallographic γB4EC1–6 zipper array, for 
comparison to the dimer-of-dimers model.
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Extended Data Fig. 6 | Data collection strategy for assessing protein 
assemblies formed by cPCDHs between liposomes. a, Grid view of 
protein–liposome aggregates (dark shadows) deposited on lacey carbon 
grids, 300 copper mesh. b, Hole view of the boxed area shown in a. 
Protein–liposome aggregates can be seen as dark shadows. Tilt-series 
collection of liposome aggregates over lacey carbon holes in thin ice 
(orange square). White crosses represent additional data collection sites; 
the cyan cross represents the focus target. c, Tilt image collected at the 
region highlighted in b. A single layer of liposomes coated in cPCDH 
density (black arrowhead), liposomes stacked on top of each other 
(white arrowhead) and—in addition—thick layers of stacked liposomes 
(asterisks) are visible in the image. Note that membranes at liposome 
contact sites appear to be parallel, and cPCDH density appears to be 
ordered. See Supplementary Video 2 for the reconstructed tomogram.
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Extended Data Fig. 7 | cPCDH zippers from the γB4EC1–6 crystal 
structure match the ordered linear arrays observed for γB6EC1–6 on 
membranes. a, Tomographic slice through a reconstructed tomogram of 
adherent γB6EC1–6-coated liposomes. The region of tomographic slices 
that is shown in close-up views in c and d is highlighted by an orange box. 
b, Molecular surface views of the γB4EC1–6 crystal lattice arrangement 
in three orientations. Each protomer is coloured in a different colour. 
c, Tomographic slices spanning 143 Å into the depth of the tomogram, 
one linear array that progresses into the plane of the tomogram is 
indicated by cyan arrowheads. Grey arrowheads indicate lipid bilayers. 
d, Crystallographic γB4EC1–6 zipper consisting of five consecutive cis 
dimers placed into the cryo-ET density of the marked γB6EC1–6 array 
(cyan arrowheads) observed between membranes. Compare the density 
and structure fit between c and d. Protomers coloured as in b. Scale bars, 
350 Å.
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Extended Data Fig. 8 | Automated tomogram annotation of cPCDH 
density and membranes. a, Training and annotation of protein density 
and lipid bilayers. Examples of representative 2D-positive (top two 
panels) and -negative (bottom) annotations are shown. Left and middle, 
regions of interest on a tomographic slice (left) and manual annotation 
(middle) identify positive (white particles on black background) features. 
Right, output after the training. A representative negative example is 
shown (bottom), in which no features are annotated by the trained neural 
network. b, Annotated tomographic slice. cPCDH density is shown in 
cyan, membranes in yellow. Orange arrowheads indicate single protomers 
to highlight examples of domain-level resolution of annotation. Scale bars, 
350 Å.
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Extended data table 1 | X-ray crystallography data collection and refinement statistics
Values in parentheses are for the outer shell. APS, Advanced Photon Source, Argonne National Laboratory; A.S.U., asymmetric unit; R.m.s., Root mean square. See Extended Data Fig. 1 and Methods for 
further details on the ellipsoidal resolution limits.
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Extended data table 2 | Interdomain angles
Interdomain deflection angles between consecutive extracellular cadherin domains are given as the deviation from 180°. Angles were calculated using UCSF Chimera. The γB2EC1–5, γB3EC1–4, γB7EC1–4 
crystal form 1, γB7EC1–4 crystal form 2 and γB7EC3–6 structures correspond to PDB 5T9T, 5K8R, 5SZO, 5SZP and 5V5X, respectively.
*The dimer-of-dimers model was generated using four-domain rigid interaction units; four copies of EC1–EC2 and EC3–EC4 from γB2EC1–5 and the two EC5–EC6/EC5–EC6 units from the γB7EC3–6 
crystal structure. The EC1–EC2, EC3–EC4 and EC5–EC6 angles are, therefore, unchanged.
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3.3 Visualization of classical cadherin assemblies by cryo-electron tomography
3.3.1 Abstract
Vertebrate classical cadherins function in cell-cell adhesion and often concentrate in protein-
dense “junctions” at cell-cell contacts. Reconstitution experiments have shown membrane-linked
type I cadherin ectodomains to spontaneously polymerize junction-like structures at intermem-
brane contacts, but whether this occurs for type II cadherin ectodomains is unknown. Here we
use cryo-electron tomography (cryo-ET) to visualize ectodomain junctions spontaneously formed
between adherent liposomes by type I (E-cadherin), type II (cadherins-6, -8, -10, -11,-19,and -20),
and vascular endothelial (VE) cadherins. Remarkably, most formed ordered lattice-like polymeric
intermembrane structures, with repetition and order most clearly visible in VE-cadherin junctions,
followed by type I cadherins, with the least order in type II junctions. Type I lattices could be mod-
eled by combinations of known cis and trans interactions, while sub-tomogram averaging revealed
VE-cadherin to utilize distinct cis interactions. Overall, cadherin lattices engage only a portion of
possible cis interactions, yielding a junction formed by a mosaic of cadherin micro-clusters.
3.3.2 Introduction
Cell-cell adhesion is often mediated through “junctions” – large multi-protein structures em-
bedded in the plasma membrane that mediate adherent contact with an adjacent cell. Members
of the cadherin superfamily – among the most abundant and widely expressed transmembrane
adhesion receptors – constitute the principal transmembrane components of numerous types of
cell-cell junctions. These include desmosomes, spot-weld-like intercellular structures that link the
intermediate filament networks of adjacent cells to impart tissue strength, mediated by desmo-
collins and desmogleins [171], adherens junctions, mediated by classical cadherins and linked to
the more dynamic actin cytoskeleton [135], and distinct endothelial junctions mediated by vascu-
lar endothelial (VE)-cadherin thought to oppose blood pressure in the vasculature [172]. In each
of these junction types, cell-cell contact appears to be mediated exclusively through trans-cellular
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interaction between the cadherin molecules, which are present in high density. Due to their large
size and characteristic appearances, the cadherin-mediated junctions were initially identified by
early electron microscopy studies, many of which noted an ordered and repetitive appearance of
the intermembrane structures we now know to represent the cadherin molecules [135].
Vertebrate classical cadherins consist of five tandem extracellular cadherin (EC) domains con-
nected by calcium-coordinating linker regions [133]. Adhesion is mediated by trans interactions
with a cognate cadherin molecule on an apposing cell surface using a conserved mechanism be-
tween the membrane-distal EC1 domains, in which the N-terminal ß strand of each protomer is
exchanged with that of the other [133, 137, 138, 139, 140, 173]. In type I cadherins, this strand
swapping is anchored by a highly conserved Trp2 residue [133, 137, 140]; however, in type II
cadherins there are two tryptophan residues, Trp2 and Trp4, that anchor this interaction [138, 139,
173]. Type II cadherins also possess a large nonpolar interface at the base of the domain, con-
tributing to their generally stronger affinities [138, 173]. Previous work on VE-cadherin classifies
it as an outlier type II; while the swapped ß-strand is anchored by the conserved Trp2 and Trp4
residues, it lacks the additional hydrophobic interactions that are present in structures of other type
II cadherins [139]. Parallel cis interactions between type I cadherins on the same cell surface oc-
cur between a surface on EC1 separate from that of the trans interaction and a region on the EC2
domain of a neighboring molecule [149]. This cis interaction combines with the above-described
trans interaction to induce the formation of ordered assemblies observed in both crystal structures
and between liposome membranes visualized by cryo-EM [149]. However, it remains unknown
whether these assemblies are formed by type II cadherins and outliers such as VE-cadherin, since
no cis interactions have been observed in crystal structures of these molecules.
The five type I cadherins (E-, N-, R-, P-, and M-cadherin) are broadly expressed in the epithe-
lial tissue, with each cell generally only expressing a single type. The type II cadherins are more
complex, with fine-grained expression patterns and multiple co-expressed in the same cell. They
have specialized functions, particularly in the central nervous system. Spinal motor neurons are
organized into pools which all target specific muscles in the limb [174, 175], and during develop-
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ment this sorting is mediated by differential expression of specific sets of type II cadherins [176].
Heterophilic interaction between type II cadherins is also responsible for the long-term synaptic
strength and morphology of CA1 and CA3 neurons in the hippocampus [177]. Differential ex-
pression of type II cadherins also controls cell aggregation and migration in the development of
the renal epithelium from mesenchymal cells [178, 179], and cadherin-8 is required for proper
synaptic coupling between cold-sensitive sensory neurons [180]. These examples paint a picture
of homo- and heterophilic cell adhesion molecules involved in precise cell sorting and targeting.
Biochemical characterization using surface plasmon resonance (SPR) demonstrated the ability
of these type II cadherins to interact heterophilically [173] in agreement with specificities observed
in cell aggregation experiments [181, 138]. Given this correspondence between molecular affinity
and cell-cell recognition on the one hand and the importance of higher-order assembly formation
observed for other cadherins on the other, we are interested in what role assembly formation plays
in the functions of various type II cadherins. Cryo-EM has been used to study higher order as-
sembly formation by VE-cadherin [182, 183, 184], which is expressed exclusively in the vascular
endothelium in vertebrates where it is concentrated into adherens junctions [172]. Ectodomain
fragments containing EC1-4 arranged on membranes were observed to form cylindrical hexamers
[183, 184], however this appears to have been an artifact produced by a lack of glycosylation due
to the use of a bacterial expression system [139]. Given the large mechanical forces withstood by
VE-cadherin, understanding the structure of these adherens junctions is of great interest.
Here we visualize classical cadherin assemblies between membranes using cryo-ET, including
type I (E-cadherin), type II (cadherin-6, -8, -10, -11,-19,and -20), and the outlier type II VE-
cadherin. Subtomogram averaging was then used to determine the arrangement of the VE-cadherin
assembly and identify the approximate location of the cis interface.
3.3.3 Results
Canonical type II cadherins show minimal to moderate order between membranes
Phylogenetic analysis of the EC1-2 sequences shows that the canonical type II cadherins cluster
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together, while VE-cadherin, though more closely related to those type IIs than E-cadherin, is an
outlier (Fig. 3.1B). To visualize the extent to which cadherins form ordered assemblies between
membranes, we purified ectodomains of various cadherins with C-terminal hexahistidine tags. Li-
posomes were prepared with phospholipids containing Ni2+-chelated head groups and incubated
with cadherin ectodomains. Cadherins tethered to these liposomes can freely diffuse and engage
any possible cis or trans interactions, mimicking their native biophysical environment. After incu-
bation with cadherins, liposomes formed visible aggregates indicative of adhesion.
Cadherins tethered to liposomes were pipetted onto lacey carbon grids and visualized using
cryo-EM. Of the type II cadherins, cadherin-6, -8, and -10 show a moderate degree of order (Fig.
3.3). Liposomes incubated with purified cadherin-6 ectodomains show inconsistent membrane and
a partially defined midline density (Fig. 3.3A). Cadherin-8 assemblies appear slightly heteroge-
neous with but with a clear midline density and with membranes spaced approximately 315Å apart
(Fig. 3.3B). Cadherin-10 seems to produce slightly more regular assemblies as evidenced by the
long stretches of parallel liposome membranes where the force generated by formation of the array
must be great enough to pull the membrane surfaces into a parallel orientation. However, it is
unlikely that it is ordered enough for successful subtomogram averaging. In areas with the most
ordered density, defined by a strong midline and parallel membrane surfaces, the intermembrane
distance is approximately 330Å (Fig. 3.3C).
Cadherin-11, -19, and -20 showed little order between membranes (Fig. 3.4). While pro-
tein density is clear, there appears to be no areas of consistent intermembrane spacing or defined
midline density. However, these ectodomains showed evidence of aggregation in size exclusion
chromatography. Thus, the lack of order between membranes cannot be conclusively said to be
intrinsic and may have been a result of low protein stability in solution.
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Figure 3.1: Sequence alignment and phylogenetic analysis of classical cadherin EC1-2 domains
(A) Sequence alignment of EC1-2 domains of cadherins in this study. Performed using MUSCLE and visu-
alized with ESPript. E-cadherin residues with 10Å2 buried surface area are underlined in green. Residues
mutated in Harrison et al. (2014) marked with green arrows. Residues involved in hydrogen bonding marked
with blue arrows. (B) Phylogenetic analysis of cadherin EC1-2 domains. Calculated using maximum likeli-
hood approach in PhyML 3.0.
E- and VE-cadherin show high levels of order between membranes
Similar to tomography data in Harrison et al. (2011), E-cadherin produces ordered density between
liposomes. We use E-cadherin as a method reproducibility control. “Top” views of regular cadherin
densities reveal a spacing of approximately 70Å consistent with ordered array formation (Fig. 3.2,
3.5). Views orthogonal to the long axis of the cadherin molecules reveal an intermembrane spacing
of 300-340Å (Fig. 3.5), consistent with previous studies [149].
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Figure 3.2: Crystal structure of E-cadherin two-dimensional array
Interactions formed by E-cadherin from PDB 3Q2V. (A) Linear array of cis interactions. Membrane-
proximal EC5 is colored dark green and membrane-distal EC1 is colored lime green. (B) trans dimer
formed by two protomers originating from opposite membranes. The blue protomer’s EC1 domain is col-
ored light blue and EC4 is colored dark blue. EC5 of the blue protomer is disordered in the crystal structure.
(C) Lattice formed by cis and trans interactions, viewed perpendicular to the plane of the lattice.
Out of all samples imaged, VE-cadherin produced the most ordered density between liposomes
(Fig. 3.6). In many places, liposome membranes are largely parallel for long stretches. Between
these sections is a strongly defined midline density and intermembrane distances of 260-300Å.
Cadherin-like density, similar to what has been observed for the desmosomes [155] and type I
cadherins [149] is evident in certain orientations (Fig. 3.6, right panel). Cadherin density on a
common membrane surface is spaced 70Å apart, measurements consistent with crystal structures
of type 1 cadherin lattices [149] (Fig. 3.2). Weak density is observed adjacent to the membrane,
likely a result of the flexible C-terminal histidine tag.
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Figure 3.3: Cadherins-6, -8, and -10 show moderate order between liposomes
Purified cadherin ectodomains were tethered to Ni-NTA functionalized liposomes and imaged via cryo-ET.
These 2D slices of the reconstructed tomograms show cadherins-6, -8, and -10 show moderate order between
membranes. White arrowheads are membrane bilayers. Solid black arrowhead is midline density. Scale bars
= 350Å. (A) Cadherin-6 ectodomain tethered to synthetic liposomes. (B) Cadherin-8 ectodomain tethered
to synthetic liposomes. (C) Cadherin-10 ectodomain tethered to synthetic liposomes.
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Figure 3.4: Cadherins-11, -19, and -20 show little order between liposomes
Purified cadherin ectodomains were tethered to Ni-NTA functionalized liposomes and imaged via cryo-ET.
These 2D slices of the reconstructed tomograms show cadherins-11, -19, and -20 show little order between
membranes. White arrowheads are membrane bilayers. Scale bars = 350Å. (A) Cadherin-11 ectodomain
tethered to synthetic liposomes. (B) Cadherin-19 ectodomain tethered to synthetic liposomes. (C) Cadherin-
20 ectodomain tethered to synthetic liposomes.
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Figure 3.5: E-cadherin shows regular spacing in agreement with previous studies
2D slice of reconstructed tomogram of purified E-cadherin ectodomain tethered to Ni-NTA functionalized
liposomes. White arrowheads are membrane bilayers. Solid black arrowhead is E-cadherin top views. Scale
bar = 350Å
Figure 3.6: VE-cadherin shows high degree of order between liposomes
2D slice of reconstructed tomogram of purified VE-cadherin ectodomain tethered to Ni-NTA functionalized
liposomes. White arrowheads are membrane bilayers. Solid black arrowhead is midline density. Dotted
black arrowhead is VE-cadherin trans dimer. Scale bar = 350Å
Sub-tomogram averaging of VE-cadherin intermembrane arrays
To further define the structure of the assemblies produced by VE-cadherin, particularly with the
lack of a full-length ectodomain crystal structure, we turned to subtomogram averaging. Tomo-
grams were imported into Dynamo [185] which was used for geometric particle picking. Surface
models along midline densities were created and particles extracted at regular intervals along those
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surfaces with the direction orthogonal to the surface used as an initial particle orientation. Particle
refinement of the oversampled arrays was performed unmasked, followed by masked refinement
after removing duplicate particle picks, leading to the final averaged volume (Fig. 3.7). Density
of cadherins in a 2D array with a 66-77Å spacing is evident. The midline density in the averaged
volume measures approximately 58Å, in close agreement with the width of a VE-cadherin trans
dimer interface [149] (Fig. 3.7). There is a notable lack of density between the membrane and
midline strong enough to account for a cis interface, suggesting the it is not located in EC4 as
previously reported [183, 184].
Figure 3.7: Subtomogram averaging of VE-cadherin reveals strong midline density and regularly
spaced crossbridges
2D slices of reconstructed tomogram of VE-cadherin ectodomain tethered to synthetic liposomes. The left
panel shows regularly spaced density at the midline. The right panel shows VE-cadherin crossbridges. Scale
bars = 73Å
3.3.4 Discussion
Cadhereins play a crucial role in cell adhesion, signaling, and targeting, and there is a body of
evidence that suggests these functions involve the formation of higher ordered assemblies between
membranes. Here we show that type II cadherins are capable of forming at least moderately-
ordered (Fig. 3.3), and in the case of the outlier VE-cadherin, potentially very highly ordered (Fig.
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3.6), homophilic assemblies. Coupled with previous work on classical cadherins [149], clustered
protocadherins [168, 146, 148, 147, 186], non-clustered protocadherins [187], and desmosomal
cadherins [155], these results expand our understanding of this phenomenon to include a group of
cadherins involved in complex cell sorting and tissue development.
Type II cadherins are functionally diverse and possess complex and often overlapping expres-
sion patterns, making it difficult to connect their structural and functional properties. For many
cadherins, the formation of higher-ordered assemblies are deeply connected to their function [149,
186, 155]. Using cryo-electron tomography, we show that type II cadherins also possess the ability
to form at least moderately ordered assemblies between membranes (Figs. 3.3,3.4). These results
are consistent with their role in cell sorting and synaptic function in the CNS [178, 179, 176, 180,
177, 188], where formation of tight junctions like those seen in type I cadherins [149] and desmo-
somes [155] may be a barrier to cell migration, such as that seen in renal tissue development [178,
179] and sorting of motor pools in the spinal cord [176].
In other cadherins, assemblies are combinations of cis and trans interactions. While there are
structures of type II cadherin trans interfaces, none exist for a potential cis interface. The cis
interface present in type I cadherins is highly conserved [149] and sequence alignment between
E-cadherin and the type II cadherins in this study reveals significant differences in the EC1 & 2
domains that mediate the cis interaction in type I cadherins (Fig. 3.1A). While our results suggest
the existence of a cis interface to explain the regular distance between VE-cadherin densities (Fig.
3.6,3.7), it is unlikely to form via the same interface as the type I cadherins, and the mosaic nature
of cadherin-microclusters observed suggest they engage only a portion of the possible cis inter-
faces. The strength and structural details of such an interface could shed light on the intermediate
level of order observed in type II cadherin-coated liposomes.
This behavior of the type II cadherins stands in contrast with what has been previously shown
for the outlier VE-cadherin. Functionally, it serves as a strict adhesion molecule that forms ad-
herens junctions in vascular endothelial tissue [189]. These junctions must withstand significant
mechanical force as they oppose blood pressure in the vasculature. Our observation that VE-
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cadherin forms highly ordered assembly between membranes (Fig. 3.6) agrees with these findings.
Indeed, the regularity and apparent strength of the array surpasses that of E-cadherin (Fig. 3.5).
Previous cryo-EM experiments showed VE-cadherin assembles as a hexamer between membrane
surfaces, with a putative cis interface at EC4 [183, 184]. We have proposed that this arrangement
is an artifact caused by a lack of glycosylation [139], a conclusion supported by subtomogram av-
eraging of VE-cadherin ectodomains expressed in mammalian cells (Fig. 3.7). The strong midline
coupled with crossbridge density the width of a single cadherin domain (Fig. 3.7) is in conflict
with a cis interface at EC4 [183, 184]. Given the sequence divergence between VE-cadherin and
E-cadherin at residues involved in the type I cadherin cis interface, it is unlikely the cis interface
is in the same position. This hypothesis is also supported by the difference in densities observed
between liposomes, particularly in the relative thicknesses of the midlines (Figs. 3.5-3.7) [149].
Further analysis by subtomogram averaging will likely yield a more precise localization of the
VE-cadherin cis interface. These results provide a structural basis for the strength of VE-cadherin
adherens junctions and their role in cell adhesion.
Cryo-ET has been used to study several representative members of various cadherin subfamilies
adhering opposed membrane surfaces. Remarkable order is observed for desmosomal cadherins
[190, 154, 155] and VE-cadherin (Fig. 3.7) corresponding to their stiffness. The type I cadherins
also polymerize into regular arrays with regularly-spaced density observed in tomograms [149].
Type II cadherins produce moderately ordered density when tethered to liposomes (Figs. 3.3)
commensurate with their roles in cell sorting and migration [178, 179, 176]. Surprisingly, the
clustered protocadherins also form lattice-like arrays [186], though they are very different from
those produced by desmosomes and classical cadherins, extending in one dimension as a signal for
neuronal self-recognition. Finally, the non-clustered protocadherins, which lack the cis interface
observed in clustered protocadherins, produce no ordered arrays between membranes and instead
simply pack trans dimers into compact junctions [187]. However, pathways that couple junction
formation with cell signaling remain to be discovered.
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3.3.5 Materials and Methods
Phylogenetic analysis
Sequences of mouse classical cadherins were obtained from Uniprot for VE-cadherin (P55284), E-
cadherin (P09803), cadherin-6 (P97326), -8 (P97291), -10 (P70408), -11 (P55288), -19 (B2RXP4),
and -20 (Q9Z0M3). Multiple sequence alignment was performed using MUSCLE [191]. Phyloge-
netic analysis was performed using the Bayesian maximum-likelihood approach implemented in
PhyML [192]. The phylogenetic tree was rendered using TreeDyn [193].
Expression of recombinant proteins
Complementary DNA (cDNA) clones encoding full-length cadherins were either cloned from
cDNA libraries or obtained as I.M.A.G.E clones (Transomic Technologies, Inc.). Amplicons were
inserted between Not1/BamH1 sites of the mammalian expression vector VRC8400 [194] pre-
ceded by the signal sequence of human Binding immunoglobulin protein (BiP; MKLSLVAAM-
LLLLSAARA) and followed by a hexahistidine affinity tag and stop codon. All expression con-
structs were checked by DNA sequencing and checked against Uniprot amino acid sequences for
VE-cadherin (P55284), E-cadherin (P09803), cadherin-6 (P97326), -8 (P97291), -10 (P70408),
-11 (P55288), -19 (B2RXP4), and -20 (Q9Z0M3). Proteins were expressed in Freestyle HEK293
suspension cells (Thermo Fisher Scientific). Polyethyleneimmine [195] diluted with Opti-Mem
reduced serum medium (Thermo Fisher Scientific) was used for transient transfection. After trans-
fection, cells were maintained in Freestyle cell culture media (Thermo Fisher Scientific) supple-
mented with 5mM CaCl2 16 hours after transfection to improve cadherin yield. Six days post-
transfection, secreted hexahistidine-tagged cadherins were collected by nickel-nitrilotriacetic acid
(Ni-NTA) affinity chromatography using a batch procedure (1h, 25°C) followed by size-exclusion
chromatography using a Superdex 200 26/60 column (GE Healthcare) on an AKTA pure fast pro-
tein liquid chromatography system (GE Healthcare). Purified proteins were concentrated to be-
tween 2.8 and 7.0mg/ml and frozen in liquid nitrogen.
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Preparation of Ni2+-functionalized liposomes
Liposomes were prepared using a hydration and extrusion method according to the manufacturer’s
protocol (Avanti Lipids) with a final 8:2 molar ratio of 2-dioleoyl-sn-glycero-3-phosphocholine
(DOPC) and nickel salt of 1,2-dioleoyl-sn-glycero-3([N(5-amino-1-carboxypentyl) iminodiaceticacid]-
succinyl) (DOGS-NTA).
Cryo-EM sample preparation
Samples were prepared in a total volume of 20μL, with a final concentration of 500μM liposomes
and 7μM purified cadherin ectodomains with C-terminal hexa-histidine tags. After addition of
protein, samples were incubated for 7 hours and checked for visible aggregation. Aggregates were
gently broken up by trituration with a 10μL pipette tip prior to grid preparation. Glow-discharged
lacey carbon grids were incubated with 3μL of each suspension of aggregated liposomes at 85%
relative humidity while re-suspending on the grid 10 times, blotted for 2.5 s and vitrified in liquid
ethane using a Gatan CP3 plunge freezer.
Cryo-EM data collection
Tilt series were collected using a Titan Krios (Thermo Fisher Scientific) operating at 300 kV
equipped with a Gatan K2 Summit direct electron detector, a post-column Gatan Bioquantum
image filter (GIF; Gatan, Inc.), and a spherical aberration corrector (CEOS GmbH). Data were
collected using Leginon [14] with a bi-directional tilt scheme with a range of -54° to 54° in 2°
increments. Fractionated amongst 13 frames with a frame rate of 85 ms per frame was an incident
flux of 2.53e-/Å2 for the 0° tilt image and increased for higher tilt angles according to the cosine
of the tilt angle. Total dose per tilt series was 150e-/Å2 with a nominal defocus of -4μm and cal-
ibrated pixel size of 1.836Å at a magnification of 64,000x. Full frame motion correction without
doseweighting was performed using MotionCor2 [125].
Tilt series alignment and reconstruction
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All tilt series were aligned without fiducials using Appion-Protomo [196]. After coarse alignment,
tilt series were manually aligned and then refined using a set of alignment thicknesses between
3200 - 4000Å. Refinement and manual alignment were iterated until refinements converged. The
best-aligned iteration was reconstructed for visual analysis using Tomo3D SIRT [78] after moder-
ate dose-compensation using the relation described in Grant and Grigorieff (2015). CTF correction
was not performed, as it was unecessary for visual inspection and low-resolution averaging. 3dmod
[71] was used to prepare the tomogram slices for Figures 3.3-3.7.
Subtomogram averaging of VE-cadherin
Subvolume picking, extraction, and refinement was performed in Dynamo [185]. Surface mod-
els were created along midlines between highly parallel liposome membranes. Coordinates were
picked at regular 70Å intervals along the surface and were extracted with a box size of 64 pixels.
An initial orientation perpendicular to the surface was assigned to each particle and an average
was calculated. This average confirmed rough alignment of the membranes and midline density.
This average was used as a starting reference for iterative refinement with a cone aperture of 60°.
After this initial refinement, particle duplicates within 32 pixels were removed and a cylindrical
mask, encompassing a presumed dimer-of-dimers and excluding membrane density, was used for
additional refinement with local searches.
3.3.6 Future perspectives
One fundamental question stands; how do adhesion molecules like the clustered protocadherins
ultimately induce repulsion? Clustered protocadherins are known to be proteolysed by metallopro-
teinase, which cleaves the ectodomain [197], and the γ-secretase complex, which separates the
intracellular domain [198, 199, 200]. The latter of these is dependent upon endocytosis [201], sug-
gesting it occurs after cleavage by metalloproteinase. It is possible, then, that these linear zippers
formed by clustered protocadherins serve two roles: first, to provide neurons with a unique cellular
identity that is highly sensitive to even a single isoform mismatch, and second, to increase the lo-
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cal concentration of clustered protocadherin intracellular domains for subsequent endocytosis and
downstream signaling. The structural description of these zippers provides a basis for testing such
hypotheses.
The type II cadherins, in contrast with the type I cadherins, engage in strong heterophilic trans
interactions and have been separated into different specificity groups, confirmed by both SPR and
cell aggregation experiments, based on the relative strengths of those interactions [173]. These
observations are complicated by the formation of moderately ordered assemblies formed by some
type II cadherins described here, which suggest a potential cis interface, and that cells can ex-
press multiple type II cadherins along with type I cadherins. These systems fall outside of the
differential adhesion hypothesis (DAH) [86], which describes cell adhesion behavior based on the
molecular affinities of a uniform surface of proteins, as adhesion and migration of such cells would
be determined by a combination of homo- and heterophilic adhesion with constituent molecules
possessing differing levels of ordered assembly formation. Any model of cell adhesion, migra-
tion, and sorting must take such complexities into account, which can only truly be done if the
higher-order structural properties of the relevant adhesion molecules are well-defined. For ex-
ample, cadherins-6, -9, and -10 are required for high-magnitude long-term potentiation (LTP) of
hypocampal CA1 and CA3 synapses in a manner dependent upon heterophilic interactions [177].
Pre-synaptic cadherin-9 interacts in trans with post-synaptic cadherins-6 and -10, and cadherins-6
and -10 may also interact in cis. Both of those type II cadherins form at least moderately-ordered
arrays (Fig. 3.3), suggesting these cis interactions are not the formation of multimers, but the poly-
merization of extended arrays. Understanding the mechanisms by which these cadherins drive LTP
will require an understanding of how heterophilic trans interactions interface with the homopilic
arrays seen in Fig. 3.3. If cis interactions between cadherin-6 and cadherin-10 are physiologically
relevant, determining whether these molecules can form heterophilic arrays will be crucial. It is
possible that the homophilic arrays observed here are sufficient, as it seems as though cadherin-6
and cadherin-10 act redundantly to drive high-magnitude LTP [177].
It is highly likely that continued subtomogram averaging efforts will yield a higher-resolution
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reconstruction of the VE-cadherin adhesion assembly. The current average (Fig. 3.7) is from
a single tilt series out of 47 collected. If even 90% of those are not suitable for subtomogram
averaging, the remaining 10% would still increase the amount of data several fold over what has
currently been used. In addition, the current average lacks any CTF correction, a processing step
which is required to reach resolutions beyond approximately 2nm. With domain-level resolution
on the order of 10Å, existing crystal structures of the VE-cadherin trans interface [139] can be
used to build a model of the VE-cadherin adhesion assembly and identify the general location of
the cis interface. This will allow us to identify and test mutations in this region that would produce
the loss of ordered density between liposomes, as was done for the type I cadherins [149].
A confounding result in this study was the low amount of order observed for cadherin-11, -19,
and -20 (Fig. 3.4). During purification, there was evidence of aggregation and protein instability
in the form of precipitation during concentration, and a lack of sharp, monodisperse peaks in SEC
(data not shown). While these data strongly suggest aggregation, this should be confirmed by SEC-
MALS so we can more confidently say the lack of order is not an intrinsic characteristic of these
type II cadherin ectodomains but rather a consequence of their instability in solution.
While liposomes have been a powerful tool in studying cadherin assembly formation, their
large and amorphous state can interfere with data collection as a significant area of the grid is
too thick for imaging. Instead, one could use lipid nanodiscs, i.e. synthetic phospholipid bilayers
formed by covalently circularized amphipathic proteins that form a belt around the outer hydropho-
bic regions of the bilayer. This allows for the creation of large nanodiscs with different shapes
[202], with diameters up to 50-100nm. These flat membranes could reduce the heterogeneity in
these samples and simplify cryo-ET data analysis.
The ultimate goal of many cryo-ET projects is to image the sample in situ. This has been
done numerous times for the desmosomes [155] and could potentially shed light on how classical
cadherins mediate adhesion and signaling. Generally, a suitable tissue will have to be identified
and prepared for cryo-FIB-SEM and/or liftout [203], with adherens junctions likely localized using
cryo-CLEM. Imaging, for example, E-cadherin adherens junctions at high resolution may give us
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more information on how the array couples to actin through α- and ß-catenin.
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Chapter 4: Structures of multiple neutralizing antibodies that target the
SARS-CoV-2 spike glycoprotein
4.1 Preface
The work described until this point, with its emphasis on cellular adhesion, continued until
the end of my 4th year as a PhD candidate. In early March of 2020, I took a weekend vacation
to upstate New York. Relatively isolated in the Catskill Mountains with no wifi and little cell
phone service, I was unaware of what was happening back home. When I returned the country had
changed as rumors of a new disease turned to harsh reality. New York Governor Andrew Cuomo
had declared a state of emergency [204]. We were told to avoid crowded places, like the subways I
took to the lab each day, and the city of New Rochelle was a containment zone [205]. The COVID-
19 pandemic was officially in New York City. For the next year and half, I would do very little
work in the lab and instead switched to collecting and processing cryo-EM data remotely.
Things also changed for the lab. Almost instantly, we began work with David Ho’s lab at the
Aaron Diamond Aids Research Center and Peter Kwong’s group at the NIH’s Vaccine Research
Center on SARS-CoV-2. Soon isolated antibodies from convalescent COVID-19 patients arrived
in the lab and we set out to determine structures of them in complex with the viral spike protein.
My work on adhesion molecules was put on pause to focus on this emerging threat. However, the
work was not entirely new. SPA is a powerful and flexible technique, and in a way, I was expanding
my use of cryo-EM to include a new kind of membrane surface interaction. The biological system
may have changed, but the technique was the same.
After a brief introduction to SARS-CoV-2, which seems almost superfluous given how this
virus has held the planet’s attention for more than a year, this chapter will be divided into four
subchapters. The first will focus on the initial isolation and characterization of SARS-CoV-2
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neutralizing antibodies. The next two will be a more detailed look at certain subsets of related
antibodies, diving into their shared features and how they vary. The final subchapter will look at a
set of antibodies that are capable of neutralizing emerging SARS-CoV-2 variants.
4.2 Introduction
The COVID-19 pandemic, caused by the severe acute respiratory syndrome coronavirus-2
(SARS-CoV-2), has spread to more than 150 million people worldwide and killed some 3 mil-
lion since it emerged in late 2019, as of May 2021 [206]. Efforts to put an end to the pandemic are
currently focused on administration of the multiple vaccines that have been developed [207, 208,
209, 210, 211], with a staggering 1.2 billion doses administered in only 6 months. However, in
the absence of complete eradication, the need for effective treatment of the disease remains. One
approach is the use of monoclonal antibodies as therapeutic agents.
This kind of therapy has been approved to treat respiratory syncytial virus (RSV) [212], human
immunodeficiency virus (HIV) [213], and ebola [214]. Patients infected with SARS-CoV-2 that
develop the COVID-19 disease produce highly-potent monoclonal antibodies against the viral S,
or spike, glycoprotein [215, 216, 217, 218, 219, 220, 221, 222]. This protein mediates fusion of the
viral membrane with the host cell membrane via interaction with angiotensis-converting enzyme
2 (ACE2) [223, 224, 225, 226], a receptor widely expressed in various human tissue [227, 228].
Once bound to ACE2, the spike protein sheds its S1 subunit, prompting a conformational change
in the S2 subunit that initiates the fusion process. Antibodies that bind to this spike protein can
inhibit viral fusion and thus protect against infection. However, the spike is a metastable machine
prone to disassembly, so when studied in vitro, either by cryo-EM or when trying to use it as a
probe to isolate antibodies that bind to it, mutations must be made to stabilize it. The appropriate
mutations, two proline mutations in the S2 subunit, were found years earlier thanks to work done
on MERS-CoV [229] and SARS-CoV-1 [230]. The first 3D model of the SARS-CoV-2 spike was
published a mere 22 days after the genome sequence was made available [231, 232]. Using such a
stabilized spike allowed many groups to isolate neutralizing antibodies against the virus relatively
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early on [215, 216, 217, 218, 219, 220, 221, 222], which can be synthesized and injected as a
therapy or prophylaxis.
This chapter will focus on my structural interrogation of neutralization of SARS-CoV-2 by
patient-derived monoclonal antibodies using cryo-EM.
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4.3 Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike
The first subchapter will look at the initial isolation and characterization of these antibodies,
which were sequenced from memory B cells that were specific to the S trimer, then expressed in
Expi293 cells and purified. Fortunately, structure determination by cryo-EM relies on a relatively
small amount of protein, typically in the range of several micrograms for a single cryo-EM grid,
allowing us to obtain reconstructions from antibody samples that were left over after neutralization
assays.
Though stabilized spike was used [233], we found that protein often looked denatured in our
early micrographs. The key optimization was lowering the pH from 7.4 to 5.5, a discovery which
led to a fascinating project listed in Appendix 1 [234]. SARS-CoV-2 fusion is known to occur at
the cell surface or in the endosome [225, 235], so we determined structures of the SARS-CoV-2
spike alone and in complex with ACE2 at serological and endosomal pH to help explain why some
antibodies bind to, but do not neutralize, the virus.
With a well-behaved spike sample and 19 neutralizing antibodies, our computational infras-
tructure was quickly outpaced by the rate of data collection. To solve this problem, I worked with
colleagues at the Simons Electron Microscopy Center to develop an Amazon Web Services (AWS)-
based processing pipeline that ran cryoSPARC [54] and could be started and expanded on-demand.
This allowed us to begin data processing without having to wait on physical infrastructure to be
built and configured.
Epitope mapping revealed two antigenic domains on the spike protein: the receptor binding
domain (RBD) and the N-terminal domain (NTD). SPA cryo-EM reconstructions of two RBD-
directed antibodies, 2-4 and 2-43, revealed that these antibodies neutralize the virus by occluding
ACE2 binding. In addition, though the initial reconstruction was solved to a lower resolution
(5.8Å), evidence suggested 2-43 bound to a quaternary epitope between two adjacent protomers of
the spike protein. As is described in the next subchapter, this quaternary epitope centered around
a glycosylation at residue N343 [236]. Only one NTD-directed antibody structure was included
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in this study, 4-8, though many more were solved later, the results of which are discussed in sub-
chapter 4.5 [206]. Significant flexibility prevented high-resolution reconstruction of the spike:fab
interface, which was visualized by 3D variability analysis [57]. These results provided our first
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The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic 
continues, with devasting consequences for human lives and the global economy1,2. 
The discovery and development of virus-neutralizing monoclonal antibodies could 
be one approach to treat or prevent infection by this coronavirus. Here we report the 
isolation of sixty-one SARS-CoV-2-neutralizing monoclonal antibodies from five 
patients infected with SARS-CoV-2 and admitted to hospital with severe coronavirus 
disease 2019 (COVID-19). Among these are nineteen antibodies that potently 
neutralized authentic SARS-CoV-2 in vitro, nine of which exhibited very high potency, 
with 50% virus-inhibitory concentrations of 0.7 to 9 ng ml−1. Epitope mapping showed 
that this collection of nineteen antibodies was about equally divided between those 
directed against the receptor-binding domain (RBD) and those directed against the 
N-terminal domain (NTD), indicating that both of these regions at the top of the viral 
spike are immunogenic. In addition, two other powerful neutralizing antibodies 
recognized quaternary epitopes that overlap with the domains at the top of the spike. 
Cryo-electron microscopy reconstructions of one antibody that targets the RBD, a 
second that targets the NTD, and a third that bridges two separate RBDs showed that 
the antibodies recognize the closed, ‘all RBD-down’ conformation of the spike. Several 
of these monoclonal antibodies are promising candidates for clinical development as 
potential therapeutic and/or prophylactic agents against SARS-CoV-2.
The novel coronavirus SARS-CoV-21,2 has caused more than 14 million con-
firmed infections globally, and has caused more than 600,000 deaths. This 
pandemic has also put much of the world on pause, with unprecedented 
disruption of lives and unparalleled damage to the economy. A return 
to some semblance of normality will depend on the ability of science to 
deliver an effective solution, and the scientific community has responded 
admirably. Drug development is well underway, and vaccine candidates 
have entered clinical trials. Another promising approach is the isolation 
of SARS-CoV-2-neutralizing monoclonal antibodies (mAbs) that could be 
used as therapeutic or prophylactic agents. The primary target for such 
antibodies is the viral spike, a trimeric protein3,4 that is responsible for bind-
ing of the virus to the ACE2 receptor on the host cell1,3,5,6. The spike protein 
is comprised of two subunits. The S1 subunit has two major structural ele-
ments, RBD and NTD; the S2 subunit mediates virus–cell membrane fusion 
after the RBD has engaged ACE2. Reports of the discovery of neutralizing 
mAbs that target the RBD have been published recently7–11. We now describe 
our efforts in isolating and characterizing a collection of mAbs that not only 
target multiple epitopes on the viral spike but also show very high potency 
in neutralizing SARS-CoV-2.
Patient selection
Forty patients with PCR-confirmed SARS-CoV-2 infection were enrolled 
in a cohort study on virus-neutralizing antibodies. Plasma samples 
from all participants were first tested for neutralizing activity against 
SARS-CoV-2 pseudovirus (Wuhan-Hu-1 spike pseudotyped with vesicu-
lar stomatitis virus). Neutralizing titres varied widely, with half-maximal 
inhibitory concentrations (IC50s) ranging from a reciprocal plasma dilu-
tion of less than 100 to roughly 13,000 (Fig. 1a). We selected five patients 
for isolation of mAbs because their plasma virus-neutralizing titres were 
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among the highest. The clinical characteristics of these five patients 
are summarized in Extended Data Table 1. All were severely ill with 
acute respiratory distress syndrome requiring mechanical ventilation.
Isolation and construction of mAbs
Peripheral blood mononuclear cells from each patient were processed 
as shown in Extended Data Fig. 1a, starting with cell sorting by flow 
cytometry. The sorting strategy focused on live memory B lymphocytes 
that were CD3−, CD19+, and CD27+ (Extended Data Fig. 1b). The final 
step focused on those cells that bound the SARS-CoV-2 spike trimer (S 
trimer)4. A total of 602, 325, 14, 147, and 145 such B cells from patients 1, 
2, 3, 4, and 5, respectively, were labelled with unique hashtags (Extended 
Data Fig. 1c). The cells were then placed into the 10X Chromium (10X 
Genomics) for single-cell 5′-mRNA and V(D)J sequencing to obtain 
paired heavy (H) and light (L) chain sequences. A careful bioinfor-
matic analysis was carried out on 1,145 paired sequences to downse-
lect ‘high-confidence’ antigen-specific mAbs. We recovered 331 mAb 
sequences, representing 252 individual clones. Only six mAbs were 
from patient 3, whereas 44 to 100 mAbs were identified from each of 
the other patients (Extended Data Fig. 2a). The VH and VL sequences of 
252 antibodies (one per clone) were codon-optimized and synthesized, 
and each VH and VL gene was then cloned into an expression plasmid 
with corresponding constant regions of H chain and L chain of human 
IgG1. Monoclonal antibodies were then expressed by co-transfection 
of paired full-length H chain and L chain genes into Expi293 cells.
Monoclonal antibody screening
All 252 transfection supernatants were screened for binding to the S trimer 
and RBD by enzyme-linked immunosorbent assays (ELISAs), as well as for 
their ability to neutralize SARS-CoV-2 pseudovirus and live virus (Fig. 1b, 
Extended Data Fig. 2). A substantial percentage of the mAbs in the super-
natants bound S trimer, and a subset of those bound RBD. Specifically, 121 
supernatants were scored as positive for S trimer binding, yielding an overall 
hit rate of 48%. Of these, 38 were positive for RBD binding while the remain-
ing 83 were negative. None of the 13 trimer-specific mAbs from patient 5 
recognized RBD. In the pseudovirus neutralization screen, 61 supernatants 
were scored as positive, indicating that half of the trimer-specific mAbs 
were virus-neutralizing. In the screen for neutralization against SARS-CoV-2 
(strain USA-WA1/2020), 41 supernatants were scored as positive. Overall, 
this screening strategy was quite effective in identifying neutralizing mAbs 
(vertical lines and labelled antibodies at the bottom of Fig. 1b) that were 
later identified as potent.
Sequence analysis of S trimer-specific mAbs
Of the 121 mAbs that bound the S trimer, 88% were IgG isotype, with 
IgG1 being predominant (Extended Data Fig. 3a). Comparison to the 
IgG repertoires of three healthy human donors12 revealed a statistically 
significant over-representation of IGHV3-30, IGKV3-20, and IGHJ6 genes 
for this collection of SARS-CoV-2 mAbs (Extended Data Figs. 3b, c). In 
addition, the average CDRH3 length was also longer (Extended Data 
Fig. 3d). Notably, the average percentages of somatic hypermutation 
in VH and VL were 2.1 and 2.5, respectively, which were significantly 
lower than those found in healthy individuals (Extended Data Fig. 3e) 
and remarkably close to those of germline sequences.
Antigen binding and virus neutralization
Since the screening for pseudovirus neutralization was performed 






























































































































Fig. 1 | Isolation of SARS-CoV-2 mAbs from infected patients with severe 
disease. a, Plasma neutralization profile of 40 patients against SARS-CoV-2 
pseudovirus (highlighted are five top neutralizers chosen for further study).  
b, All 252 transfection supernatants were screened for binding to the S trimer 
and RBD, as well as for neutralization against SARS-CoV-2 pseudovirus and live 
virus. For pseudovirus neutralization, the 50% inhibitory dilutions (IC50) of 
each supernatant are plotted. For live virus, semiquantitative representation 
of the inhibition at a dilution of 1:50, with neutralization levels ranging from (−) 
for none to (+++) for complete neutralization, is plotted. Potent antibodies 
later identified are marked by vertical lines and labelled at the bottom. The 
antibodies from each patient are coloured as in a.
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we plotted in Extended Data Fig. 2b the best-fit neutralization curves 
for 130 samples that were positive in at least one of the screens shown 
in Fig. 1b. Most were non-neutralizing or weakly neutralizing, but 18 
showed better potency. One additional supernatant was initially missed 
in the pseudovirus screen (patient 1 in Extended Data Fig. 2b) but was 
later found to be a potent neutralizing mAb. Together, these 19 mAbs 
were purified from transfection supernatants and further characterized 
for their binding and neutralization properties. As shown in Fig. 2a, 
quantitative ELISA showed that all but one (2-43) of the mAbs bound 
the S trimer. Nine of the antibodies clearly bound RBD, with little or no 
binding to NTD. Eight antibodies bound NTD to varying degrees, with 
no binding to RBD. Two mAbs bound neither RBD nor NTD, and were 
therefore categorized as ‘other’.
The pseudovirus neutralization profiles for these purified 19 mAbs 
are shown in Fig. 2b (top). The RBD-directed antibodies neutralized the 
pseudovirus with IC50 values of 0.005 to 0.512 μg ml
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Fig. 2 | Characterization of potent neutralizing mAbs against SARS-CoV-2. 
a, Binding profiles of 19 purified potent neutralizing mAbs against the S trimer 
(left), RBD (middle), and NTD (right) of SARS-CoV-2. Note that mAb 2-30 bound 
multiple proteins at high concentrations. b, Neutralization profiles of the 
pseudovirus (top) and live virus (bottom) for the 19 purified mAbs. Epitope 
classifications are listed above plots. A single replicate of the binding 
experiment and triplicates of neutralization are presented as mean ± s.e.m.
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antibodies were slightly less potent, with IC50 values ranging from 0.013 
to 0.767 μg ml−1. A common feature of the NTD mAbs was the plateauing 
of virus neutralization at levels short of 100%. Two antibodies, catego-
rized as ‘other’, neutralized with IC50 values of 0.071 and 0.652 μg ml
−1. 
Antibody neutralization of the authentic or live SARS-CoV-2 (strain 
USA-WA1/2020) was carried out using Vero cells inoculated with a mul-
tiplicity of infection of 0.1. As shown in the bottom portion of Fig. 2b, 
the RBD-directed antibodies again neutralized the virus but with IC50 
values of 0.0007 to 0.209 μg ml−1; the NTD-directed antibodies showed 
similar potency, with IC50 values ranging from 0.007 to 0.109 μg ml
−1. 
Here, the plateauing effect seen in the pseudovirus neutralization assay 
was less apparent. Antibodies 2-43 and 2-51 neutralized the live virus 
with IC50 values of 0.003 and 0.007 μg ml
−1, respectively. Overall, nine 
mAbs exhibited high potency in neutralizing authentic SARS-CoV-2 
in vitro with IC50 values of 0.009 μg ml
−1 or less, including four against 
RBD (2-15, 2-7, 1-57, and 1-20), three against NTD (2-17, 5-24, and 4-8), 
and two against undetermined regions on the S trimer (2-43 and 2-51). 
Patient 2 alone contributed five of the top nine SARS-CoV-2 neutralizing 
mAbs. A correlation of the results of the two virus-neutralizing assays 
is shown in Extended Data Fig. 4.
Epitope mapping
All 19 potent neutralizing mAbs (Fig. 2) were further studied in antibody 
competition experiments to gain insight into their epitopes. We also 
chose 12 mAbs that bound the S trimer strongly during the initial super-
natant screen, including 5 that bound RBD (1-97, 2-26, 4-13, 4-24, and 
4-29) and 7 that did not bind RBD (1-21, 2-29, 4-15, 4-32, 4-33, 4-41, and 
5-45). Four of these mAbs were weak in neutralizing SARS-CoV-2 pseu-
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2-15 104 256 142 613 671 408 190 248 1,016 1,078 1,063 1,046 897 1,066 975
5-24 350 179 491 448 508 654 503 869 522 750 692 1,032 1,003 866 1,106 1,041 2-4 54 86 76 337 458 568 79 151 1,182 1,124 1,017 1,179 971 1,188 1,099
1-68 149 131 190 322 239 531 389 718 274 385 458 1,304 994 1,067 1,138 985 1-57 92 244 124 627 673 336 128 223 1,123 953 961 905 968 950 957
4-8 319 271 442 247 449 503 441 727 325 549 950 1,573 1,395 1,346 1,245 1,015 2-38 114 101 89 137 236 122 88 108 1,326 754 753 619 1,474 1,839 1,596
2-51 224 158 275 314 220 577 382 705 352 575 614 1,288 1,321 1,367 1,418 1,156 2-30 116 170 111 399 190 1,096 97 141 819 585 939 169 1,079 1,134 1,144
2-17 299 192 409 550 557 478 431 826 324 539 622 894 1,059 871 1,010 1,086 2-7 65 598 72 407 1,002 87 76 1,319 936 1,256 966 1,172 695 909 950
4-18 552 594 673 808 724 571 478 996 652 798 915 988 1,001 1,074 1,013 957 1-20 215 321 242 846 541 816 178 318 320 598 1,220 983 932 938 914
4-19 361 320 423 657 660 539 651 638 844 957 1,076 813 1,283 1,155 973 961 4-20 127 208 151 468 272 834 134 191 157 519 1,327 951 811 958 798
5-7 615 376 691 598 788 937 739 1,196 379 1,438 1,391 799 691 1,016 875 1,053 2-36 855 773 857 776 965 952 179 244 221 576 529 906 794 942 902
4-32 420 339 565 429 488 627 640 1,069 1,325 325 356 570 644 982 1,062 1,066 2-26 1,687 1,543 1,080 905 805 981 236 320 271 308 325 742 441 675 396
4-33 400 281 491 483 516 701 542 1,058 1,320 245 293 385 675 793 1,029 1,000
CR30
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986 945 1,140 718 988 912 1,198 847 147 332 205 552 444 667 173
2-29 1,268 1,035 1,105 1,761 1,404 1,050 969 854 309 415 384 226 833 766 1,633 991 1-97 976 1,039 974 975 873 1,072 950 965 1,006 656 803 169 359 269 162
5-45 1,018 1,044 1,004 1,130 1,097 1,142 1,054 1,026 621 989 1,039 1,031 320 409 926 1,006 4-29 870 995 1,024 1,051 873 906 665 880 724 518 651 179 213 236 102
4-41 1,009 1,003 1,073 969 1,121 915 1,020 987 739 1,035 979 893 373 320 855 1,005 4-24 983 1,149 942 941 1,001 847 742 767 892 551 723 108 191 150 96
4-15 1,082 1,160 1,113 1,019 1,119 1,034 1,040 1,066 689 984 665 1,367 590 514 498 1,681 4-13 978 1,043 996 978 907 960 972 969 981 903 855 465 584 532 298
1-21 1,167 1,078 1,090 990 999 1,056 983 1,036 1,026 1,141 1,036 1,046 1,046 997 1,126 408 ACE2 161 325 219 840 584 145 101 101 136 518 983 843 905 871 1,076
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Fig. 3 | Epitope mapping of select neutralizing and non-neutralizing mAbs. 
a, Competition results of non-RBD binders (left) and RBD binders (right) in 
blocking binding of ACE2 or biotinylated mAb to the S trimer. In addition, the 
ability of each mAb to bind NTD and RBDmut is shown. The numbers in each box 
show the area under each competition curve (AUC) as tested by ELISA. Plus and 
minus signs indicate binding and no binding, respectively, of the mAb to the 
protein. The letters A to H at the bottom denote clusters of antibody epitopes 
defined by the competition experiments. b, Venn diagram interpretation of 
results from a and Extended Data Fig. 6b.
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Fig. 5). We used ELISA to evaluate 16 non-RBD mAbs for competition in 
binding to the S trimer in a ‘checkerboard’ experiment. The extent of 
the antibody competition is reflected by the intensity of the heatmap 
in Fig. 3a. There is one large cluster (A) of mAbs that competed with 
one another, which partially overlaps with a small cluster (B). A third 
cluster (C) does not overlap at all. Note that all but one of the antibodies 
in cluster A recognized NTD. Antibody 2-51 is clearly directed against 
the NTD region even though it could not bind NTD. Moreover, one mAb 
from each of clusters B and C also recognized NTD, thereby indicating 
that all three clusters are within or near the NTD. One mAb, 1-21, appears 
to have a unique non-overlapping epitope (epitope region D).
We carried out a similar ‘checkerboard’ competition experi-
ment by ELISA for 14 of our RBD-directed mAbs plus CR302213,14. 
Here, the heatmap shows four epitope clusters that are serially 
overlapping (Fig. 3a). There is one large cluster (E) that contains 
mAbs that can largely block ACE2 binding. Furthermore, four 
antibodies in this cluster lost the ability to bind to a mutant RBD 
(L455R, A475R, G502R) that could no longer bind ACE2 (unpub-
lished data). Together, these results suggest that most of the 
mAbs in cluster E are directed against the ACE2-binding interface 
of RBD. The next cluster (F) connects to both cluster E and cluster 
G, the location of which is defined by its member CR302215. Last, 
cluster G overlaps another cluster (H), which includes 1-97, which 
strongly inhibited the binding of 2-30 to the S trimer. This finding 
suggests that cluster H may be proximal to one edge of cluster E.
One potent neutralizing mAb, 2-43, did not bind the S trimer in 
ELISA (Fig. 2a) and thus could not be tested in the above competi-
tion experiments. However, 2-43 did strongly bind the S trimer 
when expressed on the cell surface, as determined by flow cytom-
etry (Extended Data Fig. 6a), and this binding was competed out by 
itself but not by RBD, NTD, ACE2, or the soluble S trimer4 (Extended 
Data Fig. 6b). NTD-directed mAbs had only a modest effect on its 
binding to cell-surface S trimer, but numerous RBD-directed mAbs 
in cluster E potently blocked the binding of 2-43, demonstrating 
that this antibody is likely to target a quaternary epitope on the 
top of RBD.
These mapping results could be represented by two sets of Venn 
diagrams shown in Fig. 3b. In the non-RBD region, the potent neutral-
izing mAbs reside exclusively in cluster A and bind a patch on the NTD. 
Weaker neutralizing mAbs recognize a region at the interface between 
clusters A and B. In the RBD region, the most potent neutralizing mAbs 
also group together within one cluster (E). Given that all block ACE2 
binding, it is likely they recognize the top of RBD and neutralize the 
virus by competitive inhibition of receptor binding. Cluster G contains 
CR3022, a mAb known to be directed against an epitope on a cryptic site 
on the side of RBD when it is in the ‘up’ position15. Cluster F is therefore 
likely situated between the top and this ‘cryptic’ site. The Venn diagram 
also suggests that cluster H may occupy a different side surface of RBD, 




























































Fig. 4 | Cryo-EM reconstructions of Fab–spike complexes and visualization 
of neutralizing epitopes on the spike surface. a, Cryo-EM reconstruction of 
2-4 Fab in complex with the S trimer at 3.2 Å overall resolution. Density is 
coloured with RBD in green, NTD in orange, and other regions in grey.  
b, Cryo-EM reconstruction of 4-8 Fab in complex with the S trimer (ribbon 
diagram, coloured as in a) at 3.9 Å overall resolution, with RBDs in the ‘all-down’ 
configuration. c, Cryo-EM reconstruction of the 2-43 Fab in complex with the S 
trimer at 5.8 Å resolution reveals a quaternary epitope involving RBD from one 
subunit and another RBD from the next. d, Mapping of the Venn diagrams from 
Fig. 3b onto the surface of the viral spike.
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Cryo-electron microscopy
We produced cryo-electron microscopy (cryo-EM) reconstructions of 
antigen-binding fragments (Fabs) from three mAbs in complex with the 
S trimer4. First, single-particle analysis of the complex with the Fab of 
mAb 2-4 (RBD-directed) yielded maps of high quality (Fig. 4a; Extended 
Data Table 2; Extended Data Fig. 7a–d), with the most abundant particle 
class representing a 3-Fab-per-trimer complex, refined to an overall 
resolution of 3.2 Å. While density for the constant portion of the Fabs 
was visible, it was blurred as a result of molecular motion, and thus 
only the variable domains were included in the molecular model. Fab 
2-4 bound the spike protein near the apex, with all RBDs in the ‘down’ 
orientation, and the structure of the antibody-bound spike protein was 
highly similar to previously published unliganded spike structures in 
the ‘all-down’ conformation3,4. Detailed interactions between mAb 2-4 
and RBD are shown in Extended Data Fig. 7e–i. Overall, the structure of 
the 2-4 Fab–spike complex shows that neutralization of SARS-CoV-2 by 
this mAb is likely to result from locking the RBD in the down conforma-
tion while also occluding access to ACE2.
We also produced 3D cryo-EM reconstructions of 4-8 Fab 
(NTD-directed) in complex with the S trimer (Extended Data Table 2, 
Extended Data Fig. 8a–f). Two main particle classes were observed—
one for a 3-Fab-bound complex with all RBDs ‘down’ at 3.9 Å resolution 
(Fig. 4b), and another a 3-Fab-bound complex with one RBD ‘up’ at 
4.0 Å resolution (Extended Data Fig. 8g). However, molecular motion 
prevented visualization of the interaction at high resolution. Never-
theless, the density in the 4-8 map reveals the overall positions of the 
antibody chains that target the NTD. It is unclear how binding to the 
tip of the NTD results in neutralization of SARS-CoV-2.
Third, a 5.8 Å resolution reconstruction of 2-43 Fab in complex with 
the S trimer (Extended Data Table 2, Extended Data Fig. 8h–k) revealed 
three bound Fabs, each targeting a quaternary epitope on the top of 
the spike that included elements of the RBDs from two adjacent S1 
protomers (Fig. 4c), consistent with the epitope mapping results 
(Fig. 3b, Extended Data Fig. 6b), including the lack of binding to iso-
lated RBD (Fig. 2a). Given these findings, the inability of 2-43 to bind the 
S trimer in ELISA studies is likely to be an artefact of the assay format, 
as this mAb did bind the spike expressed on the cell surface and in the 
cryo-EM study.
Armed with these three cryo-EM reconstructions, we used the 
Venn diagrams from Fig. 3b to map the epitopes of many of our 
SARS-CoV-2-neutralizing mAbs onto the surface of the spike (Fig. 4d). 
This is obviously a rough approximation because antibody footprints 
are much larger than the area occupied by the mAb number. However, 
the spatial relationship of the antibody epitopes should be reasonably 
represented by Fig. 4d.
mAb 2-15 protects hamsters against SARS-CoV-2
To assess the in vivo potency of mAb 2-15, we performed a protection 
experiment in a golden Syrian hamster model of SARS-CoV-2 infec-
tion. The hamsters were first given an intraperitoneal injection of the 
antibody at a dose of 1.5 mg kg−1 or 0.3 mg kg−1, or PBS alone. Intranasal 
inoculations of 105 plaque-forming units (PFU) of the HKU-001a strain 
of SARS-CoV-2 were carried out 24 h later. Four days after virus chal-
lenge, lung tissues were removed to quantify the viral load. As shown 
in Fig. 5, both viral RNA copy numbers and infectious virus titres were 
reduced by 4 logs or more in hamsters given 1.5 mg kg−1 of mAb 2-15. 
The protection at 0.3 mg kg−1 was borderline, as we had estimated. This 
pilot animal study demonstrates that the potency of mAb 2-15 in vitro is 
reflected in vivo, with complete elimination of infectious SARS-CoV-2 
at a relatively modest antibody dose.
Discussion
We have identified a collection of SARS-CoV-2-neutralizing mAbs that 
are not only potent but also diverse. Nine of these antibodies can neu-
tralize the authentic virus in vitro at concentrations of 9 ng ml−1 or 
less (Fig. 2b), including four directed against the RBD, three directed 
against the NTD, and two directed against nearby quaternary epitopes. 
Unexpectedly, many of the these mAbs have V(D)J sequences close 
to germline sequences, without extensive somatic hypermutations 
(Extended Data Fig. 3e), a finding that bodes well for vaccine devel-
opment. Our most potent RBD-specific mAbs (for example, 2-15, 2-7, 
1-57, and 1-20) compare favourably with such antibodies recently 
reported7,8,10,16–20, including those with high potency9,11,21,22. The in vitro 
potency of 2-15 is well reflected in vivo in the hamster protection experi-
ment (Fig. 5). It appears from the epitope-mapping studies that mAbs 
directed against the top of the RBD compete strongly with ACE2 binding 
and potently neutralize the virus, whereas those directed against the 
side surfaces of the RBD do not compete with ACE2 and neutralize less 
potently (Figs. 3b, 4d). Our collection of non-RBD neutralizing mAbs is 
unprecedented, to our knowledge, in that such antibodies have been 
reported only sporadically and only with substantially lower poten-
cies22–24. The most potent of these mAbs are directed against (for exam-
ple, 2-17, 5-24, and 4-8) or overlapping with (2-51) a patch on the NTD 
(Figs. 3b, 4d). It is unclear how NTD-directed mAbs block SARS-CoV-2 
infection and why their neutralization profiles are different from those 
of RBD-directed antibodies (Fig. 2b). Nevertheless, vaccine strategies 
that do not include the NTD will be unable to induce an important class 
of virus-neutralizing antibodies.
The isolation of two mAbs (2-43 and 2-51) directed against epitopes 
that do not map to the RBD or NTD is also unprecedented, to our knowl-
edge. Cryo-EM of 2-43 Fab bound to the S trimer has confirmed its 
epitope as quaternary in nature, crossing from the top of one RBD to 
the top of another RBD (Fig. 4c). It will be equally informative to under-
stand the epitope of 2-51. We have also shown cryo-EM evidence for a 
neutralizing mAb (4-8) bound to the NTD of the viral spike (Fig. 4b), 
as well as another high-resolution structure of an mAb (2-4) bound to 
the RBD (Fig. 4a).
The potency and diversity of our SARS-CoV-2-neutralizing mAbs 
are probably attributable to patient selection. Infected individuals 
with severe disease develop a more robust virus-neutralizing antibody 
response25. If patient 2 had not been included, five of the top neutral-
izing mAbs would have been lost. The diversity of our antibodies is also 
attributable, in part, to the choice of using the S trimer to sort from 
































Fig. 5 | Efficacy of mAb 2-15 in protecting against SARS-CoV-2 infection in 
lung tissues of hamsters. One day before intranasal challenge with 
SARS-CoV-2, each group of hamsters was given a single intraperitoneal dose of 
1.5 mg kg−1 of mAb 2-15 (n = 4), 0.3 mg kg−1 of mAb 2-15 (n = 4), or saline as control 
(n = 4). The viral loads in the lung tissues on day 4 after viral challenge were 
determined by quantitative PCR with reverse transcription (qRT–PCR; red), as 
well as by an assay to quantify PFUs of infectious SARS-CoV-2 (blue). All data 
points are shown, along with the mean ± s.d. The differences between the 
1.5 mg kg−1 group and the control group are statistically significant at P < 0.05.
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memory B cells, while most groups have used the RBD7,9–11,16–19,21. The 
characterization of this diverse collection of mAbs has allowed us to 
observe that all potent SARS-CoV-2-neutralizing antibodies described 
to date are directed against the top of the viral spike. RBD and NTD 
are, undoubtedly, quite immunogenic. Neutralizing antibodies to 
the stem region of the S trimer remain to be discovered. In conclu-
sion, we believe that several of our monoclonal antibodies with strong 
virus-neutralizing activity are promising candidates for development 
as modalities to treat or prevent SARS-CoV-2 infection.
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Methods
No statistical methods were used to predetermine sample size. The 
experiments were not randomized and the investigators were not 
blinded to allocation during experiments and outcome assessment, 
except where stated.
Expression and purification of SARS-CoV-2 proteins
The mammalian expression vector that encodes the ectodomain of 
the SARS-CoV-2 S trimer and the vector encoding RBD fused with SD1 
at the N terminus and an HRV-3C protease cleavage site followed by a 
mFc tag and an 8 × His tag at the C terminus were kindly provided by 
Jason McLellan4. SARS-CoV-2 NTD (aa1-290) with an HRV-3C protease 
cleavage site, a mFc tag, and an 8 × His tag at the C terminus was also 
cloned into mammalian expression vector pCAGGS. Each expression 
vector was transiently transfected into Expi293 cells using 1 mg/ml 
polyethylenimine (Polysciences). Five days after transfection, the S 
trimer was purified using Strep-Tactin XT Resin (Zymo Research), and 
the RBD-mFc and NTD-mFc were purified using protein A agarose (Ther-
moFisher Scientific). In order to obtain RBD-SD1 and NTD, the mFc 
and 8 × His tags at the C terminus were removed by HRV-3C protease 
(Millipore-Sigma) and then purified using Ni-NTA resin (Invitrogen) 
followed by protein A agarose.
Sorting for S trimer-specific B cells and single-cell B cell 
receptor sequencing
Peripheral blood mononuclear cells from five patients and one 
healthy donor were stained with LIVE/DEAD Fixable Yellow Dead Cell 
Stain Kit (Invitrogen) at ambient temperature for 20 min, followed 
by washing with RPMI-1640 complete medium and incubation with 
10 μg/ml S trimer at 4 °C for 45 min. Afterwards, the cells were washed 
again and incubated with a cocktail of flow cytometry and hashtag 
antibodies, containing CD3 PE-CF594 (BD Biosciences), CD19 PE-Cy7 
(Biolegend), CD20 APC-Cy7 (Biolegend), IgM V450 (BD Biosciences), 
CD27 PerCP-Cy5.5 (BD Biosciences), anti-His PE (Biolegend), and 
human Hashtag 3 (Biolegend) at 4 °C for 1 h. Stained cells were then 
washed, resuspended in RPMI-1640 complete medium and sorted 
for S trimer-specific memory B cells (CD3−CD19+CD27+S trimer+ live 
single lymphocytes). The sorted cells were mixed with mononuclear 
cells from the same donor, labelled with Hashtag 1, and loaded into the 
10X Chromium chip of the 5′ Single Cell Immune Profiling Assay (10X 
Genomics) at the Columbia University Human Immune Monitoring 
Core (HIMC; RRID:SCR_016740). The library preparation and quality 
control were performed according to the manufacturer’s protocol and 
sequenced on a NextSeq 500 sequencer (Illumina).
Identification of S trimer-specific antibody transcripts
For each sample, full-length antibody transcripts were assembled using 
the VDJ module in Cell Ranger (version 3.1.0, 10X Genomics) with default 
parameters and the GRCh38 genome as reference. To identify cells 
from the antigen sort, we first used the count module in Cell Ranger 
to calculate copies of all hashtags in each cell from the Illumina NGS 
raw reads. High-confidence antigen-specific cells were identified as 
follows. In brief, based on the copy numbers of the hashtags observed, 
a cell must contain more than 100 copies of the antigen sort-specific 
hashtag to qualify as an antigen-specific cell. Because hashtags can 
fall off cells and bind to cells from a different population in the sam-
ple mixture, each cell usually has both sorted and spiked-in-specific 
hashtags. To enrich for true antigen-specific cells, the copy number 
of the specific hashtag has to be at least 1.5× higher than that of the 
non-specific hashtag. Low-quality cells were identified and removed 
using the cell-calling algorithm in Cell Ranger. Cells that did not have 
productive H and L chain pairs were excluded. If a cell contained more 
than two H or/and L chain transcripts, the transcripts with fewer than 
three unique molecular identifiers were removed. Cells with identical 
H and L chain sequences, which may have resulted from mRNA leakage, 
were merged into one cell. Additional filters were applied to remove 
low-quality cells and/or transcripts in the antibody gene annotation 
process.
Antibody transcript annotation and selection criteria
Antigen-specific antibody transcripts were processed using our bio-
informatics pipeline SONAR for quality control and annotation26. In 
brief, V(D)J genes were assigned for each transcript using BLAST27 with 
customized parameters against a germline gene database obtained 
from the international ImMunoGeneTics information system (IMGT) 
database26,28. On the basis of BLAST alignments of V and J regions, CDR3 
was identified using the conserved second cysteine in the V region 
and WGXG (H chain) or FGXG (L chain) motifs in the J region (X repre-
sents any amino acid). For H chain transcripts, the constant domain 1 
(CH1) sequences were used to assign isotype using BLAST with default 
parameters against a database of human CH1 genes obtained from 
IMGT. A BLAST E-value threshold of 10−6 was used to find significant iso-
type assignments, and the CH1 allele with the lowest E-value was used. 
Sequences other than the V(D)J region were removed and transcripts 
containing incomplete V(D)J or/and frame shift were excluded. We then 
aligned each of the remaining transcripts to the assigned germline V 
gene using CLUSTALO29 and calculated the somatic hypermutation 
level.
To select representative antibodies for functional characterization, 
we first clustered all antibodies using USEARCH30 with the following 
criteria: identical heavy chain V and J gene assignments, the same length 
of CDRH3, and CDRH3 identity higher than 0.9. For each cluster, cells 
with the same light chain V and J gene assignments were grouped into 
a clone. All clone assignments were manually checked. We then calcu-
lated the clonal size for each clone, and one H and L chain pair per clone 
was chosen for antibody synthesis. For clones with multiple members, 
the member with the highest somatic hypermutation level was chosen 
for synthesis. For cells having multiple high quality H or L chains, which 
may be from doublets, we synthesized all H and L chain combinations.
Analysis of S trimer-specific antibody repertoire
Because 88% of the S trimer-specific antibodies were IgG isotype, 
we compared the repertoire features to IgG repertoires from three 
healthy donors12 (17,243 H chains, 27,575 kappa L chains, 20,889 lambda 
L chains). The repertoire data from the three healthy donors were com-
bined and annotated using SONAR with the same process as above.
Antibody expression and purification
For each antibody, variable genes were optimized for human cell 
expression and synthesized by GenScript. VH and VL were inserted 
separately into plasmids (gWiz or pcDNA3.4) that encode the constant 
region for H chain and L chain. Monoclonal antibodies were expressed 
in Expi293 (ThermoFisher, A14527) by co-transfection of H chain and 
L chain expressing plasmids using polyethylenimine and culture at 
37 °C with shaking at 125 rpm and 8% CO2. On day 3 after transfection, 
400 μl supernatant were collected for screening for binding to the S 
trimer and RBD by ELISA, and for neutralization of SARS-CoV-2 pseu-
dovirus and authentic virus. Supernatants were also collected on day 
5 for antibody purification using rProtein A Sepharose (GE, 17-1279-01) 
affinity chromatography.
Production of pseudoviruses
Recombinant Indiana vesicular stomatitis virus (rVSV) expressing 
the SARS-CoV-2 spike was generated as previously described31,32. 
HEK293T cells were grown to 80% confluency before transfection 
with pCMV3-SARS-CoV-2-spike (Sino Biological) using FuGENE 6 
(Promega). Cells were cultured overnight at 37 °C with 5% CO2. The 
next day, medium was removed and VSV-G pseudotyped ΔG-luciferase 
(G*ΔG-luciferase, Kerafast) was used to infect the cells in DMEM at a 
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MOI of 3 for 1 h before the cells were washed three times with 1× DPBS. 
DMEM supplemented with 2% fetal bovine serum, 100 IU/ml of penicil-
lin and 100 μg/ml of streptomycin were added to the inoculated cells, 
which were cultured overnight as described above. The supernatant 
was removed the following day and clarified by centrifugation at 300g 
for 10 min before aliquoting and storing at −80 °C.
Pseudovirus neutralization
Neutralization assays were performed by incubating pseudovi-
ruses with serial dilutions of heat-inactivated plasma together with 
supernatant or purified antibodies, and scored by the reduction in 
luciferase gene expression. In brief, Vero E6 cells (ATCC) were seeded in 
a 96-well plate at a concentration of 2 × 104 cells per well. Pseudoviruses 
were incubated the next day with serial dilutions of the test samples 
in duplicate or triplicate for 30 min at 37 °C. The mixture was added 
to cultured cells and incubated for an additional 24 h. The lumines-
cence was measured using a Britelite plus Reporter Gene Assay System 
(PerkinElmer). IC50 was defined as the dilution at which the relative light 
units were reduced by 50% compared with the virus control wells (virus 
+ cells) after subtraction of the background in the control groups with 
cells only. The IC50 values were calculated using nonlinear regression 
in GraphPad Prism 8.0.
Authentic SARS-CoV-2 neutralization
Supernatants containing expressed mAbs were diluted 1:10 and 1:50 in 
EMEM with 7.5% inactivated fetal calf serum and incubated with authen-
tic SARS-CoV-2 (strain USA-WA1/2020; MOI 0.1) for 1 h at 37 °C. After 
incubation, the mixture was transferred onto a monolayer of Vero-E6 
cells that was cultured overnight. After incubation of the cells with 
the mixture for 70 h at 37 °C, cytopathic effects (CPEs) caused by the 
infection were scored for each well from 0 to 4 to indicate the degree 
of virus inhibition. Semi-quantitative representation of the inhibition 
for each antibody-containing supernatant at a dilution of 1:50 is shown 
in the lowest panel of Fig. 1b with neutralization levels ranging from (−) 
for none to (+++) for complete neutralization.
An end-point dilution assay in a 96-well plate format was performed to 
measure the neutralization activity of select purified mAbs. In brief, each 
antibody was serially diluted (fivefold dilutions) starting at 20 μg/ml. 
Triplicates of each mAb dilution were incubated with SARS-CoV-2 at a 
MOI of 0.1 in EMEM with 7.5% inactivated fetal calf serum for 1 h at 37 °C. 
After incubation, the virus–antibody mixture was transferred onto a 
monolayer of Vero-E6 cells grown overnight. The cells were incubated 
with the mixture for 70 h. CPEs were visually scored for each well in a 
blinded fashion by two independent observers. The results were then 
converted into percentage neutralization at a given mAb concentra-
tion, and the averages ± s.e.m. were plotted using a five-parameter 
dose–response curve in GraphPad Prism 8.0.
Epitope mapping by ELISA
We coated 50 ng per well of S trimer, 50 ng per well of RBD, and 100 ng 
per well of NTD onto ELISA plates at 4 °C overnight. The ELISA plates 
were then blocked with 300 μl blocking buffer (1% BSA and 10% bovine 
calf serum (BCS) (Sigma)) in PBS at 37 °C for 2 h. Afterwards, superna-
tants from the antibody transfection or purified antibodies were serially 
diluted using dilution buffer (1% BSA and 20% BCS in PBS), incubated at 
37 °C for 1 h. Next, 100 μl of 10,000-fold diluted Peroxidase AffiniPure 
goat anti-human IgG (H+L) antibody ( Jackson ImmunoResearch) was 
added into each well and incubated for 1 h at 37 °C. The plates were 
washed between each step with PBST (0.5% Tween-20 in PBS). Finally, 
the TMB substrate (Sigma) was added and incubated before the reac-
tion was stopped using 1 M sulfuric acid. Absorbance was measured 
at 450 nm.
For the competition ELISA, purified mAbs were biotin-labelled using 
One-Step Antibody Biotinylation Kit (Miltenyi Biotec) following the 
manufacturer’s recommendations and purified using 40K MWCO 
Desalting Column (ThermoFisher Scientific). Serially diluted com-
petitor antibodies (50 μl) were added into S trimer-precoated ELISA 
plates, followed by 50 μl of biotinylated antibodies at a concentration 
that achieves an OD450 reading of 1.5 in the absence of competitor anti-
bodies. Plates were incubated at 37 °C for 1 h, and 100 μl of 500-fold 
diluted Avidin-HRP (ThermoFisher Scientific) was added into each well 
and incubated for another 1 h at 37 °C. The plates were washed with 
PBST between each of the previous steps. The plates were developed 
afterwards with TMB and absorbance was read at 450 nm after the 
reaction was stopped.
For the ACE2 competition ELISA, 100 ng of ACE2 protein (Abcam) was 
immobilized on the plates at 4 °C overnight. The unbound ACE2 was 
washed away by PBST and then the plates were blocked. After washing, 
100 ng of S trimer in 50 μl dilution buffer was added into each well, 
followed by addition of another 50 μl of serially diluted competitor 
antibodies and then incubation at 37 °C for 1 h. The ELISA plates were 
washed four times with PBST and then 100 μl of 2,000-fold diluted 
anti-strep-HRP (Millipore Sigma) was added into each well for another 
1 h at 37 °C. The plates were then washed and developed with TMB, and 
absorbance was read at 450 nm after the reaction was stopped.
For all the competition ELISA experiments, the relative binding of 
biotinylated antibodies or ACE2 to the S trimer in the presence of com-
petitors was normalized by comparing to competitor-free controls. 
Relative binding curve and the area under curve (AUC) were gener-
ated by fitting the nonlinear five-parameter dose–response curve in 
GraphPad Prism 8.0.
Cell-surface competition binding assay
Expi293 cells were co-transfected with vectors encoding 
pRRL-cPPT-PGK-GFP (Addgene) and pCMV3-SARS-CoV-2 (2019-nCoV) 
Spike (Sino Biological) at a ratio of 1:1. Two days after transfection, 
cells were incubated with a mixture of biotinylated mAb 2-43 (0.25 
μg/ml) and serially diluted competitor antibodies at 4 °C for 1 h. Then 
100 μl of diluted APC-streptavidin (Biolegend) was added to the cells 
and incubated at 4 °C for 45 min. Cells were washed three times with 
FACS buffer before each step. Finally, cells were resuspended and 
binding of 2-43 to cell-surface S trimer was quantified on an LSRII flow 
cytometer (BD Biosciences). The mean fluorescence intensity of APC 
in GFP-positive cells was analysed using FlowJo and the relative binding 
of 2-43 to the S trimer in the presence of competitors was calculated as 
the percentage of the mean fluorescence intensity compared to that 
of the competitor-free controls.
Cryo-EM data collection and processing
SARS-CoV-2 S trimer at a final concentration of 2 mg/ml was incu-
bated with sixfold molar excess per spike monomer of the antibody 
Fab fragments for 30 min in 10 mM sodium acetate pH 5.5, 150 mM 
NaCl, and 0.005% n-dodecyl-β-d-maltoside (DDM). Sample (2 μl) was 
incubated on C-flat 1.2/1.3 carbon grids for 30 s and vitrified using 
a Leica EM GP Plunge Freezer. Data were collected on a Titan Krios 
electron microscope operating at 300 kV equipped with a Gatan K3 
direct detector and energy filter using the Leginon software package33. 
A total electron fluence of 51.3 e/Å2 was fractionated over 40 frames, 
with a total exposure time of 2 s. A magnification of 81,000× resulted 
in a pixel size of 1.058 Å, and a defocus range of −0.4 to −3.5 μm was 
used. All processing was done using cryoSPARC v2.14.234. Raw movies 
were aligned and dose-weighted using patch motion correction, and 
the CTF was estimated using patch CTF estimation. A small subset of 
approximately 200 micrographs were picked using blob picker, fol-
lowed by 2D classification and manual curation of particle picks, and 
used to train a Topaz neural network35. This network was then used to 
pick particles from the remaining micrographs, which were extracted 
with a box size of 384 pixels.
For the 2-4 Fab dataset, 2D classification followed by ab initio mod-
elling and 3D heterogeneous refinement revealed 83,927 particles 
with three 2-4 Fabs bound, one to each RBD. A reconstruction of these 
particles using non-uniform refinement with imposed C3 symmetry 
resulted in a 3.6 Å map, as determined by the gold standard Fourier shell 
correlation (FSC). Given the relatively low resolution of the RBD–Fab 
interface, masked local refinement was used to obtain a 3.5 Å map with 
improved density. A masked local refinement of the remainder of the S 
trimer resulted in a 3.5 Å reconstruction. These two local refinements 
were aligned and combined using the vop maximum function in UCSF 
Chimera36. This was repeated for the half maps, which were used, along 
with the refinement mask from the global non-uniform refinement, to 
calculate the 3D FSC37 and obtain an estimated resolution of 3.2 Å. All 
maps have been submitted to the EMDB with the ID EMD-22156.
For the 4-8 Fab dataset, image preprocessing and particle picking 
were performed as above. 2D classification, ab initio modelling, and 
3D heterogeneous classification revealed 47,555 particles with 3 Fabs 
bound, one to each NTD and with all 3 RBDs in the down conforma-
tion. While this particle stack was refined to 3.9 Å using non-uniform 
refinement with imposed C3 symmetry, substantial molecular motion 
prevented the visualization of the Fab epitope at high resolution 
(EMD-22159). In addition, 105,278 particles were shown to have 3 Fabs 
bound, but with 1 RBD in the up conformation. These particles were 
refined to 4.0 Å using non-uniform refinement with C1 symmetry 
(EMD-22158), and suffered from the same conformational flexibility 
as the all-RBD-down particles. This flexibility was visualized using 3D 
variability analysis in cryoSPARC.
For the 2-43 Fab dataset, which was collected at an electron fluence 
of 51.69 e/Å2, image preprocessing was performed as above, and par-
ticle picking was performed using blob picker. 2D classification, ab 
initio modelling, and 3D heterogeneous classification revealed 10,068 
particles with 3 Fabs bound, which was refined to 5.8 Å resolution 
(EMD-22157).
Cryo-EM model fitting
An initial homology model of the 2-4 Fab was built using Schrodinger 
Release 2020-2: BioLuminate38. The RBD was initially modelled using 
the coordinates from PDB ID 6W41. The remainder of the S trimer was 
modelled using the coordinates from PDB ID 6VSB. These models 
were docked into the consensus map using Chimera. The model was 
then fitted interactively using ISOLDE 1.0b539 and COOT 0.8.9.240, and 
using real space refinement in Phenix 1.1841. In cases where side chains 
were not visible in the experimental data, they were truncated to ala-
nine. Validation was performed using Molprobity42 and EMRinger43. 
The model was submitted to the PDB with the ID 6XEY. Figures were 
prepared using ChimeraX44.
Hamster protection experiment
In vivo evaluation of mAb 2-15 in an established golden Syrian hamster 
model of SARS-CoV-2 infection was performed as described previously 
with slight modifications45. Approval was obtained from the University 
of Hong Kong (HKU) Committee on the Use of Live Animals in Teaching 
and Research. In brief, 6–8-week-old male and female hamsters were 
obtained from the Chinese University of Hong Kong Laboratory Animal 
Service Centre through the HKU Laboratory Animal Unit and kept in 
biosafety level-2 (BSL-2) housing with access to standard pellet feed and 
water ad libitum until virus challenge in the BSL-3 animal facility. Each 
hamster (n = 4 per group) was intraperitoneally administered one dose 
of 1.5 mg/kg of mAb 2-15 in phosphate-buffered saline (PBS), 0.3 mg/kg 
of mAb 2-15 in PBS, or PBS alone as control. Twenty-four hours later, 
each hamster was intranasally inoculated with a challenge dose of 100 
μl Dulbecco’s modified Eagle medium containing 105 PFU of SARS-CoV-2 
(HKU-001a strain, GenBank accession no: MT230904.1) under intra-
peritoneal ketamine (200 mg/kg) and xylazine (10 mg/kg) anaesthesia. 
The hamsters were monitored twice daily for clinical signs of disease 
and killed on the fourth day after the challenge. Half of each hamster’s 
lung tissue was used for viral load determination by a quantitative 
SARS-CoV-2 RdRp/Hel RT–PCR assay46 and an infectious virus titration 
using a plaque assay described previously45. Student’s t-test was used 
to determine significant differences among the groups, and P < 0.05 
was considered statistically significant.
Ethics statement
The acquisition of samples from recovering patients for isolation and 
identification of potent monoclonal antibodies against COVID-19 
(AAAS9517) was approved by the Columbia University Institutional 
Review Board. Informed consent was obtained from all participants 
or surrogates.
Reporting summary
Further information on research design is available in the Nature 
Research Reporting Summary linked to this paper.
Data availability
The 19 neutralizing antibodies have been deposited in GenBank 
(https://www.ncbi.nlm.nih.gov/genbank/) with accession numbers 
from MT712278 to MT712315. Coordinates for the antibody 2-4 complex 
have been deposited in the Protein Data Bank as PDB 6XEY. Cryo-EM 
maps and data have been deposited in EMDB with deposition codes 
EMDB-22156 for antibody 2-4, EMDB-22158 and EMDB-22159 for anti-
body 4-8, and EMDB-22275 for antibody 2-43. These data are used in 
Fig. 4 and Extended Data Figs. 7, 8.
Code availability
Next-generation sequencing data of antibody repertoires were 
processed using Cell ranger v3.1.0, SONAR V1, BLAST v2.2.25, 
CLUSTALO1.2.3, and USEARCH v9.2.64. Cryo-EM data was collected 
using Leginon 3.4.beta. Cryo-EM data was processed using cryoSPARC 
v2.14.2, MotionCor2, Topaz v0.2.4, 3DFSC v3.0, UCSF Chimera v1.13.1, 
ChimeraX v0.93, ISOLDE v1.0b5, Phenix v1.18, and COOT v0.8.9.2.
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Extended Data Fig. 1 | SARS-CoV-2 S trimer-specific antibody isolation 
strategy. a, Schema for isolating of S trimer-specific mAbs from memory B 
cells in the blood of infected patients. b, Sorting results on the isolation of S 
trimer-specific memory B cells using flow cytometry. c, Magnified 
representation of the panel of S trimer-positive memory B cells for each 
patient. Inset numbers indicate the absolute number and the percentage of S 
trimer-specific memory B cells isolated from each case.
Article
Extended Data Fig. 2 | Summary of mAb screening of transfection 
supernatants. a, Numbers of binding and neutralizing antibodies from 
patients 1 to 5. b, The best-fit pseudovirus neutralization curves for 130 
samples that were positive in at least one of the screens shown in Fig. 1b.  
The 18 transfection supernatants that showed evidently better potency are 
highlighted in colours, while others with non-neutralizing or weakly 
neutralizing activities are shown in grey. One additional supernatant (Patient 1) 
that was initially missed in the pseudovirus screen but later found to be a 
potent neutralizing mAb (1-87) is also highlighted.
Extended Data Fig. 3 | See next page for caption.
Article
Extended Data Fig. 3 | Genetic features of SARS-CoV-2-specific antibody 
repertoire. a, 108 of the 123 antigen-specific antibodies are from IgG isotype. 
The kappa and lambda light chains are comparably used. b, Compared to IgG 
repertoires of healthy human donors (17,243, 27,575, and 20,889 transcripts for 
heavy, kappa, and lambda chains respectively), IGHV3-30 (antigen-specific 
n = 26 and healthy donor n = 1117) and IGKV3-20 genes (antigen-specific n = 15 
and healthy donor n = 4,071) are over-represented in heavy and light chain 
repertoires respectively (P values are 6.415 × 10−11 and 0.04332 respectively,  
χ2-test with 1 degree of freedom). We did not test the enrichment of other genes 
because the numbers of antigen-specific antibodies are less than 15. c, The 
usage of IGHJ6 gene (antigen-specific n = 36 and healthy donor n = 3646) was 
significantly higher in antigen-specific antibodies (χ2-test with 1 degree of 
freedom, P = 0.02807). d, The CDRH3 length of antigen-specific antibodies is 
significantly longer than in healthy donors (two-sided Kolmogorov–Smirnov 
test, P = 0.014). e, For both heavy and light chains, the V region nucleotide 
somatic hypermutation levels are significantly lower than in antibodies of 
healthy donors (two-sided Kolmogorov–Smirnov test, P < 2.2  × 10−16 for both 
heavy and light chains). For the boxplots, the middle lines are medians. The 
lower and upper hinges correspond to the first and third quartiles respectively. 
The upper whisker extends to values no larger than 1.5× IQR (the interquartile 
range or distance between the first and third quartiles) from the hinge. The 
lower whisker extends to values no smaller than 1.5× IQR from the hinge. Data 
points beyond the whiskers were plotted as outliers using dots.
Extended Data Fig. 4 | Correlation of neutralizing antibody titres of the top 
19 mAbs in the live SARS-CoV-2 assay versus the pseudovirus assay. Green 
circles represent RBD-directed antibodies; orange circles represent 
NTD-directed antibodies; and black circles represent antibodies in the ‘Others’ 
category. The Pearson correlation coefficient (R) and the p value were 
calculated using GraphPad Prism. Experiments were performed in triplicates 
for all mAbs tested.
Article
Extended Data Fig. 5 | The pseudovirus neutralization profiles for 12 
purified mAbs that strongly bound the S trimer but with weak or no 
virus-neutralizing activities. The four mAbs with weak neutralizing activities 
against SARS-CoV-2 pseudovirus are shown in sold lines, and the remaining 8 
non-neutralizing mAbs are shown in dashed lines.
Extended Data Fig. 6 | Cell-surface staining with antibodies. a, Antibody 
binding to the SARS-CoV-1 (blue) and SARS-CoV-2 (red) spike proteins 
expressed on the cell surface. Expi293 cells were co-transfected with GFP and 
full-length SARS-CoV-1 or SARS-CoV-2 spike genes. After 48 h, antibody binding 
to spike protein in the GFP-positive cells was detected by flow cytometer.  
The data show all antibodies tested were able to recognize the wildtype 
SARS-CoV-2 spike protein but not SARS-CoV-1 spike protein. b, Monoclonal Ab 
2-43 bound to S trimer expressed on Expi293 cell surface can be competed out 
by mAbs directed against RBD but only minimally by mAbs to the NTD region. 
Shown are representative data from three independent experiments.
Article
Extended Data Fig. 7 | Cryo-EM analysis of antibody 2-4 in complex with the 
S trimer. a, Representative micrograph and CTF of the micrograph. 8,324 
micrographs were collected in total. b, Representative 2D class averages.  
c, Resolution of the consensus map with C3 symmetry as calculated by 3DFSC. 
d, The local resolution of the full map as calculated by cryoSPARC at an FSC 
cutoff of 0.5. e, Representative density of the Fab 2-4 (blue) and RBD (green) 
interface, showing interactions of CDR H3 in red, L1 in magenta, and L3 in light 
magenta (left), along with CDR H2 and the N-linked glycosylation added by 
SHM at ASN58 (right). f, Fab 2-4 binding interface with RBD. VH is shown in blue, 
VL in light blue, with CDRs H1 in orange, H2 in yellow, H3 in red, L1 in magenta, 
and L3 in light magenta. g, Positions of antibodies 2-4, S3098, and BD-239 on the 
trimeric CoV-2 spike. h, Antibody BD-239 in complex with S trimer. i, Somatic 
hypermutations found only in the antibody 2-4 heavy chain, shown in brown. 
The mutation A60T creates an NxT sequence leading to N58 glycosylation.
Extended Data Fig. 8 | Cryo-EM data processing for antibodies 4-8 and 2-43 
in complex with S trimer. a, Representative 4-8 micrograph and CTF of the 
micrograph. 3,153 micrographs were collected in total. b, Representative 2D 
class averages. c, Resolution of the spike in the RBD down conformation in 
complex with Fab 4-8. d, Resolution of the spike in the RBD up conformation in 
complex with Fab 4-8. e, Local resolution of the spike in the RBD down 
conformation in complex with Fab 4-8 at an FSC cutoff of 0.5, with two 
thresholds shown. f, Local resolution of the spike in the RBD up conformation 
in complex with Fab 4-8 at an FSC cutoff of 0.5, with two thresholds shown.  
g, Although the map was reconstructed at 4.0Å resolution, density for 4-8 Fab 
is poor due to molecular motion. A rigid body fit with SARS-CoV-2 spike and an 
antibody variable domain model is shown. h–k, Cryo-EM data processing for 
antibody 2-43 in complex with the S trimer. h, Representative 2-43 micrograph 
and CTF of the micrograph. i, Representative 2D class averages. j, Resolution of 
Fab 2-43 in complex with S trimer. k, The local resolution of the full map as 
calculated by cryoSPARC at an FSC cutoff of 0.5.
Article
Extended Data Table 1 | Patient information
ARDS, acute respiratory distress syndrome; MV, mechanical ventilation; hsCRP, high sensitivity C-reactive protein, ULN >10 mg/l; ESR, erythrocyte sedimentation rate, ULN = 20 mm/h;  
Interleukin 6, ULN = 5 pg/ml; Ferritin, ULN = 150 ng/ml; D-dimer quantitative ULN = 0.8 ug/ml FEU.
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4.4 Modular basis for potent SARS-CoV-2 neutralization by a prevalent VH1-2-derived
antibody class
Antibodies with heavy chains derived from the VH1-2 gene are the second-most common in
patients infected with SARS-CoV-2. In many studies, they are also the most potent [218, 237, 219,
222, 221], with IC50 values as low as 0.0007μg/ml. Our work showed that these antibodies recog-
nize nearly identical epitopes, though the exact orientation of the light chain varied. Interestingly,
these antibodies achieve their significant potency with very little somatic hypermutation, though
the mutations present do improve binding to the spike.
As was initially observed in Liu et al. (2020), the glycosylation at N343 on the spike protein
plays an important role in recognition by the VH1-2 class. The high-resolution structure of 2-4
revealed minor contacts with the N343 glycosylation, as was evidenced by the presence of F(ab)
bound to the RBD in either the ‘up’ or the ‘down’ conformation, with the latter being the only
one compatible with recognition of the glycan. Thus, these interactions are not essential for 2-
4-mediated neutralization. On the other hand, antibody 2-43 forms extensive contacts with the
N343 glycan, as is discussed in this section. Not only does the atomic model reveal a network
of hydrogen bonds, but cryo-EM analysis revealed no populous classes with F(ab) bound to an
‘up’ RBD, suggesting binding to the N343 glycan is critical for this antibody. This interaction is
mediated by a very long CDRH3 loop, a critical module for VH1-2-derived antibody neutraliza-
tion. At the opposite end of the ‘quaternary recognition’ spectrum is antibody H4. The cryo-EM
reconstruction presented here is resolved to 5.1Å, and during processing no classes were obtained
with F(ab) bound to a ‘down’ RBD. With an IC50 of 0.896μg/ml, it is possible that compatibility
with binding to ‘down’ RBD or both ‘up’ and ‘down’ is important for the high potency of the other
VH1-2 members.
Indeed, the most potent antibody in our initial study [218], 2-15, binds to both RBD ‘up’ and
‘down’ according to the cryo-EM analysis in this subchapter. Unfortunately, the complex was only
resolved to 5.9Å. This is primarily due to significant spike disassembly in the presence of excess
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2-15 F(ab). Initial experiments used a 9:1 molar ratio of F(ab):spike, typical of our other samples.
2D classification revealed almost no intact spike (Fig. S2 [236]). Only when we reduced the
molar ratio to 1:1 did we see intact spike and F(ab) complexes, though there were still a significant
number of disassembled spike trimers. These data, though preliminary, suggest 2-15 may achieve
its significant potency not only by occluding ACE2 binding but by destabilizing the spike trimer,
perhaps causing it to transition into the post-fusion conformation prematurely. While the cryo-
EM reconstruction provides no definitive answers, one possibility is that the CDRH3 loop repels
the N343 glycan, a hypothesis supported by the far more extended conformation of CDRH3 in
the crystal structure compared to the density observed in our cryo-EM reconstruction, and at high
enough concentrations this can destabilize the spike. Understanding the structural basis for the
high potency of 2-15 is a notable direction for further research.
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SUMMARY
Antibodies with heavy chains that derive from the VH1-2 gene constitute some of the most potent severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-neutralizing antibodies yet identified. To provide
insight into whether these genetic similarities inform commonmodes of recognition, we determine the struc-
tures of the SARS-CoV-2 spike in complex with three VH1-2-derived antibodies: 2-15, 2-43, and H4. All three
use VH1-2-encoded motifs to recognize the receptor-binding domain (RBD), with heavy-chain N53I-
enhancing binding and light-chain tyrosines recognizing F486RBD. Despite these similarities, class members
bind both RBD-up and -down conformations of the spike, with a subset of antibodies using elongated
CDRH3s to recognize glycan N343 on a neighboring RBD—a quaternary interaction accommodated by an
increase in RBD separation of up to 12 Å. The VH1-2 antibody class, thus, uses modular recognition encoded
by modular genetic elements to effect potent neutralization, with the VH-gene component specifying recog-
nition of RBD and the CDRH3 component specifying quaternary interactions.
INTRODUCTION
Studies on human antibody responses to viral pathogens,
including HIV-1, influenza, Ebola, and malaria, have revealed
prominent classes of similar neutralizing antibodies (nAbs),
which arise commonly in numerous individuals in response to
infection or vaccination (Ehrhardt et al., 2019; Imkeller et al.,
2018; Joyce et al., 2016; Kallewaard et al., 2016; Pappas et al.,
2014; Zhou et al., 2013, 2015). Such multi-donor antibody clas-
ses are defined based on similar V(D)J gene recombination and
similar modes of structural recognition—with this combination
indicative of a common evolutionary process in antibody devel-
opment (Kwong and Mascola, 2012). Multi-donor antibody clas-
ses are thought to arise based on effective function, combined
with genetic accessibility because of class requirements for
V(D)J recombination and somatic hypermutations of sufficient
frequency to be present in the antibody human repertoire.
Some multi-donor antibody classes are potent, broadly neutral-
izing, and frequent in human antibody repertoire (Imkeller et al.,
2018; Joyce et al., 2016; Zhou et al., 2013). A prominent mode
of rational vaccine design, ‘‘lineage-based vaccine design,’’ en-
deavors to elicit such antibody classes by vaccination (Haynes
et al., 2012; Jardine et al., 2013; Kwong and Mascola, 2018),
and this approach to human vaccination has recently entered
clinical assessment (Diemert and McElrath, 2018).
Severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2), the causative agent of the ongoing coronavirus disease
2019 (COVID-19) pandemic, has infected more than 80 million
people and has claimed over 1 million deaths since the outbreak
began in late 2019 (Dong et al., 2020; Zhou et al., 2020; Zhu et al.,
2020). Therapies and vaccines are urgently needed to end the
pandemic. Many nAbs have now been isolated from COVID-19
convalescent donors, with the most potent nAbs showing prom-
ise as prophylactic or therapeutic agents (Brouwer et al., 2020;
Chen et al., 2020; Kreer et al., 2020; Liu et al., 2020a; Robbiani
et al., 2020; Rogers et al., 2020; Tortorici et al., 2020; Zost
et al., 2020). This growing set of nAbs provides an opportunity
to identify effective human antibody responses to SARS-CoV-2
common in the population, which will inform therapeutic strate-
gies and help to interpret vaccine readouts.
SARS-CoV-2 nAbs predominantly target the viral spike glyco-
protein, which interacts with angiotensin-converting enzyme 2
(ACE2) receptors on the host-cell surface to mediate virus entry
(Hoffmann et al., 2020; Wang et al., 2020). The ectodomain of the
Cell Reports 35, 108950, April 6, 2021 ª 2021 The Author(s). 1
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
ll
OPEN ACCESS
prefusion spike comprises three copies of both S1 and S2 sub-
units (Wrapp et al., 2020). The S1 subunit is responsible for ACE2
binding, and the S2 subunit mediates fusion with host-cell mem-
brane. Each S1 subunit comprises an N-terminal domain (NTD)
and a receptor-binding domain (RBD). The RBDs are very flex-
ible, adopting either an ‘‘up’’ conformation (open state) or a
‘‘down’’ conformation (closed state), with only the up RBDs
capable of interacting with ACE2 (Wang et al., 2020). Currently,
many nAbs have been characterized that bind to epitopes on
either the up and/or down RBDs (Barnes et al., 2020a; Liu
et al., 2020a; Tortorici et al., 2020). These RBD-targeting nAbs
neutralize SARS-CoV-2 through mechanisms that include
competition with ACE2 for RBD binding and locking the RBDs
in the down conformation.
Human SARS-CoV-2 nAbs develop with few somatic hyper-
mutations and strong avidity effects (Barnes et al., 2020b;
Kreer et al., 2020; Liu et al., 2020a; Robbiani et al., 2020).
Characterization of genetic features of SARS-CoV-2 nAbs
identified to date show enrichment of antibody-variable
genes, including VH3-53, VH1-2, VH1-69, VH3-66, VH1-58,
and VH3-30 (Liu et al., 2020a; Robbiani et al., 2020; Yuan
et al., 2020). So far, structural characterization of multiple
nAbs have revealed two separate RBD-targeted classes
derived from the similar VH3-53 and VH3-66 genes. One of
these is characterized by heavy-chain complementarity-deter-
mining region 3 (CDRH3) of 15 amino acids or shorter—and
recognizes the RBD ridge in the up position on SARS-CoV-2
spike (type I) (Yuan et al., 2020). The second VH3-53/-66
class—with longer CDRH3s—recognizes a similar region of
RBD but adopts an approach angle with the heavy- and
light-chain orientation rotated 180 (type II), suggesting
CDRH3 to be critical for the classification of VH3-53/-66
antibodies (Barnes et al., 2020a; Wu et al., 2020a). Different
VH3-30 originated antibodies can recognize at least three
different regions of RBDs (Barnes et al., 2020a; Hansen
et al., 2020), demonstrating that they do not form a single
gene-restricted antibody class. Nevertheless, whether nAbs
derived from VH1-2 and other germline genes form gene-
restricted classes that represent shared effective antibody re-
sponses remains unaddressed. Currently, three VH1-2, potent
nAbs (2-4, S2M11, and C121) show similar modes of RBD
recognition but differences in quaternary epitope recognition
(Barnes et al., 2020a; Liu et al., 2020a; Tortorici et al., 2020).
It is, thus, still unclear whether RBD-targeting VH1-2 anti-
bodies form a gene-restricted class. If so, what are the key
genetic and structural signatures and determinants of neutral-
ization potency?
Here, we present the structures of three VH1-2-derived nAbs
(2-15, 2-43, and H4), revealing that they recognize a SARS-
CoV-2 RBD epitope with similar modes of RBD recognition
and similar angles of approach. Overall, recognition is modular
with RBD predominantly recognized by a VH1-2-gene-encoded
module. The second recognition module is represented by the
diverse CDRH3s of the VH1-2 antibodies, whichmediate quater-
nary recognition of N343 glycan from an adjacent RBD for a
subset of class members. Thus, we define a multi-donor VH1-2
antibody class; members of which can achieve very high neutral-
ization potency, which is prevalent in human responses to
SARS-CoV-2. The shared genetic and structural signatures
inform strategies to improve members of the VH1-2 antibody
class.
RESULTS
VH1-2 antibodies are prevalent in human response to
SARS-CoV-2 infection
To identify common features of the human antibody response to
SARS-CoV-2, 158 spike-specific antibodies with characterized
neutralization potencies were collected from 10 studies (Table
S1) (Brouwer et al., 2020; Hansen et al., 2020; Ju et al., 2020;
Kreer et al., 2020; Liu et al., 2020a; Robbiani et al., 2020; Rogers
et al., 2020; Tortorici et al., 2020; Wu et al., 2020b; Zost et al.,
2020). The V(D)J gene usage analysis showed that VH1-2 was
the second most frequently used germline gene (Figure 1A; 25
in total). Comparison of neutralization potencies revealed that
11 of 25 (44%) of the VH1-2 antibodies are potent (half maximal
inhibitory concentration [IC50] < 0.1 mg/mL; Figure 1B). Within
four studies (Hansen et al., 2020; Liu et al., 2020a; Tortorici
et al., 2020; Zost et al., 2020), VH1-2 antibodies ranked the
most potent of gene-delimited sets of antibodies (IC50 ranges
from 0.015 to 0.0007 mg/mL). All 25 of the VH1-2-derived anti-
bodies have been reported to bind to the SARS-CoV-2 RBD
(Brouwer et al., 2020; Hansen et al., 2020; Ju et al., 2020; Kreer
et al., 2020; Liu et al., 2020a; Robbiani et al., 2020; Rogers et al.,
2020; Tortorici et al., 2020; Wu et al., 2020b; Zost et al., 2020).
Sequence alignment of the VH1-2 nAbs showed the heavy
chains to carry few somatic hypermutations, with each having
a unique CDRH3 with length varying from 11 to 21 amino acids
(Figures 1C and S1A; Kabat definition), and using different D
genes (Figure S1B). The VH1-2 antibodies used both kappa
and lambda genes with enrichment of the IGLV2-14 gene
(Figure 1C).
As described below, we determined structures of three nAbs:
2-15, 2-43, and H4, with the highly potent antibodies 2-15 and 2-
43 isolated from donor 2 of our previous study (Liu et al., 2020a),
whereas H4 was from a different donor (Wu et al., 2020b). The 2-
15, 2-43, and H4 nAbs neutralize authentic SARS-CoV-2 ‘‘live’’
virus with an IC50 of 0.0007, 0.003, and 0.896 mg/mL, respec-
tively. These three antibodies derived from different heavy- and
light-chain gene recombinations and, hence, three different B
cell lineages (Figure S1B). Both 2-43 and 2-15 use the DH2-
15*01 gene and have a long CDRH3 of 20 amino acids (Fig-
ure S1C), but they have different HJ gene origins (JH6*03 and
JH3*02, respectively). The light chains of 2-43 and 2-15 were
derived from recombination of a novel allele of the VL2-14
gene with JL3*02 and JL1*01, respectively (Figure S1D). H4
usedDH2-2*01 and JH2*01 genes and had aCDRH3 of 17 amino
acids (Wu et al., 2020b). The H4 light chain was derived from
VK2-40*01 and JK4*01.
Structures of antibodies 2-15, 2-43, and H4 in complex
with SARS-CoV-2 spike or RBD
To understand SARS-CoV-2 spike recognition by the VH1-2-
derived antibodies, we used single-particle cryo-electron micro-
scopy (cryo-EM) to produce high-resolution 3D-reconstructions
of antigen-binding fragments (Fabs) from 2-15, 2-43, and H4 in




complex with the SARS-CoV-2 spike (Table S2). The reconstruc-
tion of the 2-43 complex with spike, refined to a global resolution
of 3.60Å (Figures S2A–S2E), is significantly improved than in our
previous study (5.8Å resolution) (Liu et al., 2020a). The recon-
struction revealed a predominant class with three Fabmolecules
bound per spike trimer (Figure 2A). Each 2-43 Fab used the
heavy-chain-variable domain to bind one primary RBD, with an
orientation similar to the previously published antibody 2-4 (Liu
et al., 2020a), with all RBDs in the down conformation (Figure 2A).
The 2-43 heavy and light chains also recognize a quaternary
epitope from the adjacent RBD. The three-dimensional (3D) clas-
sification revealed less-populated states with 1 and 2 Fabs
bound, but in every case, the Fab was bound to a down RBD.
This dependence upon the down conformation is likely due to
extensive interactions between the Fab CDRH3 loop and the
N-linked glycosylation at residue N343 on the adjacent RBD (Fig-
ure S2E). This suggests a neutralization mechanism by which the
Fab simultaneously occludes ACE2 binding and locks the RBDs
in the down conformation.
For the complex of 2-15 with spike (Figure 2B), approximately
56% of the particles were bound to an RBD in the up conforma-
tion, and 44% bound to RBD in the down conformation (Figures
S2F–S2I), differing from antibody 2-43, which bound only to
down RBDs. Because of increased conformational heterogene-
ity of the RBD-up class, the RBD-down class was the focus of
our structural analysis (Figure 2B). In our initial attempt, a 9-
fold molar excess of Fab was incubated with the S trimer. How-
ever, this resulted in spike disassembly (Figure S2J). To over-
come this issue for structural determination, we found that a
1:1 molar ratio left spike-complexes intact, although some spike
disassembly was still observed (Figure S2K). Although we were
unable to resolve the 2-15-to-spike interaction at an atomic res-
olution, the cryo-EM analysis did reveal the overall orientation of
the Fab, along with the position of the peptide backbone for
several of the CDR loops.
To understand the binding mode of the 2-15 at an atomic
resolution, we determined the crystal structure of the 2-15 in
complex with isolated RBD. The structure was determined by
molecular replacement at 3.18-Å resolution to a final crystallo-
graphic Rwork/Rfree of 18.6%/23.8% with good overall geometry
(Table S3). The electron density for RBD (corresponding to S1-
subunit residues 333–527) was well defined for residues 344–
518, with missing internal stretches of four (362–366) and seven
(383–390) residues, with the C-terminal 18 residues (519–537)
disordered (Figure 2C). For Fab 2-15, all residues were visualized
in density, with the exception of heavy-chain residues 142–145 in
the Fc region. We then docked the crystal structure to the 2-15-
spike complex cryo-EM density map by superposing RBD from
the crystal structure on RBD from the cryo-EMmap, with subse-
quent rigid body fitting to density.
Overall, the conformation of the 2-15 in the crystal structure
agrees with the density observed in the cryo-EM map of the
complex with the spike—particularly in the V-gene-encoded
CDR regions. However, the conformation of the long CDRH3
loop differs and is far more elongated in the crystal structure (Fig-
ure S2L). In the cryo-EM map, it appears that the CDRH3 loop is
pushed away from the N343 glycan and the helix encompassing
residues 364–371 from the adjacent down RBD. The two light
chains exhibit more-significant conformational differences.
Save for CDRL3, which bends slightly away from RBD in the
Figure 1. SARS-CoV-2 infection in humans
induces potently neutralizing VH1-2 anti-
bodies
(A) Gene usage of SARS-CoV-2-neutralizing anti-
bodies. SARS-CoV-2 spike-specific VH1-2 anti-
bodies are frequently induced in infected humans.
VH1-2 antibodies are more-significantly enriched
in the antigen-specific antibody repertoire than
they are in healthy donors. Antibody repertoires
from 17 healthy donors were used for the analysis.
(B) Many SARS-CoV-2-neutralizing VH1-2 anti-
bodies (red) isolated from human donors achieve
high potency, comparable with the most frequent
IGHV3-53/-66 antibodies (blue). The half-maximal
inhibitory concentration (IC50) of neutralization is
shown, except IC100 is shown for antibodies from
Kreer et al., (2020). Live virus neutralization po-
tency is shown for antibodies from nine studies,
except the Hansen et al. (2020) study. IC50 values
greater than 10 mg/mL are set to 10 mg/mL.
Neutralizing antibodies targeting both RBD and
non-RBD epitopes are included.
(C) SARS-CoV-2-neutralizing VH1-2 antibodies
use diverse light-chain genes.
(D) Sequence alignment of the heavy chain of six
VH1-2 antibodies. Antibodies with structures re-
ported in this study are highlighted in red. Residues
identical to germline gene are shown as dots.
See also Figure S1 and Table S1.




crystal structure, the conformations of the loops are quite similar,
but the chain is shifted down closer to the RBD.
Finally, a reconstruction of Fab H4 revealed spike complexes
with a single Fab bound to RBD in the up conformation (Figures
2D and S2M–S2P). Interestingly, no Fab was seen bound to a
down RBD. The conformational flexibility of the RBD in the up
conformation made a high-resolution cryo-EM reconstruction
unattainable, and the map was refined to an overall resolution
of 5.08 Å. Similar to Fab 2-15, the peptide backbone for many
CDR loops was observed, and a homology model of the Fab var-
iable domain was docked into the density. The superimposition
of modeled H4 to the 2-43/spike complex showed that H4
adopts an RBD approaching angle similar to that of 2-43 (Fig-
ure S2Q). However, the light chain of H4 rotates toward the inter-
face between RBDs such that the long CDRL1 of H4 clasheswith
N343 glycan from an adjacent down RBD (Figure S2R), which
suggests a possible explanation for the apparent lack of H4 bind-
ing to down RBDs.
Conserved mode of RBD recognition
To understand the similarity in RBD recognition, we character-
ized the epitope and paratope interactions of 2-43 and 2-15
and compared them with the three published VH1-2 antibodies:
2-4, S2M11, and C121 (Barnes et al., 2020a; Liu et al., 2020a;
Tortorici et al., 2020). Overall, 2-43 interacts predominantly
with the receptor-binding motif (RBM; residues 438–508) on
Figure 2. Structures of three SARS-CoV-2-
neutralizing VH1-2 antibodies reveal both
‘‘RBD-down’’ and ‘‘RBD-up’’ modes of spike
recognition
(A) Side and top views of three 2-43 antibody Fabs
bound to the prefusion SARS-COV-2 spike in the
closed state. Color schemes are 2-43, green; RBD,
salmon; NTD, yellow; N-linked glycans, magenta;
other spike regions, gray.
(B) Side and top views of one 2-15 antibody Fab in
complex with the prefusion SARS-COV-2 spike in
the closed state. 2-15 is colored blue.
(C) Overview of the crystal structure of 2-15 in
complex with SARS-CoV-2 RBD. Residue seg-
ments missing in the structure are shown as
dashed lines.
(D) Side and top views of one H4 Fab recognizing
an up RBD on the prefusion SARS-COV-2 spike.
H4 is colored cyan.
See also Figure S2 and Tables S2 and S3.
one down RBD protomer and simulta-
neously binds the N343 glycan from an
adjacent down RBD protomer (Figure 3A).
We describe the N343 glycan interaction
below in the last section focused on qua-
ternary interactions. The interaction be-
tween 2-43 and the ‘‘primary’’ RBD bound
through its RBM buries a total of 756-Å2
paratope body surface area (BSA); 83%
of which is contributed by heavy chain
(Figures 3A and S3A). Heavy-chain frame-
work 1 (FWH1), CDRH1, CDRH2, and CDRL3 of 2-43 form
hydrogen-bond networks with three RBD regions. In the first re-
gion, residues in FWH1 and the DE-loop in FWH3 form a groove
to hold Y449RBD. Hydrogen bonds are observed between FWH1
residues and Y449RBD and Q498RBD (Figure 3A, second panel).
In the second region, involving the ‘‘flat’’ region of RBM, T30HC
forms a hydrogen bond with S494RBD. In the third region or the
RBD ridge region, Y33HC, N52HC, and S54HC form a hydrogen-
bond network with E484RBD. Light-chain residues Y91LC and
S95LC further the hydrogen bond with G485RBD and F486RBD.
In addition, Y30LC, Y32LC, Y91LC, and Y100jHC also form a hydro-
phobic pocket to hold F486RBD (Figure S3B), with p-p stacking
observed between Y30LC and F486RBD (Figure 3A, right panel).
The crystal structure of 2-15 complexed with SARS-CoV-2
RBD revealed 2-15 to use similar heavy- and light-chain regions
to recognize the RBM (Figure 3B, left panel). Similar to 2-43, 2-15
forms convergent hydrogen bonds to Y449RBD, S494RBD,
E484RBD, and G485RBD as well as p-p stacking with F486RBD
(Figure 3B, right three panels). Nonetheless, 2-15 interactions
that are different from 2-43 are also observed at the RBM flat
and ridge regions (Figure 3B, right two panels).
Comparedwith 2-43 and 2-15, the published VH1-2 antibodies,
2-4, S2M11, and C121, showed a similar RBM approach angle
and binding mode (Figures 3C, 3D, S3C, and S3D). Typically, in-
teractions between the VH1-2 antibodies and the RBD are medi-
ated predominantly by the heavy chain (RBDA column in




FigureS3C). For all antibodies, the VH1-2-gene-encoded residues
formamodule for RBM recognition. Despite these antibodies hav-
ing different light-chain gene origins, convergent tyrosine residues
in CDRL1 and CDRL3 pack against F486RBD (Figure S3B), which
constitutes another module for RBD recognition. Because each
antibody has a unique CDRH3, no conserved polar or hydropho-
bic interaction is observed (Figures 3 and S3B–S3D), albeit
CDRH3 contributes the most BSA among the CDRs, except in
2-15 (Figure S3A). Altogether, the germline gene residues from
the VH1-2 gene as well as light-chain V genes anchor the anti-
bodies to the RBM in a similar modewith the heavy-chain V region
having a dominant role in determining the mode of recognition.
The VH1-2 antibody class and similarity to other SARS-
CoV-2 RBD targeting antibodies
To gain an overall understanding of the similarity in the binding
orientations of the VH1-2 antibodies, we superposed RBD and
antibody complexes and calculated pairwise root-mean-square
deviation (RMSD) to compare relative binding orientations of the
six VH1-2 antibodies (2-43, 2-15, H4, 2-4, C121, and S2M11) as
well as the 31 additional RBD-targeting antibodies originated
from other VH genes. Overall, the VH1-2 antibodies have similar
binding orientations (Figures 4A, 4B, and S4A). Their epitopes
overlap with the ACE2 binding site (Figures S4B and S4C). The
similarity in their genetic origin, details of their interactions with
RBD (unavailable for H4), and their angles of approach, suggests
that these six antibodies form a VH1-2 antibody class.
The structural, recombination, and somatic hypermutation an-
alyses (described below in the next section) presented here re-
vealed critical residues that determine the specificity and binding
affinity of the VH1-2 class antibodies. We define residues form-
ing the conserved side chain polar and/or hydrophobic interac-
tions as genetic signatures. The heavy-chain signatures include
a T30-x-x-Y33 motif in CDRH1 and an [NS]52-x-[NIV]-S54 motif
Figure 3. Common epitope-paratope interactions define a VH1-2 antibody class
(A) Overview of the 2-43 epitope (left panel) and close-up view of the hydrogen bond networks between 2-43 and the SARS-CoV-2 RBD (right three panels). The
RBD epitope recognized by 2-43 heavy (forest) and light (lime green) chains are colored wheat and orange, respectively (RBDA, light gray). Epitope residues
interacting with both heavy and light chains are colored lemon. 2-43 also binds to the N343 glycan (magenta) from a neighboring RBD (RBDB, dark gray).
Hydrogen bonds and p-p stacking are shown as black dashed lines.
(B) Overview of the epitope of 2-15 (left panel) and close-up view of the hydrogen bond networks andp-p stacking between 2-15 and the SARS-CoV-2 RBD (right
three panels). 2-15 heavy and light chains are colored marine and blue, respectively. Epitope residues interacting with both heavy and light chains are colored
lemon.
(C) Overview of the epitope of 2-4 (left panel) and close-up view of the hydrogen-bond networks between 2-4 and the SARS-CoV-2 RBD (right three panels). The
heavy and light chains of 2-4 are colored chocolate and salmon, respectively. Epitope residues interacting with both heavy and light chains are colored lemon.
See also Figure S3.




(x represents any amino acid) in CDRH2 (Figure 4C), with no
conserved motif observed in CDRH3 (Figure S1A). Searches of
germline gene databases using this signature showed only al-
leles of the VH1-2 gene to match both motifs (Figure 4E), sug-
gesting that the antibody class is likely to be restricted to VH1-2.
For light chain, residues Y32LC and Y91LC are signature resi-
dues that interact with both the primary RBD (Figures 3 and
S3B) and the N343 glycan from adjacent RBDs (described below
in the quaternary recognition section). However, because the
light-chain interaction signatures can be found in many germline
genes (Figures 4D and S4D), the VH1-2 antibody class may not
be restricted with respect to light-chain origin gene.
To understand the conservation of the VH1-2 antibody
epitope, we calculated the conservation score for each RBD res-
idue and observed that the flat region is highly conserved in the
natural SARS-CoV-2 reservoir. The four RBD residues critical for
VH1-2 antibody recognition—Y449RBD, E484RBD, F486RBD, and
Q493RBD—showed low mutation frequencies (approximately 0,
3, 7, and 7 per 10,000 sequences, respectively). Nonetheless,
SARS-CoV-2 strains with mutations at the four positions are
resistant to C121 and S2M11 of the VH1-2 antibody class
(Barnes et al., 2020a; Tortorici et al., 2020).
In addition, the VH1-2 antibodies show high similarity in
approach angle and epitope to antibody C144 (Figures 4C and
S4A), a type-II VH3-53/-66 antibody. However, C144 uses
different CDRH1 and CDRH2 motifs for interacting with the
conserved residues in the flat region and ridge of RBD (e.g.,
the N32-Y33 and [T/S]54-G-G-[T/S]57 motifs in the VH3-53/-66
Figure 4. The VH1-2 antibody class
(A) Overview of modes of RBD recognition by the
VH1-2 class antibodies: 2-43, 2-15, 2-4, H4,
S2M11, and C121. The RBD and antibody com-
plexes are superimposed on RBDs.
(B) Approach angles of SARS-CoV-2 RBD-target-
ing antibodies originated from different VH genes.
Members of the VH1-2 antibody class have similar
approach angles. The VH3-53 class antibody C144
has an angle of approach similar to that of the VH1-
2 antibody class.
(C) Overview of VH1-2 signature motifs (green) and
type II VH3-53 class (orange) on the RBD surface.
The RBD is colored with the conservation score
calculated from the circulating SARS-CoV-2
strains. The 2-43 structure is used to generate the
conservation plot. Residues in gray have no mu-
tation, whereas residues colored red have rela-
tively high mutation frequency.
(D) Signature motifs and compatible germline V
genes of the VH1-2 antibody class.
See also Figures S1 and S4.
antibodies) (Figure 4C) (Barnes et al.,
2020a; Wu et al., 2020a). The CDRH2 of
C144 shifts toward the RBD ridge,
perhaps because the CDRH2s of the
VH3-53/-66 genes are one residue
shorter than the VH1-2 gene. Nonethe-
less, both antibody classes use similar
light-chain genes, including VL2-14 and
VL2-23, which provide key Tyr residues that interact with
F486RBD.
Somatic hypermutations and avidity improve antibody
potency
To understand the effects of somatic hypermutation (SHM) on
binding affinity and neutralization potency, we reverted SHMs
in the paratope regions of 2-43, 2-15, and 2-4 to their germline
residues individually and in combination. The 2-43 only has
one SHM in the paratope region, S76THC (Figure S1A); the rever-
sion of which reduces the immunoglobulin G (IgG)-apparent
binding affinity and pseudovirus neutralization potency by about
6-fold and 5-fold, respectively (Figures 5A, 5B, and S4E). For 2-
15, three paratope SHMs were observed: N53IHC, G55DHC, and
Y32FLC. The reversion of N53IHC and Y32FLC individually
reduced binding affinity by 56-fold and 12-fold, respectively (Fig-
ure 5A), as well as neutralization potency by 217-fold and 42-
fold, respectively (Figure 5B). The results suggested that the
N53IHC and F32YHC mutations are critical for the affinity matura-
tion of 2-15. Structural analysis showed that the N53IHCmutation
allows the Ile side chain to fit a hydrophobic pocket on RBD (Fig-
ures 3B and S5A). A convergent mutation is also observed in
S2M11 (N53IHC) and C121 (N53VHC). We then introduced the
N53IHC mutation to 2-43 and 2-4 and observed significant im-
provements of both binding affinity and neutralization potency
(both IC50 and maximum potency) (Figure 5). These results sug-
gested that mutation to a hydrophobic residue at 53HC can be
used to improve members of the VH1-2 antibody class. The




crystal structure further showed that 2-15 32LC does not interact
with RBD (Figure S3B); the Y32FLC SHMmay alter the interaction
with RBD indirectly. For 2-4, the SHM A60THC generates an N-
glycosylation site at position N58HC. The N58HC glycan interacts
with the RBD ridge (Figure 3C). The reversion of this SHM re-
duces binding affinity and neutralization by about 6-fold and 9-
fold, respectively (Figure 5). In summary, somatic hypermutation
analysis revealed that the precursors of these antibodies could
bind antigens with nanomolar-apparent binding affinity, sug-
gesting that the precursors of these antibodies can be activated
efficiently by the SARS-CoV-2 spike protein. Nonetheless, SHMs
significantly improve both the binding affinity and the neutraliza-
tion potency of these antibodies. Because the observed SHMs
are frequently generated by the somatic hypermutation machin-
ery (Figure S1A), we anticipate that requirements for somatic
hypermutations are unlikely to present a significant barrier for af-
finity maturation of this antibody class.
In addition, previous studies showed that bivalent binding
(avidity) is critical for certain RBD-directed antibodies to achieve
high potency (Barnes et al., 2020b; Liu et al., 2020b). We, there-
fore, examined whether avidity contributes to the observed high
potency of the VH1-2 antibody class. Comparison of neutraliza-
tion potency between IgGs and Fabs revealed that the Fabs of 2-
43, 2-15, and 2-4 have potencies of about 140-, 95-, and 14-fold
less than their IgG forms, respectively (Figure S5C), suggesting
that avidity effects are critical for achieving high-neutralization
potency by the VH1-2 class antibodies.
Recognition of quaternary epitopes modulates spike
conformation
Our previous study with a low-resolution cryo-EM structure
showed that 2-43 recognizes a quaternary epitope (Liu et al.,
2020a). However, details on the quaternary interactions and their
functional relevance have not yet been characterized. Here,
high-resolution cryo-EM reconstructions revealed atomic-level
Figure 5. N53I mutation improves many
VH1-2 class members
(A) Apparent binding affinities of 2-43, 2-15, and 2-
4 IgGs and revertants. Somatic hypermutations
improve the binding affinities of the three anti-
bodies. N53IHC was introduced to 2-43 and 2-4
and showed a significantly increased binding af-
finity. The numbers in parentheses represent
standard errors in the last integer.
(B) Pseudovirus neutralization profiles of 2-43, 2-
15, 2-4, and their somatic hypermutation re-
vertants. Data represent means ± SEM of technical
triplicates.
See also Figures S1, S3, and S5.
interactions between 2-43 and the qua-
ternary epitope. Overall, 2-43 interacts
comprehensively with N343 glycan as
well as helix 364–371 from an adjacent
down-RBD protomer (RBDB) (Figures 6A
and S6A), burying a total of 999-Å BSA
(Figure S3A). The quaternary interaction
is predominantly mediated by the long
CDRH3, which is held by the two branches of the N343 glycan;
the structure of which is highly flexible and has not been
observed in previous studies. The tip of one N343 glycan branch
is further stabilized by hydrogen bonding with the 2-43 CDRL1
and the ridge of RBDA (Figure S6A). Altogether, 2-43 forms
strong quaternary interactions with the adjacent down RBD,
which is critical for locking RBDs in the all-down conformation.
In contrast to 2-43, the cryo-EM density maps of the 2-15 and
H4 spike complexes revealed no quaternary contacts (Figures
2D, S2L, and 6B).
Comparison of quaternary interactions among the five VH1-2-
derived antibodies revealed two structural groups. Group 1 in-
cludes 2-43, 2-4, and S2M11, which bind predominantly down
RBDs. Group 2 includes 2-15, H4, and C121, which bind both
up and down or only up RBDs. For group 1, the quaternary
recognition is mediated mostly by CDRH3, followed by CDRL1
and CDRL2 (Figures 6C and S3A). Differences between each
antibody-specific CDRH3 determine that each antibody has a
unique quaternary epitope (Figures 6A–C, S3B, and S6B).
Different from other class members, which bind both the spike
and isolated RBDs (Liu et al., 2020a; Robbiani et al., 2020; Tor-
torici et al., 2020; Wu et al., 2020b), the quaternary interaction
is indispensable for 2-43 (Liu et al., 2020a). The quaternary
epitope of 2-4, only part of which appears to be visible in the
cryo-EMmap (Liu et al., 2020a), comprises only the N343 glycan
from the adjacent down-RBD protomer (Figure 6C), likely
because 2-4 has a short CDRH3. The quaternary epitope of
S2M11 includes the N343 glycan and helices 339–343 and
364–371 of the adjacent RBD (Figure S6B). Altogether, accom-
modation of the N343 glycan from the adjacent down RBD is a
common feature of quaternary recognition by group-1 anti-
bodies. The diverse CDRH3s of the group-1 antibodies form a
module for quaternary recognition. In contrast, group-2 anti-
bodies 2-15 and C121 show minor interactions with neighboring
down RBDs (Figures 2C, 6B, S2R, and S3A), which may explain




why they do not lock the trimeric RBDs in an all-down
conformation.
To understand whether antibody binding induces conforma-
tion change in the SARS-CoV-2 spike protein, we compared
the antibody-bound and ligand-free spike structures in the
closed (all down) prefusion conformation. These comparisons
showed that the binding of the VH1-2 antibodies (except
S2M11), as well as other RBD-directed antibodies leads to
significantly larger distances and less contacts between the
trimeric down RBDs (Figures 6D and 6E). Each of these anti-
bodies has a role in bridging the interactions between RBDs as
well as in reorienting the conformation of the N343 glycan. How-
ever, antibodies like 2-15, which does not form strong interac-
tions with the adjacent RBD, may disassemble the spike when
three Fabs bind to the RBDs (Figures S2J and S2K). In addition,
superposition of 2-15 on the down RBD in the ligand-free spike
revealed the light chain to significantly clash with an adjacent
up RBD (Figure S6D), suggesting members of the VH1-2 anti-
body class to either bind only down RBDs when a neighboring
down RBD is available or push the neighboring up RBD away
to bind down RBDs. Consistent with the first mechanism, we
did not observe a neighboring up RBD adjacent to 2-15, and
2-4 bound down RBDs in the cryo-EM data. In contrast, C121
adopts the second mechanism through light-chain interaction
with the adjacent up RBD (Figure S6D) (Barnes et al., 2020a).
In summary, the quaternary interaction and angle of approach
determine that the VH1-2 antibody class modulates the SARS-
CoV-2 spike conformation when binding to a down RBD.
DISCUSSION
In this study, we determined structures of three nAbs: 2-43, 2-15,
and H4, which revealed a VH1-2 antibody class with a common
RBD-binding mode and similar angles of approach. The VH1-2
antibody class uses two modules for spike recognition with the
VH1-2-gene-encoded module for recognition of RBD and
CDRH3 module for quaternary recognition. The VH1-2 antibody
class has little or no restraint on CDRH3 length. The prevalence
of the VH1-2 antibody class in numerous donors (Brouwer et al.,
2020; Hansen et al., 2020; Ju et al., 2020; Kreer et al., 2020; Liu
et al., 2020a; Robbiani et al., 2020; Rogers et al., 2020; Tortorici
et al., 2020; Wu et al., 2020b; Zost et al., 2020) suggests it to be a
common component of the effective antibody response to SARS-
CoV-2, which can include highly potent neutralizing antibodies.
For some members of the VH1-2 class, recognition of a qua-
ternary epitope can lock RBDs in the down conformation,
providing an additional mechanism by which to achieve high
neutralization potency. The quaternary epitopes of the VH1-2
class include the N343 glycan and helix 364–371 of an adjacent
RBD. A similar quaternary epitope is recognized by the type-II
Figure 6. Subset of the VH1-2 antibody class
uses an elongated CDRH3 to recognize the
glycan N343 from a neighboring RBD, a qua-
ternary interaction that expands the SARS-
CoV-2 spike
(A) Close-up view of the quaternary epitope of 2-
43. The 2-43 CDRH3 forms two hydrogen-bond
networks (black dashed lines) with an adjacent
RBD (RBDB) N343 glycan and also interacts with
helix 364–371 of RBDB.
(B) Close-up view of potential quaternary in-
teractions between 2-15 and the neighboring RBD
(RBDB). 2-15 reconstructed from cryo-EM data
shows a minor quaternary interaction.
(C) Close-up view of the interaction between 2-4
and the N343 glycan of the neighboring RBD.
(D) Distance between antibody-free and antibody-
bound trimeric RBDs. Antibody binding induces
significantly larger expansion of the trimeric RBDs.
The three RBDs are gray. Residues at the RBD
interfaces are cyan, light blue, and blue for proto-
mers RBDA, RBDB, and RBDC. respectively. The
distances between RBD protomers was measured
using Ca of position 503. Note: because of low
resolution, the interface residues between RBDs
were not shown for the 2-15 bound spike. 2-15
(dashed circle) binds to protomer RBDC.
(E) Distance of Ca of position 503 between the
trimeric down RBDs. Antibody-free spikes have a
shorter distance than the antibody-bound spikes.
For the boxplots, themiddle lines aremedians. The
lower and upper hinges correspond to the first and
third quartiles, respectively. The Mann-Whitney U
test was used. Outliers are shown as gray tri-
angles.
See also Figures S2, S3, and S6.




VH3-53/-66 class antibody C144 (Barnes et al., 2020a). Thus,
this quaternary epitope appears to represent a supersite at
which antibodies lock the RBDs in the all-down conformation.
We also observe that the quaternary interaction can induce
distinct conformational changes of the trimeric down RBDs.
The quaternary interaction observed in S2M11 does not signifi-
cantly alter the distance between spike protomers (Figure 4E)
(Tortorici et al., 2020). In contrast, the quaternary interactions
of 2-43 and 2-4, mediated predominantly by CDRH3, increase
the distance of the trimeric RBDs (Figure 4). For 2-15, the cryo-
EM structure of one Fab-bound spike revealed a CDRH3 confor-
mationmoving away from the adjacent down RBD to avoid a ste-
ric clash. Despite that, 2-15 also increases the distance among
RBDs, which may be the result of mobile quaternary contacts
that cannot be observed in the low-resolution cryo-EM recon-
struction. We anticipate that the interactions among RBDs could
be further weakened when all three protomers are bound by 2-
15, which may be the cause of the observed spike disassembly
by 2-15 (Figures S2J and S2K). The disassembly of the spike
may be another mechanism for 2-15 to achieve ultrapotent
neutralization. In addition, the crystal structure of 2-15 in com-
plex with isolated RBDs showed 2-15 to have another stable
binding mode in the absence of a quaternary contact. We hy-
pothesize that this binding mode may be observed when 2-15
binds to up RBDs and cannot form quaternary interactions.
The structural information we present also provides clues for
further optimizationof theVH1-2antibodyclass.Despitemembers
of the class achieving high potency with germline gene-mediated
interactions, we observe that somatic hypermutations can further
improve this class significantly. The conserved mode of RBD
recognition implies thatmembers of the antibodyclasswill be sen-
sitive to similar viral escape mutations. In particular, K417NRBD,
L452RRBD, E484KRBD, and N501YRBD mutations are observed in
emerging SARS-CoV-2 variants (e.g., B.1.351, B.1.1.7, and
B.1.429) with transmission rates dramatically higher than that of
preexisting strains (Davies et al., 2021; Tegally et al., 2020). We
found that positions 452 and 484 are within the VH1-2 antibody
epitopes (Figure S3E). Mutation E484KRBD, but not K417NRBD
andN501YRBD, impairs both binding affinity and neutralization po-
tency of the VH1-2 antibody class (Barnes et al., 2020a; Tortorici
et al., 2020; Wang et al., 2021). We anticipate that L452RRBD will
also impair the recognitionby theVH1-2antibodyclass, but further
investigation is required to examine the hypothesis.
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Schäfer, A., Reidy, J.X., Trivette, A., Nargi, R.S., et al. (2020). Potently neutral-
izing and protective human antibodies against SARS-CoV-2. Nature 584,
443–449.






REAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
2-43 Liu et al., 2020b N/A
2-15 Liu et al., 2020b N/A
2-4 Liu et al., 2020b N/A
H4 Wu et al., 2020b N/A
anti-VSV-G antibody ATCC Cat#CRL-2700; RRID:CVCL_G654
Bacteria and virus strains
SARS-CoV-2 pseudovirus Liu et al., 2020b N/A
Chemicals, peptides, and recombinant proteins
polyethylenimine Polysciences, Inc. Cat# 23966
Turbo293 Speed BioSystems Cat#PXX1002
HRV-3C protease Thermo fisher Cat# SAE0045
SARS-CoV-2 spike S2P Wrapp et al., 2020 N/A
SARS-CoV-2 spike provided by Dr. Peihui Wang, China N/A
SARS-CoV-2 RBD This study N/A
Critical commercial assays
Strep-Tactin XT Superflow 50% Zymo research Cat#P2004-1-5
Sensor Chip CM5 Cytiva Cat#BR100030
His Capture Kit Cytiva Cat#28995056
Glycine 1.5 Cytiva Cat# BR100354
HBS-EP+ Buffer Cytiva Cat# BR100826
QuikChange II site directed mutagenesis kit Agilent Cat# 200524
rProtein A Sepharose GE Cat#17-1279-01
NI-NTA GE Health care Cat# 17-0921-09
Superdex 200 Increase 10/300 GL Cytiva Cat# 28990945
Pierce Fab Preparation Kit Thermo fisher Cat# 44985
Deposited data
New IGVL2-14 gene allele (IGVL2-14*0X) This study ENA: PRJEB31020
Cryo-EM structures: SARS-CoV-2 spike Walls et al., 2020 PDB ID: 6VXX
Cryo-EM structures: SARS-CoV-2 spike Henderson et al., 2020 PDB ID: 6X2C
Cryo-EM structures: SARS-CoV-2 spike Herrera et al., 2020 PDB ID: 6X6P
Cryo-EM structures: SARS-CoV-2 spike Henderson et al., 2020 PDB ID: 6X29
Cryo-EM structures: SARS-CoV-2 spike McCallum et al., 2020 PDB ID: 6X79
Cryo-EM structures: SARS-CoV-2 spike Zhou et al., 2020 PDB ID: 6XLU
Cryo-EM structures: SARS-CoV-2 spike Zhou et al., 2020 PDB ID: 6XM5
Cryo-EM structures: SARS-CoV-2 spike Cai et al., 2020 PDB ID: 6XR8
Cryo-EM structures: SARS-CoV-2 spike Toelzer et al., 2020 PDB ID: 6ZB4
Cryo-EM structures: SARS-CoV-2 spike Wrobel et al., 2020 PDB ID: 6ZGE
Cryo-EM structures: SARS-CoV-2 spike Wrobel et al., 2020 PDB ID: 6ZGI
Cryo-EM structures: SARS-CoV-2 spike Xiong et al., 2020 PDB ID: 6ZOX
Cryo-EM structures: SARS-CoV-2 spike Xiong et al., 2020 PDB ID: 6ZOY
Cryo-EM structures: SARS-CoV-2 spike Xiong et al., 2020 PDB ID: 6ZOZ
Cryo-EM structures: SARS-CoV-2 spike Xiong et al., 2020 PDB ID: 6ZP0
(Continued on next page)





REAGENT or RESOURCE SOURCE IDENTIFIER
Cryo-EM structures: SARS-CoV-2 spike Xiong et al., 2020 PDB ID: 6ZP1
Cryo-EM structures: SARS-CoV-2 spike Xiong et al., 2020 PDB ID: 6ZP2
Cryo-EM structures: SARS-CoV-2 spike Bangaru et al., 2020 PDB ID: 7JJI
Cryo-EM structures: SARS-CoV-2 spike Wrobel et al., 2020 PDB ID: 6ZGG
Crystal structure: SARS-CoV-2 RBD Wu et al., 2020b PDB ID: 7BZ5
Crystal structure: CH65 UCA Schmidt et al., 2013 PDB ID: 4HK0
Cryo-EM structure: 2-4 Liu et al., 2020b PDB ID: 6XEY
Cryo-EM structure: S2M11 Tortorici et al., 2020 PDB ID:7K43
Cryo-EM structure: C121 Barnes et al., 2020a PDB ID: 7K8X
Cryo-EM structure: C002 Barnes et al., 2020a PDB ID: 7K8T
Cryo-EM structure: C144 Barnes et al., 2020a PDB ID: 7K90
Cryo-EM structure: BD23 Cao et al., 2020 PDB ID: 7BYR
Cryo-EM structure: B38 Wu et al., 2020b PDB ID: 7BZ5
Cryo-EM structure: S2H13 Tortorici et al., 2020 PDB ID: 7JV2
Cryo-EM structure: S309 Pinto et al., 2020a PDB ID: 6WPS
Cryo-EM structure: C119 Barnes et al., 2020a PDB ID: 7K8W
Cryo-EM structure: C102 Barnes et al., 2020a PDB ID: 7K8M
Cryo-EM structure: C104 Barnes et al., 2020a PDB ID: 7K8U
Cryo-EM structure: C110 Barnes et al., 2020a PDB ID: 7K8V
Cryo-EM structure: S2E12 Tortorici et al., 2020 PDB ID:7K45
Cryo-EM structure: C135 Barnes et al., 2020a PDB ID: 7K8Z
Cryo-EM structure: COVA1-16 Liu et al., 2020a PDB ID: 7JMW
Cryo-EM structure: P17 Yao et al., 2021 PDB ID: 7CWO
Crystal structure: BD-236 Du et al., 2020 PDB ID: 7CHB
Crystal structure: BD-368-2 Du et al., 2020 PDB ID: 7CHE
Crystal structure: BD-629 Du et al., 2020 PDB ID: 7CH5
Crystal structure: P2C-1F11 Wang et al., 2020 PDB ID: 7CDI
Crystal structure: P2D-1A3 Wang et al., 2020 PDB ID: 7CDJ
Crystal structure: EY6A Zhou et al., 2020 PDB ID: 6ZER
Crystal structure: CV07-250 Kreye et al., 2020 PDB ID: 6XKQ
Crystal structure: CV07-270 Kreye et al., 2020 PDB ID: 6XKP
Cryo-EM structure: S309 Pinto et al., 2020b PDB ID: 6WPT
Crystal structure: P2B-2F6 Ju et al., 2020 PDB ID: 7BWJ
Crystal structure: CB6 Shi et al., 2020 PDB ID: 7C01
Cryo-EM structure: BD-23 Cao et al., 2020 PDB ID: 7BYR
Crystal structure: B38 Wu et al., 2020b PDB ID: 7BZ5
Crystal structure: COVA2-39 Wu et al., 2020a PDB ID: 7JMP
Crystal structure: COVA2-04 Wu et al., 2020a PDB ID: 7JMO
Crystal structure: H014 Lv et al., 2020 PDB ID: 7CAH
Crystal structure: CR3022 Huo et al., 2020 PDB ID: 6YM0
Crystal structure: CV30 Hurlburt et al., 2020 PDB ID: 6XE1
Cryo-EM structure: REGN10933 Hansen et al., 2020 PDB ID: 6XDG
Cryo-EM structure: REGN10987 Hansen et al., 2020 PDB ID: 6XDG
Cryo-EM structure: C105 Barnes et al., 2020b PDB ID: 6XCN
Cryo-EM structure: CC12.1 Yuan et al., 2020 PDB ID: 6XC2
Cryo-EM structure: CC12.3 Yuan et al., 2020 PDB ID: 6XC4
Crystal structure: 2-15 This study PDB ID: 7L5B
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Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Zizhang
Sheng (zs2248@cumc.columbia.edu).
Materials availability
Expression plasmids generated in this study for expressing SARS-CoV-2 proteins and antibodymutants will be shared upon request.
Data and code availability
Cryo-EMmaps and fitted coordinates of 2-43, H4, and 2-15 were deposited to the EMDB (2-43: EMDB-23165; H4: EMDB-23167; 2-
15: EMDB-23166) and RCSB (2-43: 7L56; H4: 7L58; 2-15: 7L57 and 7L5B) respectively. The new IGVL2-14 gene allele (IGVL2-14*0X)
Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
Cryo-EM structure: 2-43 This study PDB ID: 7L56; EMDB-23165
Cryo-EM structure: 2-15 This study PDB ID: 7L57; EMDB-23166
Cryo-EM structure: H4 This study PDB ID: 7L58; EMDB-23167
Experimental models: Cell lines
Expi293 ThermoFisher Cat#A14527; RRID:CVCL_D615
HEK293T/17 ATCC Cat# CRL-11268; RRID:CVCL_1926
Vero E6 ATCC Cat# CRL-1586; RRID:CVCL_0574
Expi293F GnTI- Cells Thermo Fisher Cat# A39240
Recombinant DNA
pVRC8400 vector https://www.addgene.org Cat#63160; RRID:Addgene_63164
gWiz Aldeveron Cat# 5008
pcDNA3.4 ThermoFisher Cat# A14697
Software and algorithms
GraphPad Prism 7.01 Software GraphPad Prism Software, Inc. N/A




SONAR Schramm et al., 2016 https://github.com/scharch/SONAR
Muscle Edgar, 2004 https://drive5.com/usearch/
CLUSTALO Sievers and Higgins, 2018 http://clustal.org/omega/
Python v3.8.3 https://www.python.org/downloads/ N/A
cryoSPARC, v2.15.0 Punjani et al., 2017 https://cryosparc.com/
UCSF Chimera, v1.14 Pettersen et al., 2004 https://www.cgl.ucsf.edu/chimera/
UCSF ChimeraX, v1.1 Goddard et al., 2018 https://www.cgl.ucsf.edu/chimerax/
Schrödinger Release 2020-2:BioLuminate Zhu et al., 2014 https://www.schrodinger.com/products/
bioluminate
ISOLDE, v.1.0.1 Croll, 2018 https://isolde.cimr.cam.ac.uk/
COOT, 0.9 Emsley et al., 2010 https://www2.mrc-lmb.cam.ac.uk/
personal/pemsley/coot/
Phenix, v1.18 Adams et al., 2010 https://www.phenix-online.org/;
Leginon, v.3.5beta Suloway et al., 2005 N/A
XDS Kabsch, 2010 https://xds.mpimf-heidelberg.mpg.de/
CCP4i (Aimless) Winn et al., 2011 https://www.ccp4.ac.uk
PDB-redo Joosten et al., 2014 https://pdb-redo.eu/
MolProbity Chen et al., 2010 http://molprobity.biochem.duke.edu
Other
Free style Media Invitrogen Cat # 12338026




was deposited to European Nucleotide Archive (ENA): PRJEB31020. All deposited data will be available upon publication of the
study.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Expi293 cells and Expi293F GnTI- Cells were from ThermoFisher Scientific Inc (ThermoFisher, cat#A14527 and cat# A39240 respec-
tively). HEK293T/17(cat# CRL-11268) and Vero E6 cells (cat# CRL-1586) were from ATCC.
METHOD DETAILS
Expression and purification of SARS-CoV-2 spike and RBD proteins
Themammalian expression vector that encodes the ectodomain of the SARS-CoV-2 S trimer was kindly provided by JasonMcLellan
(Wrapp et al., 2020). SARS-CoV-2 S trimer expression vector was transiently transfected into Expi293TM cells using 1mg/mL of poly-
ethylenimine (Polysciences). Five days post transfection, the S trimer was purified using Strep-Tactin XT Resin (Zymo Research).
The SARS-CoV-2 RBD (residues 331-528), was cloned into the pVRC-8400 mammalian expression plasmid, with a C-terminal 6X-
His-tag and an intervening HRV-3C protease cleavage site. Expression vector was transiently transfected into Human Embryonic
Kidney (HEK) 293 GnTI- Freestyle cells suspension culture in serum-free media (Invitrogen) using polyethyleneimine (Polysciences).
Media was harvested 4 days after transfection and the secreted protein purified using Ni-NTA IMAC Sepharose 6 Fast Flow resin (GE
Healthcare) followed by size exclusion chromatography (SEC) on Superdex 200 (GEHealthcare) in 10mM, Tris pH 8.0, 150mMNaCl.
Peak fractions containing RBD were pooled and HRV-3C protease (Thermo fisher, cat# SAE0045) was added in a mass ratio 1:100
relative to RBD, followed by incubation for 24 h at 20C, to remove the C-terminal histidine-tag. The protein solution was again
passed through the NI-NTA column to remove the His-tag and any traces of uncleaved protein. Protein purity was analyzed by
SDS-PAGE and buffer exchanged to SEC buffer and concentrated to 5 mg/mL and used for crystallization experiments.
Antibody production and mutagenesis
For each antibody, the variable genes were optimized for human cell expression and synthesized by GenScript. VH and VL were in-
serted separately into plasmids (gWiz or pcDNA3.4) that encoding the constant region for heavy chain and light chain respectively.
Monoclonal antibodies were expressed in Expi293 (ThermoFisher, A14527) by co-transfecting heavy chain and light chain express-
ing plasmids using polyethylenimine (PEI, Linear, MV25,000, Polysciences, Inc. Cat. No. 23966) and culture in 37.0C degree shaker
at 125RPM and 8%CO2. Supernatants were collected on day 5, antibodies were purified by rProtein A Sepharose (GE, 17-1279-01)
affinity chromatography.
For H4, the antibody expression constructs were synthesized (Gene Universal Inc, Newark DE) and subcloned into corresponding
pVRC8400 vectors. To express the antibodies, equal among of heavy and light chain plasmid DNA were transfected into Expi293F
cells (Life Technology) by using Turbo293 transfection reagent (Speed BioSystems). The transfected cells were cultured in shaker
incubator at 120 rpm, 37C, 9%CO2 for 5 days. Culture supernatants were harvested and purified over Protein A (GEHealth Science)
resin in columns. Each antibody was eluted with IgG elution buffer (Pierce), immediately neutralized with one tenth volume of 1M Tris-
HCL pH 8.0. The antibodies were then buffer exchanged in PBS by dialysis.
Antibody gene mutations were introduced by QuikChange II site directed mutagenesis kit (Agilent, cat#200524)
Production of Fab from IgG
Fab fragments were produced from purified IgGs of monoclonal antibodies 2-15, 2-43 and H4 by digestion with Papain in the pres-
ence of the reducing agent 30 mM cysteine and were purified by affinity chromatography on protein A following the manufacturer’s
protocols (Thermo fisher). The purity of the resultant Fabswas analyzed by SDS-PAGE, and buffer exchanged into SECbuffer (10mM
Tris pH 7.4 and 150 mM NaCl) for crystallization experiments.
IgG Surface Plasmon Resonance binding experiments
SPR binding assays for IgGs binding to spike, were performed using a Biacore T200 biosensor, equipped with a Series S CM5 chip
(cat# BR100030, Cytiva, MA), in a running buffer of 10mM HEPES pH 7.4, 150mM NaCl, 3 mM EDTA, 0.05% P-20 (HBS-EP+ buffer,
Cytiva, MA) at 25C. SARS-CoV-2 spike protein was captured through its C-terminal his-tag over an anti-his antibody surface. These
surfaces were generated using the His-capture kit (Cat#: 28995056, Cytiva, MA) according to the instructions of the manufacturer,
resulting in approximately 10,000 RU of anti-his antibody over each surface. Spike protein was captured over a single flow cell at a
capture level of 125-200 RU. An anti-his antibody surface was used as a reference flow cell to remove bulk shift changes from the
binding signal.
IgGswere tested using a three-fold dilution series of IgGswith concentrations ranging from 33.3 nM to 1.2 nM. The association and
dissociation rates were eachmonitored for 55 s and 300 s respectively, at 50 mL/min. The bound spike/IgG complex was regenerated
from the anti-his antibody surface using 10 mM Glycine pH 1.5. Blank buffer cycles were performed by injecting running buffer
instead of IgG to remove systematic noise from the binding signal. The resulting data was processed and fit to a 1:1 binding model
using Biacore Evaluation Software.





Recombinant Indiana VSV (rVSV) expressing SARS-CoV-2 spikes were generated as previously described (Han et al., 2021; Liu et al.,
2020b). HEK293T cells were grown to 80% confluency before transfection with pCMV3-SARS-CoV-2-spike (kindly provided by Dr.
Peihui Wang, Shandong University, China) using FuGENE 6 (Promega). Cells were cultured overnight at 37Cwith 5% CO2. The next
day,mediumwas removed and VSV-G pseudo-typedDG-luciferase (G*DG-luciferase, Kerafast) was used to infect the cells in DMEM
at anMOI of 3 for 1 hr before washing the cells with 1X DPBS three times. DMEM supplemented with anti-VSV-G antibody (I1, mouse
hybridoma supernatant fromCRL-2700; ATCC) was added to the infected cells and theywere cultured overnight as described above.
The next day, the supernatant was harvested and clarified by centrifugation at 300 g for 10 min and aliquots stored at 80C.
Neutralization assays were performed by incubating pseudoviruses with serial dilutions of antibodies, and scored by the reduction
in luciferase gene expression. In brief, Vero E6 cells were seeded in a 96-well plate at a concentration of 23 104 cells per well. Pseu-
doviruses were incubated the next daywith serial dilutions of the test samples in triplicate for 30mins at 37C. Themixture was added
to cultured cells and incubated for an additional 24 hr. The luminescence was measured by Britelite plus Reporter Gene Assay Sys-
tem (PerkinElmer). IC50 was defined as the dilution at which the relative light units were reduced by 50% compared with the virus
control wells (virus + cells) after subtraction of the background in the control groups with cells only. The IC50 values were calculated
using non-linear regression in GraphPad Prism.
Antibody gene assignments and genetic analyses
The 158 SARS-COV-2 neutralizing antibodies were collected from ten publications. We annotated these antibodies using IgBLAST-
1.16.0 with the default parameters (Ye et al., 2013). For antibodies which have cDNA sequences deposited, the V and J genes were
assigned using SONAR version 2.0 (https://github.com/scharch/sonar/) with germline gene database from IMGT (Lefranc et al.,
2009; Schramm et al., 2016). For each antibody, the N-addition, D gene, and P-addition regions were annotated by IMGT V-QUEST
(Brochet et al., 2008). To identify somatic hypermutations, each antibody sequence was aligned to the assigned germline gene using
MUSCLE v3.8.31 (Edgar, 2004). Somatic hypermutations were identified from the alignment. In addition, the analysis of single cell
antibody repertoire sequencing data of SARS-CoV-2 patient 2 from Liu et al. (2020b), from which 2-15 and 2-43 were isolated,
showed that 29 of the 38 unique transcripts assigned to IGLV2-14*01 share nucleotide mutations G156T and T165G. These muta-
tions lead to amino acid mutations E50D and N53K. Both nucleotide mutations are also observed in 82 of 90 unique IGLV2-14 tran-
scripts from patient 1 of the same study. Because these transcripts having different VJ recombination and paired with different heavy
chain genes, the chances that the two convergent mutations are the results of somatic hypermutation are very low. Thus, we suspect
that both donors contain a new IGVL2-14 gene allele (IGVL2-14*0X), whichwas deposited to European Nucleotide Archive (ENA) with
project accession numbers: PRJEB31020. 2-43 and 2-15 were assigned to the IGLV2-14*0X allele.
Cryo-EM data collection and processing
For mAb 2-43, SARS-CoV-2 spike protein at a concentration of 2 mg/ml was incubated with six-fold molar excess per spike trimer of
the antibody Fab fragments for 30 minutes in 10 mM sodium acetate pH 5.5, 150 mM NaCl, and 0.005% n-dodecyl-b-D-maltoside
(DDM). 2mL of the sample was incubated on C-flat 1.2/1.3 carbon grids for 30 s and vitrified using a Leica EMGP. Data were collected
on a Titan Krios electron microscope operating at 300 kV, equipped with a Gatan K3 direct electron detector and energy filter, using
the Leginon software package (Suloway et al., 2005). A total electron fluence of 51.69 e-/Å2 was fractionated over 40 frames, with a
total exposure time of 2.0 s. Amagnification of 81,000x resulted in a pixel size of 1.058 Å, and a defocus range of0.4 to3.5 mmwas
used.
For mAb 2-15, SARS-CoV-2 spike protein at a concentration of 1 mg/ml was incubated with a molar ratio of 1:1 Fab fragments to
spike trimer for 30minutes in 10mMsodium acetate pH 5.5, 150mMNaCl, and 0.005%%DDM. 2mL of the sample was incubated on
C-flat 1.2/1.3 carbon grids for 30 s and vitrified using a Leica EMGP. Data were collected on a Titan Krios electron microscope oper-
ating at 300 kV, equipped with a Gatan K3 direct electron detector and energy filter, using the Leginon software package (Suloway
et al., 2005). A total electron fluence of 52.40 e-/Å2 was fractionated over 60 frames, with a total exposure time of 3.0 s. A magnifi-
cation of 81,000x resulted in a pixel size of 1.070 Å, and a defocus range of 0.8 to 3.4 mm was used.
For mAb H4, SARS-CoV-2 spike protein at a concentration of 1 mg/ml was incubated with eight-fold molar excess per spike trimer
of the antibody Fab fragments for 30minutes in 10mMsodium acetate pH 5.5, 150mMNaCl, and 0.005%%DDM. 2mL of the sample
was incubated on C-flat 1.2/1.3 carbon grids for 30 s and vitrified using a Leica EMGP. Data were collected on a Titan Krios electron
microscope operating at 300 kV, equipped with a Gatan K3 direct electron detector and energy filter, using the Leginon software
package. A total electron fluence of 42.00 e-/Å2 was fractionated over 40 frames, with a total exposure time of 3.0 s. A magnification
of 81,000x resulted in a pixel size of 1.070 Å, and a defocus range of 0.5 to 3.5 mm was used.
All processing was done using cryoSPARC v2.15.0 (Punjani et al., 2017). Rawmovies were aligned and dose-weighted using patch
motion correction, and the CTF was estimated using patch CTF estimation. A small subset of approximately 200 micrographs were
picked using blob picker, followed by 2D classification and manual curation of particle picks, and used to train a Topaz neural
network. This network was then used to pick particles from the remaining micrographs, which were extracted with a box size of
384 pixels.
For the mAb 2-43 dataset, 2D classification followed by ab initiomodeling and 3D heterogeneous refinement revealed 61,434 par-
ticles with three Fabs bound, one to each RBD. A reconstruction of these particles with imposed C3 symmetry resulted in a 3.78 Å




map, as determined by gold standard Fourier shell correlation (FSC). Symmetry expansion followed by masked local refinement was
used to obtain a 3.81 Å map of the Fab and RBD. The remainder of the S trimer was subjected to local refinement to obtain a 3.61 Å
map. These two separate local refinements were aligned and combined using the vop maximum function in UCSF Chimera (Pet-
tersen et al., 2004). This was repeated for the half maps, whichwere used alongwith the refinementmask from the global non-uniform
refinement to calculate the 3D FSC (ref) and obtain an estimated resolution of 3.60 Å. All maps have been submitted to the EMDBwith
the ID EMDB-23165.
For the mAb 2-15 dataset, 2D classification followed by ab initiomodeling and 3D heterogeneous refinement revealed 16,590 par-
ticles with one Fab bound to an RBD in the ‘down’ conformation and 21,456 particles with one Fab bound to an RBD in the ‘up’
conformation. The particles with Fab bound to RBD down were refined using Non-uniform refinement and C1 symmetry to a global
resolution of 5.73 Å as determined by gold standard FSC. The RBD and Fab weremasked and subjected to local refinement to obtain
a map at 6.21 Å. The remainder of the trimer was also refined locally to 5.63 Å. A consensus map was obtained as described for mAb
2-43, with a resolution of 5.87 Å. All maps have been submitted to the EMDB with the ID EMDB-23166.
For the mAb H4 dataset, 2D classification followed by ab initiomodeling and 3D heterogeneous refinement revealed 102,290 par-
ticles with one Fab bound to an RBD in the ‘up’ conformation. No classes with Fab bound to ‘down’ RBD were identified. 3D Vari-
ability Analysis was used to visualize the significant conformational heterogeneity of the ‘up’ RBD. Using the first and last frames of
the reaction coordinate as referencemaps, representing the extremes of the orientations adopted by the RBD, heterogeneous refine-
ment was repeated to separate the Fab-bound spikes into more homogeneous classes. 56,080 particles adopted a more stable
conformation and were refined to 4.78 Å using homogeneous refinement and C1 symmetry. Like the previously described datasets,
the Fab and RBD were refined locally to 5.03 Å, with the remainder of the S trimer being refined to 4.32 Å. The final consensus map
was estimated to have a resolution of 5.07 Å. All maps have been submitted to the EMDB with the ID EMDB-23167.
Cryo-EM model building
An initial homologymodel of the 2-43 Fab was built using Schrödinger Release 2020-2:BioLuminate (Zhu et al., 2014) and of H4 using
ABodyBuilder (Leem et al., 2016). For mAb 2-15, the crystal structure determined here (PDB: 4HK0) was used as a starting model for
the Fab variable domain and the associated RBD. For all models, the S trimer wasmodeled using the coordinates from PDB ID 6XEY.
Thesemodels were docked into the consensusmap usingChimera. Themodel was then fitted interactively using ISOLDE 1.0.1 (Croll,
2018) and COOT 0.8.9.2 (Emsley and Cowtan, 2004) and using real space refinement in Phenix 1.18 (Adams et al., 2004). For Fab 2-
43, in cases were side chains were not visible in the experimental data, they were truncated to alanine except for residues very close
to the RBD:Fab interface. Both H4 and 2-15 were built as poly-alanine models due to the low resolution of the experimental data.
Validation was performed using Molprobity (Davis et al., 2004) and EMRinger (Barad et al., 2015). Models were submitted to the
PDBwith the following IDs: mAb 2-43 is 7L56,mAbH4 is 7L58, and 2-15 is 7L57. Figures were prepared using UCSFChimeraX (God-
dard et al., 2018).
X-ray data collection, structure solution, model building and refinement
For determination of the complex of with RBD, the two proteins were mixed at 1:1 molar ratio and incubated at 4.0C for 60 min.
RBD:2-15 complexwas then isolated by gel filtration on Superdex-200 (GEHealthcare). Fractions containing complexeswere pooled
and concentrated to 6.5 mg/ml in SEC buffer. Screening for initial crystallization conditions was carried out in 96-well sitting drop
plates using the vapor-diffusion method with a Mosquito crystallization robot (TTP LabTech) using various commercially available
crystallization screens. Diffracting crystals were obtained from 0.1 M HEPES pH 7.5 and 70% MPD. Crystals were directly frozen
and X-ray diffraction data was collected to 3.18 Å resolution at 100 K from a single flash-cooled crystal on beamline ID-C at the
Advance Photon Source (APS) at Argonne National Laboratory. Diffraction data were processed with XDS (Kabsch, 2010) and scaled
using AIMLESS (Evans, 2006) from the CCP4 software suite (Collaborative Computational ProjectNumber 4, 1994). Molecular
replacement was performed with Phaser (McCoy et al., 2007), with previously reported RBD structure (PDB 7BZ5) and Fab (PDB
code, 4HK0) as search models. Manual rebuilding of the structure using COOT (Emsley et al., 2010) was alternated with refinement
using Phenix refine (Afonine et al., 2012) and PDB-REDO (Joosten et al., 2014). The Molprobity server was used for structure valida-
tion and PyMOL (version 2.1, Schrödinger, LLC) for structure visualization (Chen et al., 2010). A summary of the X-ray data collection
and refinement statistics are shown in Table S2. PISA was used to identify paratope-epitope interfaces and to calculate buried sur-
face area (Krissinel and Henrick, 2007). Hydrogen bonds were identified with a cutoff of 3.8Å. 2-15 model was submitted to the PDB
with the following IDs: 7L5B.
Calculation of angle of approach
Tomeasure the RBD approaching angle of antibodies, we first identify shared epitope residues among the fivemembers of the VH1-2
antibody class. PyMOL was used to determine the center of mass of the shared epitope residues. We then determined the center of
mass for heavy (the center of mass of the conserved Cys at 22 and 92) and light chains (the center of mass of the conserved Cys at 23
and 88). The heavy and light chain approaching angle was determined by linking the chain center of mass to the center of mass of the
shared epitope. PyMOL was used to make structure figures. For antibody B38, the epitope center of mass was determined using the
epitope residues of the antibody.




QUANTIFICATION AND STATISTICAL ANALYSIS
The statistical analyses for the pseudovirus neutralization assessments were performed using GraphPad Prism. The SPR data were
fitted using Biacore Evaluation Software. Cryo-EM data were processed and analyzed using CryoSparc and Relion. Cryo-EM struc-
tural statistics were analyzed with Phenix and Molprobity. Statistical details of experiments are described in Method details or figure
legends.




4.5 Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain
target a single supersite
Neutralizing antibodies that target the N-terminal domain (NTD) are far-less studied than those
targeting RBD, even though they have comparable levels of neutralization [218]. Their ability to
target a wholly different domain makes them obvious choices to combine with RBD-directed anti-
bodies for therapeutic use. In this work, we solved multiple structures of NTD-directed antibodies
using cryo-EM. Our work and others [238, 239] show that these antibodies target a single antigenic
supersite.
Much of the NTD is heavily shielded by glycosylation, and the supersite is the most exposed
surface. It is also a highly electropositive surface defined by a mobile ß-hairpin and several flexible
loops. The flexibility of these loops may be responsible for the relatively low resolution of the
reconstruction of an NTD-directed F(ab) bound to spike in our initial study [218]. The solution to
this problem was to further lower the pH of the sample during preparation for vitrification from
5.5, which largely works well for RBD-directed antibodies, to 4.5. This allowed high-resolution
reconstruction of numerous NTD-directed antibodies. Unfortunately, not all antibodies bind at
such a low pH and were often resolved to lower resolution as samples had to be vitrified at pH 5.5
to preserve binding.
The neutralization mechanisms of NTD-directed antibodies appear complex. Though their
general position may sterically inhibit binding of ACE2, they do not compete with ACE2 binding
[218]. There is some evidence that these antibodies interfere with a post-attachment step in the
fusion process [239] or possibly by interfering with spike binding to an auxiliary receptor.
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Cerutti et al. report structural analysis of
seven potent neutralizing antibodies
targeting the N-terminal domain of SARS-
CoV-2 spike. All antibodies recognize a
common glycan-free, electropositive
surface comprised of a mobile b-hairpin
and flexible loops. While RBD-directed
antibodies recognize non-overlapping
epitopes, these findings indicate that
NTD-directed antibodies predominantly
target a single supersite.
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SUMMARY
Numerous antibodies that neutralize SARS-CoV-2 have been identified, and these generally target either the
receptor-binding domain (RBD) or the N-terminal domain (NTD) of the viral spike. While RBD-directed anti-
bodies have been extensively studied, far less is known about NTD-directed antibodies. Here, we report
cryo-EM and crystal structures for seven potent NTD-directed neutralizing antibodies in complex with spike
or isolated NTD. These structures defined several antibody classes, with at least one observed in multiple
convalescent donors. The structures revealed that all seven antibodies target a common surface, bordered
by glycans N17, N74, N122, and N149. This site—formed primarily by a mobile b-hairpin and several flexible
loops—was highly electropositive, located at the periphery of the spike, and the largest glycan-free surface of
NTD facing away from the viral membrane. Thus, in contrast to neutralizing RBD-directed antibodies that
recognize multiple non-overlapping epitopes, potent NTD-directed neutralizing antibodies appear to target
a single supersite.
INTRODUCTION
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
2), the causative agent for coronavirus disease 2019 (COVID-
19), emerged in 2019, rapidly establishing an ongoing worldwide
pandemicwith tens ofmillions infected and over onemillion dead
(Callaway et al., 2020; Cucinotta and Vanelli, 2020; Dong et al.,
2020). In response, an unprecedented global effort to develop
vaccines and therapeutics is well underway. One promising
approach is the identification of SARS-CoV-2-neutralizing anti-
bodies, which could be used as therapeutic or prophylactic
agents. Analysis of such antibodies can reveal viral sites of
vulnerability to antibody neutralization, which can help guide
the development of vaccines or therapeutics (Burton and
Walker, 2020). The primary target for neutralizing antibodies is
the viral spike protein, a trimeric type I viral fusionmachine (Walls
et al., 2020; Wrapp et al., 2020b) that binds virus to the ACE2 re-
ceptor on host cells (Benton et al., 2020; Yan et al., 2020; Zhou
et al., 2020) andmediates fusion between the viral and cell mem-
branes. The spike protein is comprised of two subunits: the S1
subunit comprising the N-terminal domain (NTD), the receptor-
binding domain (RBD) and several other subdomains, and the
S2 subunit that mediates virus-cell membrane fusion (Walls
et al., 2020; Wrapp et al., 2020b).
The majority of SARS-CoV-2 neutralizing antibodies so far
identified target RBD (Brouwer et al., 2020; Cao et al., 2020;
Chen et al., 2020; Chi et al., 2020; Ju et al., 2020; Liu et al.,
2020b; Pinto et al., 2020; Robbiani et al., 2020; Rogers
et al., 2020; Seydoux et al., 2020; Wang et al., 2020a; Wrapp
et al., 2020a; Wu et al., 2020; Zeng et al., 2020; Zost et al.,
2020). Structural studies (Barnes et al., 2020a, 2020b; Liu
et al., 2020a; Wang et al., 2020b; Yuan et al., 2020b) and bind-
ing competition experiments (Liu et al., 2020a) have revealed
neutralizing antibodies to recognize RBD at multiple distinct
sites and further revealed multi-donor RBD-directed antibody
classes that appear to be elicited with high frequency in the hu-
man population (Barnes et al., 2020b; Robbiani et al., 2020; Wu
et al., 2020; Yuan et al., 2020b), as well as in mice with a hu-
manized immune system (Hansen et al., 2020). Neutralization
for many RBD-directed antibodies can be explained by interfer-
ence with RBD-ACE2 interaction and/or impeding the ability of
RBD to adopt the ‘‘up’’ conformation (Barnes et al., 2020b; Liu
et al., 2020a; Yuan et al., 2020b) required for ACE2 binding
(Benton et al., 2020).
Cell Host & Microbe 29, 819–833, May 12, 2021 ª 2021 Elsevier Inc. 819
ll
NTD-directed neutralizing antibodies targeting the Middle
East respiratory syndrome (MERS) betacoronavirus have been
extensively characterized (Chen et al., 2017; Pallesen et al.,
2017; Wang et al., 2018; Zhou et al., 2019). For SARS-CoV-2,
three cryo-EM structures have been reported for NTD-directed
neutralizing antibodies: 4A8 (Chi et al., 2020), FC05 (Wang
et al., 2021), and CM25 (Voss et al., 2020) in complex with
SARS-CoV-2 spike, the last two reported near the time of sub-
mission of this paper. NTD-directed antibodies have also been
observed in electron microscopy (EM) analyses of antibodies
from the sera of convalescent donors (Barnes et al., 2020b;
Brouwer et al., 2020), and a low-resolution structure of a very
potent antibody 4-8 has been reported (Liu et al., 2020a). This
report was also notable for the identification of multiple NTD-
neutralizing antibodies with potencies rivaling those of the best
RBD-directed neutralizing antibodies.
Here, we describe cryo-EM and crystal structures for seven
potently neutralizing antibodies in complex with either SARS-
CoV-2 spike or NTD. We analyzed the genetic basis of recogni-
tion for each of the seven antibodies and further clustered them
into antibody classes with similar genetics and modes of recog-
nition. We also analyzed the antibody angles of approach and
their recognized epitope. Remarkably, all seven antibodies
targeted a single glycan-free surface of NTD, defining an NTD-
antigenic supersite. We propose that all potently neutralizing
NTD-directed SARS-CoV-2 neutralizing antibodies might target
this site.
RESULTS
NTD-directed SARS-CoV-2 neutralizing antibodies
Prior studies have identified SARS-CoV-2-neutralizing anti-
bodies that are S1-directed, but do not recognize RBD (Brouwer
et al., 2020; Kreer et al., 2020; Rogers et al., 2020; Seydoux et al.,
2020; Zost et al., 2020). Other studies have further delineated
recognition and shown such antibodies to recognize NTD (Chi
et al., 2020; Liu et al., 2020a; Zost et al., 2020). We identified a
total of 17 published NTD antibodies, confirmed by the ELISA
binding and competition data (Figure S1). We found that they
derived from only nine VH genes, with antibodies originating
from five genes (VH1-24, VH1-69, VH3-30, VH1-8, and VH4-39)
evident in multiple donors. While these observations were
sparse, they raised the possibility that NTD-directed neutralizing
responses in different individuals could involve the convergent
development of similar antibodies.
Structures for seven such antibodies in complex with SARS-
CoV-2 spike or isolated NTD are presented below, grouped by
VH gene.
NTD-directed neutralizing antibodies derived from VH1-
24 represent a multi-donor class
Four NTD-directed neutralizing antibodies identified from conva-
lescent donors—antibodies 1-68 and 1-87 from ‘‘donor 1,’’ 2-51
from ‘‘donor 2’’ (Liu et al., 2020a), and antibody 4A8 from a third
donor (Chi et al., 2020)—all of which derive from the VH1-24
gene (Figure 1A). In addition to utilizing the same VH gene, three
of these antibodies, 1-68, 1-87, and 4A8, utilized an identical set
of heavy-chain-antibody genes—VH1-24, D6-19, and JH6—and
showed significant similarity in their heavy chain third-comple-
mentarity-determining regions (CDR H3s), each of which was
21 amino acids in length (Figure S2). Antibody 2-51 also utilized
VH1-24, but utilized different D and J genes, D6-13 and JH4, en-
coding a shorter CDR H3 region of only 14 amino acids. These
VH1-24-derived antibodies utilized four different VL-genes:
1-87, 2-51, and 1-69 utilized lambda light chains VL2-14,
VL2-8, and VL2-18, respectively, while 4A8 utilized kappa light
chain VK2-24.
We determined cryo-EM structures for the spike complexes
with antibodies 1-68, 1-87, and 2-51 at overall resolutions of
3.8, 3.63, and 3.71 Å, respectively (Figures 1B and S3A; Table
S1). We also produced a locally refined cryo-EM map around
the antibody:spike interface for 1-87 at 3.83-Å resolution, which
allowed construction and refinement of an atomic model (Fig-
ure 1C). However, resolution in the antibody:spike interface
region was blurred by domain motions for antibodies 2-51 and
1-68. We therefore produced crystals for 2-51 in complex with
NTD, which provided an X-ray structure at 3.65-Å resolution (Fig-
ure 1D; Table S2).
Cryo-EM reconstructions of the VH1-24-derived 1-68, 1-87,
and 2-51 antibodies each show a single Fab bound to the NTD
of one subunit of the trimeric spike (Figure 1B). All antibodies
target, with similar angle of approach, a single region on
NTD—the loop region furthest from the spike-trimer axis. More-
over, the epitope and angle of approach for antibodies 1-68, 1-
87 and 2-51 appear similar to those of antibody 4A8 (Chi et al.,
2020), also derived from the VH1-24 gene.
Chi et al. (2020) defined the NTD loops in the 4A8-binding re-
gion as N1-N5 (corresponding to residue stretches 14 to 26, 67
to 79, 141 to 156, 177 to 186, and 246 to 260, respectively), and
we adopt this nomenclature here. We note that the region
defined as the N3 loop corresponds to a b-hairpin that includes
both b strands that form a stem region and a short loop that
connects them. The N1-N5 loops are disordered in most struc-
tures of spike, but some of these loops become ordered in anti-
body complexes. The structure of antibody 1-87 in complex
with spike reveals almost all interactions to be mediated
through heavy chain, with heavy chain accounting for 1057 Å2
buried surface area and light chain 126 Å2. The 19-residue
CDR H3 loop provides the predominant interaction (Figure 1C,
middle), with additional contributions mainly from CDR H1 (Fig-
ure 1C, right). CDR H3, which inserts between the N3 and N5
loops of NTD (Figure 1C, left) includes several hydrophobic res-
idues (Ile96HC, Val98HC, Ile99HC, Pro100bHC, and Tyr100 hHC)
that interact with aromatic residues in N3, including Tyr145NTD
and Trp152NTD, and with hydrophobic residues of N5. Residues
Ser100dHC and Asp101HC in CDR H3 also form hydrogen
bonds with Trp152NTD and Gly252NTD, respectively; the N-ter-
minal glutamine residue of the heavy chain is also involved
in hydrogen bonds with Ser254NTD and Ser255NTD in N5.
Residues in CDR H1 form a network of hydrogen bonds
involving positively charged residues from N3(Lys147NTD), and
N5(Arg246NTD), with interactions by the side chains of CDR
H1 residues Tyr27HC and Glu31HC. Two additional VH1-24-
gene-specific glutamic acid residues—Glu53HC in CDR H2 (Fig-
ure S4A)—and framework residue Glu71HC each participate in
salt bridges with NTD. The only interaction mediated by the
light chain is a hydrophobic interaction between Tyr49LC in
CDR L2 and Pro251NTD in N5.
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Figure 1. NTD-directed neutralizing antibodies derived from the VH1-24 gene define a multi-donor antibody class
(A) Sequence alignment of VH1-24-derived NTD-directed antibodies showing paratope residues, somatic hypermutations, and gene-specific substitution profile
(GSSP) showing somatic hypermutation probabilities for VH1-24 gene. Antibody positions are assigned using the Kabat scheme, the CDRs are assigned by IMGT
scheme. Paratope residues are highlighted by underscoring and colored by interaction types. Amino acids in GSSP are colored by chemical property.
(B) Cryo-EM reconstructions for spike complexes with antibodies 1-87, 1-68, and 2-51. NTD is shown in orange, RBD in green, and glycans in red, with antibody
heavy chains in magenta and light chains in gray.
(C) Expanded view of 1-87 interactions with NTD showing overall interface (left), recognition by CDR H3 (middle), and recognition by CDR H1 (right). NTD regions
N3 (residues 141–156) and N5 (residues 246–260) are colored in shades of orange; CDRH1, H2, and H3 are colored in shades of magenta; CDR L1, L2, and L3 are
colored in shades of gray. Nitrogen atoms are colored in blue and oxygen atoms in red; hydrogen bonds (distance < 3.2 Å) are represented as dashed lines.
(D) Crystal structure of antibody 2-51 complexed with NTD, colored as in (B).
(E) Expanded view of 2-51 interactions with NTD showing overall interface (left), recognition by CDR H3 (middle), and recognition by CDR H1 (right), colored as
in (C).
See also Figures S1–S7 and Tables S1 and S2.
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The crystal structure of antibody 2-51 in complex with NTD
reveals recognition remarkably similar to that of 1-87. The
14-residue CDR H3 loop of 2-51 inserts between the N3 and
N5 loops of NTD (Figure 1E, left) with additional interactions
from CDR H1. CDR H3 includes three aromatic residues
(Trp96HC, Tyr98HC, and Tyr102HC), which interact with aromatic
residues in N3, including Tyr145NTD and Trp152NTD, and with
hydrophobic residues of N5, including Tyr248NTD, Leu249NTD,
and Pro251NTD (Figure 1E, middle). The heavy chain Gln1HC
residue is involved in hydrogen bonds with Thr250NTD and
Pro251NTD in N5, similar to the hydrogen-bonding pattern
observed for 1-87. The only interaction mediated by the light
chain is a hydrogen bond between Ser56LC in CDR L2 and
Asp253NTD in N5. Residues of CDR H1 form a network of
hydrogen bonds nearly identical to the network formed in
the 1-87 crystal structure (Figure 1E, right). Comparison of the
1-87 and 2-51 structures reveals a comparable level of similar-
ity with VH1-24-derived antibody 4A8.
Overall, their common derivation from a common gene and
highly similar recognition show the VH1-24 antibodies to define
a multi-donor antibody class. Overall, the interaction is domi-
nated by conserved contacts in CDRH1, alongwith hydrophobic
interactionsmediated by CDRH3. The VH1-24 gene restriction is
explained partly by the conserved interactions of CDR H1,
including those of the VH1-24-specific Glu31 and VH1-24-spe-
cific residues Glu53 and Glu71 (Figure S5A).
NTD-directed neutralizing antibodies derived from VH3-
30 and VH3-33 genes show distinct recognition
Three neutralizing antibodies directed against NTD have been
reported that derived from the highly similar VH genes VH3-30
and VH30-33. The high similarity of these genes, which encode
only two amino acid differences between them (Figure 2A),
raised the possibility that these antibodies might represent a
multi-donor class despite their derivation from two distinct
genes. We therefore determined cryo-EM structures for spike
complexes with antibodies derived from each gene: antibody
4-18 from VH3-30 and antibody 5-24 from VH3-33 at 2.97 and
3.93 Å resolutions, respectively (Figures 2B–2C, S3B, and S3C;
and Table S1).
The cryo-EM structure of antibody 4-18 in complex with spike
reveals an epitope that overlaps the VH1-24 antibodies, but with
a significantly different overall mode of recognition. Overall, in-
teractions are primarily mediated by CDR H2 and CDR L3, with
additional contributions from CDRs H3, L1, and L2 (Figure 2D,
left; Figure S4B). While CDR H3 inserts between NTD loops N3
and N5 like VH1-24 antibodies, the light chain CDR L3 binds
adjacent to this region and also forms interactions with the
NTD N1 loop. CDR H2 mediates extensive hydrogen bonding
and hydrophobic interactions with NTD (Figure 2D, middle).
CDR H2 residues Ser55HC and Asn56HC form hydrogen bonds
with both backbone and side chain of Asn17NTD at the base of
the NTD N17 glycan in the N1 region. CDR H2 residues Ser52HC
and His58HC also form hydrogen bonds with Tyr248NTD in N5.
Hydrophobic interactions are observed for CDR H2 residue
Val50HC with Leu249NTD and Tyr52aHC with Pro251NTD in N5. In
the light chain, Tyr95bLC from the CDR L3 loop hydrogen bonds
with glycan N17 (Figure 2D, right) within the N-terminal region,
which is typically disordered in ligand-free spikes.
Despite containing multiple aromatic residues in CDR H3, for
the most part, these residues do not form substantial hydropho-
bic interactions with residues from NTD, with exceptions of
Tyr98HC and Tyr100HC, which bury 98 and 205 Å
2 accessible sur-
face area in the interface, respectively (Figure S4B, left). Rather,
the primary interactions mediated by CDR H3 are hydrogen
bonds, including from the backbone carbonyl of Tyr98HC with
the backbone amide of NTD Ser247NTD and a hydrogen bond
from the side chain hydroxyl of Tyr100HC with the side chains
from NTD residues Glu156NTD and Arg158NTD.
The structure of VH3-33-derived antibody 5-24 (Figure 2C) in
complex with spike reveals targeting of an overlapping epitope
in NTD, but with overall recognition mediated by CDR H3 with
additional contributions from CDR H1, but without the involve-
ment of CDR L3 as seen for antibody 4-18 (Figure 2E, left).
Also different from 4-18, four aromatic residues in the CDR H3
region of antibody 5-24 make extensive hydrophobic contacts
with NTD loop N5 and the stem of the N3 b-hairpin (Figure 2E,
middle), distinct from the hydrogen bond-dominated recognition
observed in 4-18; recognition by other CDRs is also different.
Overall, while they target overlapping regions in NTD, recogni-
tion by VH3-33-derived antibody 5-24 is substantially different
from thatmediated by VH3-30-derived antibody 4-18. These dis-
similarities show that, despite their derivation from highly similar
VH genes, theNTD-directed neutralizing antibodies fromVH3-30
and VH3-33 are not members of a single antibody class. Struc-
tural analysis showed that Ser52HC from VH3-30 forms a
hydrogen bond with Tyr248NTD. Substitution of Ser52HC with
the VH3-33-encoded Trp would lead to significant clashes with
residues in CDR H2 and NTD loops N1 and N5 (Figure S4C),
which could abolish the interaction between 4-18 and NTD.
This suggests that the VH3-33 antibodies containing Trp52HC
cannot recognize NTD through a binding mode similar to VH3-
30 antibody 4-18.
NTD-directed neutralizing antibodies derived from the
VH1-69 gene appear to comprise both reproducible and
distinct classes
Of the 17 currently characterized NTD-directed or likely NTD-
directed neutralizing antibodies (Figure S1A), three—antibodies
2-17 and 4-8 (Liu et al., 2020a) and antibody COV2-2676 (Zost
et al., 2020)—derived from the VH1-69 gene, with antibodies
2-17 and 4-8 deriving from the VH1-69*01 and VH1-69*02 al-
leles, respectively (Figure 3A). Further, the CDR L3 regions of
2-17 and COV2-2676 showed high similarity (Figure 3E). To un-
derstand the recognition of these VH1-69-derived antibodies,
we determined cryo-EM structures for spike complexes with
the twomost potent: antibodies 2-17 and 4-8 with IC50 potencies
of 0.007 and 0.009 mg/mL.
Single-particle cryo-EM data for antibody 4-8 yielded a 3D
reconstruction at 3.25-Å resolution (Figures 3B and S3D; Table
S1); however, like antibody 2-17 (Figures 3C and S3E; Table
S1), and as reported previously (Liu et al., 2020a), high mobility
of the bound Fab blurred the interface region. We used local
refinement with particle subtraction to obtain a high-quality
reconstruction for the 4-8 interface with spike (Figure 3D). Like
the VH1-24-derived antibodies, CDR H3 binds between the
NTD N3 and N5 loops, but in a distinctive way; CDR H3 domi-
nates the interface and its approach to the N3/N5 region is nearly
ll
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Figure 2. NTD-directed neutralizing antibodies derived from the closely related VH3-30 and VH3-33 genes show distinct binding modes
(A) Sequence alignment of VH3-30-derived (4-18) and VH3-33-derived (5-24) NTD-directed antibodies showing paratope residues, somatic hypermutations, and
gene-specific substitution profile (GSSP) showing positional somatic hypermutation probabilities for VH3-30 gene. Substitutions between VH3-30 and VH3-33
germline genes are highlighted in green.
(B) Cryo-EM reconstruction for spike complex with antibody 4-18 from two orthogonal views; NTD is shown in orange, RBD in green, and glycans in red, with
antibody heavy chain in blue and light chain in gray.
(C) Cryo-EM reconstruction for spike complex with antibody 5-24 from two orthogonal views; NTD is shown in orange, RBD in green, and glycans in red, with
antibody heavy chain in brown and light chain in gray.
(D) Expanded view of 4-18 interactionswith NTD showing the overall interface (left), recognition in CDRH2 (middle), and recognition in CDR L3 (right). NTD regions
N1 (residues 14–26), N3 (residues 141–156), and N5 (residues 246–260) are shown in shades of orange; CDRH1, H2, andH3 are shown in shades of blue; CDR L1,
L2, and L3 are shown in shades of gray.
(E) Expanded view of 5-24 interactions with NTD showing the overall interface (left), recognition in CDR H3 (middle), and recognition in CDR H1 (right), colored as
in (D) except for CDR H1, H2, and H3, which are colored in shades of brown.
See also Figures S1, S3, and S6, and Table S1.
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Figure 3. NTD-directed neutralizing antibodies derived from the closely related VH1-69*01 and VH1-69*02 genes show distinct bind-
ing modes
(A) Sequence alignment for VH1-69*01-derived (2-17) and VH1-69*02-derived (4-8) NTD-directed antibodies showing somatic hypermutations and paratope
residues, with gene-specific substitution profile (GSSP) showing positional somatic hypermutation probabilities for VH1-69. Residues that differ between VH1-
69*01 and VH1-69*02 alleles are highlighted in green.
(B) Cryo-EM reconstruction for spike complex with antibody 4-8; NTD is shown in orange, RBD in green, glycans and in red, with antibody heavy chain in teal and
light chain in gray. Heavy and light chain footprint on NTD (right).
(C) Cryo-EM reconstruction for spike complex with antibody 2-17 (left); NTD is shown in orange, RBD in green, and glycans in red, with antibody heavy chain in
dark green and light chain in gray. Heavy and light chain footprint on NTD (right, NTD shown with template-based modeling).
(D) Expanded view of 4-8 interactions with NTD showing the overall interface (left), recognition in CDR H3 (middle), and recognition in CDR L2 (right). NTD regions
N1 (residues 14–26), N3 (residues 141–156), and N5 (residues 246–260) are shown in shades of orange; CDRH1, H2, and H3 are shown in shades of teal; CDR L1,
L2, and L3 are shown in shades of gray.
(E) Sequence alignment of light chain of VH1-69-derived antibodies showing diverse germline gene usage (2-17 and COV2-2676 utilizes kappa light chain; 4-8
utilizes lambda light chain); IGKV3-15*01 is used as reference. Paratope residues of 4-8 are colored as in (A).
See also Figures S1, S3, and S6, and Table S1.
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orthogonal to that observed for CDR H3 in the VH1-24 class an-
tibodies (Figure 3D, middle). Recognition by other CDRs is also
distinct from the other NTD-directed neutralizing antibodies (Fig-
ure 3D, right; Figure S4D)
We also collected single-particle cryo-EM data for antibody 2-
17, yielding a 3D reconstruction at 4.47-Å resolution (Figures 3C
and S3E; Table S1). Despite the poor resolution of the 2-17 cryo-
EM maps, we were able to locally refine the interface region and
model the antibody in complex with NTD as Ca chains.
We compared the heavy and light chain epitope footprints on
NTD for antibodies 4-18 (Figure 3B, right) and 2-17 (Figure 3C,
right). Notably, the orientation of the heavy and light chains be-
tween 2-17 and 4-8 were rotated 90 degrees from each other,
indicating different modes of recognition and showing that they
are of different classes.
We next asked whether other NTD-directed neutralizing anti-
bodies derived from VH1-69 heavy chain might be members of
the 2-17 or 4-8 classes. Analysis of light chains indicated anti-
bodies 2-17 and COV2-2676, derived from genes KV3-15 and
KV3-11, respectively, to be remarkably similar in their light chain
CDR L3 regions, suggesting that 2-17 and COV2-2676 might be
of the same class. Overall, we observed NTD-directed neutral-
izing antibodies from VH1-69 to form at least two classes, with
similarity of light chains suggesting antibodies 2-17 and COV2-
2676 might represent a reproducible class observed in two
different donors.
Functional requirements for somatic
hypermutation (SHM)
Sequence analyses showed that all NTD-directed antibodies
accumulate somatic hypermutations (SHMs) in their paratope
regions (Figures 1A, 2A, and 3A). To help understand charac-
teristics of the antibody precursors, we reverted the
paratope-region somatic hypermutations observed in seven
NTD-directed antibodies (1-87, 1-68, 2-51, 4-18, 5-24, 4-8,
and 2-17) to their respective germline residues. Overall, these
germline-reverted antibodies showed substantially reduced
binding affinities and neutralization potencies (Figure S6). For
the VH1-24 multi-donor antibody class, antibodies 1-87, 1-68,
and 2-51 shared two convergent SHMs (T30I and G55A/V) in
heavy chain, reversion of which showed significantly (4-20-
fold) reduced binding affinity (Figures S6A and S6B). For anti-
bodies 4-18 and 5-24, derived from VH3-30 and VH3-33,
respectively, reversion of SHMs in combination in each anti-
body nearly abolished neutralization (Figure S6C). For the two
VH1-69-derived antibodies 2-17 and 4-8, neutralization was
improved by SHMs by 20- and 8-fold, respectively. Thus,
all of the NTD-directed potently neutralizing antibodies we
tested required affinity maturation to achieve high binding affin-
ity and high potency. The VH3-30 and VH3-33 antibodies were
more sensitive to SHMs than the antibodies derived from other
VH genes. Nonetheless, antibodies corresponding to the initial
recombinants, with reversion of all paratope SHMs in combina-
tion, could still bind to spike with apparent IgG KDs 2–70 nM,
suggesting that precursor B cells of the NTD antibodies are
likely to be efficiently activated by spike binding. Gene-specific
substitution profiles (Sheng et al., 2017) showed that the
observed SHMs are each generated by the SHM machinery
with high frequencies (Figures 1A, 2A, and 3A), suggesting
that requirements for SHM are unlikely to present a significant
barrier to antibody development.
NTD-directed potently neutralizing antibodies have
similar angles of approach
To gain an overall understanding of the angle of antibody
approach to the spike by these NTD-directed potently neutral-
izing antibodies, we determined their angles of approach around
a latitudinal axis to define freedom between viral and host cell
membranes, and around a longitudinal axis to define freedom
within the plane of the membrane. Relative to the viral spike,
the latitudinal axis is perpendicular to the trimer axis, and the lon-
gitudinal axis is parallel to this axis. Latitudinal and longitudinal
approach angles among the NTD-neutralizing antibodies were
similar—with antibodies approaching spike with antigen-
combining surface oriented toward the viral membrane (Figures
4A–4C).
We also analyzed the heavy-light chain orientations in the
complexes with spike (Figure 4D). Here, the NTD-directed an-
tibodies differed, with three of the antibodies, 4-18 from VH3-
30 and 2-17 and 4-8 from VH1-69, showing heavy and light
chain angles of approach that differed from the other five an-
tibodies. Thus, while the heavy/light orientation relative to
spike could differ substantially, lesser differences were
observed in latitudinal and longitudinal angles of approach,
with all NTD-neutralizing antibodies approaching spike from
‘‘above’’ with their antigen-binding surfaces oriented toward
the viral membrane.
NTD-directed antibodies induce conformational
changes in NTD and spike
To gain insight into the impact of antibody recognition on the
conformation of NTD, we superimposed antibody-spike or anti-
body-NTD complexes onto the NTD domain and examined the
structural alteration in NTD versus NTD in the ligand-free spike
(PDB: 6ZGE), calculating the per-residue Camovement between
bound and ligand-free (Figure 5A), which ranged as high as 16–
18 Å for most of the NTD-directed antibodies, though 4-8 (10.1 Å)
and 5-24 (11.7 Å) were somewhat lower. The largest structural
change occurred in the N3 b-hairpin, although the mobile N1
and N5 loops also showed large deviations (Figure 5B). In gen-
eral, the regions of NTD that moved were contacted by antibody
(Figure 5C), indicating that the conformational changes were a
direct consequence of antibody binding. In addition to the
conformational change induced in NTD, we observed other
changes in spike. Notably, the 4-18 antibody-bound spike was
substantially better ordered than the other NTD-bound spikes
(achieving a nominal cryo-EM resolution of 2.97 Å, which was
1 Å better than most of the other complexes). Examination of
the 4-18 bound spike indicated almost 40 rotation in the central
S2 triple helical bundle (Figure S4E).
Overall, binding of NTD-directed antibodies induced substan-
tial structural rearrangements, not only in recognized loops but
also of the N3 b-hairpin. The higher immunogenicity observed
with flexible regions likely stems from increased accessibility
due to lower glycan coverage as well as the ability of these re-
gions to assume distinct conformations required for diverse an-




Cell Host & Microbe 29, 819–833, May 12, 2021 825
The NTD supersite
To define the spike surface recognized by potent NTD-directed
neutralizing antibodies, we analyzed the epitopes for all eight
of the NTD-directed neutralizing antibodies with defined struc-
tures: the seven described in this study as well as antibody
4A8, described previously (Table S3) (Chi et al., 2020). These
ranged in potency from remarkably potent 2-17 and 2-51
antibodies with IC50 of 0.007 mg/mL to the neutralizing, but sub-
stantially less potent, 4A8 with IC50 of 0.39 mg/mL; all eight of
these antibodies recognize overlapping epitopes on NTD (Fig-
ure 6A). Antigenic sites containing epitopes for genetically
diverse antibodies have been widely denoted as antigenic
‘‘supersites’’ in prior studies involving influenza virus and HIV an-
tibodies (Kong et al., 2013; Kumar et al., 2020; Lee and Wilson,
Figure 4. Angles of approach for NTD-directed neutralizing antibodies
(A) Overall approach of NTD-directed neutralizing antibodies to spike with angles defined with red arrows. The 3-fold axis is indicated by a black triangle. An-
tibodies are represented by long axes of the Fabs and colored by heavy chain colors defined in Figures 1, 2, and 3.
(B) Latitudinal and longitudinal angles of approach.
(C) Angles of recognition for antibodies grouped by VH gene. Notably, only those from VH1-24 show a consistent orientation.
(D) Heavy-light chain orientations show graphically (left) and quantitatively (right).
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2015; Longo et al., 2016; Moyo et al., 2020; Zhou et al., 2015;
Zhou et al., 2014); we define the spike surface recognized by
at least two antibodies, from different classes, of these eight
potent NTD-directed antibodies, as the NTD supersite (Fig-
ure 6B; Tables S4 and S5).
The NTD supersite was located at the periphery of the spike,
distal from the 3-fold axis, and facing away from the viral mem-
brane. This surface was surrounded by four glycans, N17, N74,
N122, and N149, and nominally ‘‘glycan free,’’ although molecu-
lar dynamics simulations with fully glycosylated spike indicated
some glycan coverage, though less than adjacent regions
more proximal to the spike 3-fold (Figure 6C).
To gain insight into the structural features of the NTD super-
site, we first analyzed the distribution of epitopes versus po-
tency, but did not observe substantial variation in potency over
the NTD supersite (Figure 6D, left). In addition, we measured
Fab affinity to spike (Table S6) but found no correlation with po-
tency. Electrostatic surface analysis revealed the supersite to
have strong positive electrostatic potential (Figure 6D, middle),
while recognizing antibodies had complementary strong electro-
negative potential (Figure S7).
With respect to recognized conformation, we compared the
ligand-free conformation of the supersite versus its antibody-
bound conformation; the recognized b strands at the center of
the epitope were displaced3 Å, with loops N1, N3, and N5mov-
ing substantiallymore, up to 18 Å (Figure 6D, right).With respect to
correlation with potency, we observed the magnitude of induced
NTD conformational change to trend inversely with potency. This
is not surprising in that the requirement for conformational change
is likely to lower the energy of binding. Notably, antibodies that
induced larger conformational changes were also more electro-
negative, potentially providing an explanation for the observation
that increasing negative charge trended with reduced potency.
Overall, the NTD supersite comprised a structurally plastic
surface, formed primarily by the N3 b-hairpin and including other
flexible regions such as the N1 and N5 loops. This surface was
also both glycan-free and highly electropositive—and facing
away from the electronegative viral membrane.
NTD supersites in other betacoronaviruses
To understand the generality of the single-NTD supersite that we
observe for SARS-CoV-2, we examined the recognition of
Figure 5. NTD-directed antibodies induce conformational changes in NTD and spike
(A) Conformational changes in NTD induced by binding of neutralizing antibodies. Antibody-bound NTDs are shown in cartoon representation and colored by per-
residue Ca movements compared to unliganded NTD. Antibodies are shown in gray cartoon. Major NTD loops interacting with antibodies are labeled.
(B) Sequence of NTD highlighting antibody contact and conformational change. Epitope residues for each antibody are marked with a number representing Ca
movements (Å) from unliganded NTD; the symbol ‘‘X’’ indicates movement 10 Å and above. Potential glycosylation sites on NTD are highlighted in green (dis-
tances are shown for antibodies with sufficiently resolved interfaces; antibody 2-17 was only at 4.4 Å, and the interface of antibody 1-68 showed extensive
mobility.
(C) Epitope regions on NTD (red) and their conformational change. Glycans on NTD are shown as green spheres.
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NTD-directed neutralizing antibodies targeting other betacorona-
viruses. Searches of the PDB found only two NTD-directed anti-
bodies targeting other betacoronaviruses: these two antibodies,
G2 (Wang et al., 2018) and 7d10 (Zhou et al., 2019), both neutral-
ized MERS and targeted overlapping glycan-free surfaces on
NTD facing away from the viral membrane (Figure 7A). The
Figure 6. A structurally plastic antigenic supersite in the distal-loop region of NTD revealed by comparison of antibodies derived from the
four multi-donor classes
(A) Epitopes of NTD-targeting antibodies colored by potency (cryo-EM structures were of sufficient resolution to define all epitopes, except for 2-17 and 1-68,
which utilized polyAla-based template modeling and homology modeling, respectively). Epitope residues are listed in Table S3.
(B) The supersite of vulnerability on NTD. Supersite residues are listed in Table S5.
(C) Glycan coverage of the spike. The NTD supersite is surrounded by glycans at N17, N74, N122, and N149.
(D) NTD structural properties and antibody potency. Epitope surfaces of different antibodies were overlaid onto NTD with shades of red representing potency
(left). Electrostatic potential on NTD (middle). Structural variation of NTD bound by NTD-directed antibodies (right).
See also Figures S1, S6, and S7, and Tables S3–S6.
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epitopes for both of these antibodiespartially overlapped the anal-
ogous surface comprising the NTD supersite in SARS-CoV-2 but
weremore centrally located andmoreproximal to the spike 3-fold.
Quantification of the average number of proximal glycan
atoms indicated lower glycan density over the NTD supersite
than over the equivalent surfaces recognized by G2 and 7d10
antibodies. The epitopes recognized by these two antibodies
also showed substantially less conformational mobility. Thus,
potent NTD-directed neutralizing antibodies targeting SARS-
CoV-2 preferentially recognized a less glycosylated, more
flexible region than the analogous surfaces recognized by
NTD-directed antibodies neutralizing MERS.
Since the MERS- and SARS-CoV-2-directed antibodies both
targeted glycan-free sites on NTD facing away from the viral
membrane, we sought to understand the properties of the anal-
ogous surfaces of other coronavirus spikes. We calculated the
sequence divergence of other betacoronoviruses and mapped
this to the NTD surface, which showed high diversity in sequence
(Figure 7B). Wemodeled the sequence-predicted glycans on the
HKU1 spike structure (PDB: 5I08) and examined the location of
glycans on HKU1 NTD (Figure 7C). Notably, glycan N171 was
observed to be directly the region of overlap between the equiv-
alent positions of the SARS-CoV-2 supersite, 7d10 and G2 epi-
topes. Thus, the presence of glycans may impact the presence
or absence of NTD sites of vulnerability in betacoronaviruses.
DISCUSSION
Antibodies directed to NTD and to RBD can neutralize with high
potency (less than 0.01 mg/mL IC50). While RBD shows many
non-overlapping sites of vulnerability to antibody (Barnes et al.,
2020a; Brouwer et al., 2020; Lv et al., 2020; Pinto et al., 2020;
Yuan et al., 2020a), NTD appears to contain only a single site
Figure 7. NTD supersite onMERS betacoro-
naviruses
(A) Epitopes of MERS NTD antibodies target a site
closer to the trimer axis. Borders of epitopes of
antibody G2 and 7d10 are colored teal and cyan,
respectively. SARS-CoV-2 NTD supersite is show
as red boundary line. Glycans are shown as green
spheres.
(B) Spike sequence entropy between betacor-
onaviruses.
(C) NTD of HKU1 spike is substantially glyco-
sylated.
of vulnerability to neutralization. As dis-
cussed above, one reason for this may
be the high glycan density on NTD, with
8 N-linked glycans in 300 residues, a
density of one glycan per 40 residues,
and few glycan-free surfaces that can be
easily recognized by the immune system.
A second reason may be the restricted
approach angle that we observed for all
known NTD-directed neutralizing anti-
bodies, including the seven reported
here, which all approach spike from
‘‘above.’’ We note in this context that competition analysis indi-
cates other NTD-directed antibodies capable of recognizing
spike and forming a separate competition group to be non-
neutralizing (Liu et al., 2020a)—and the other large surface on
NTD that is exposed on spike faces toward the viral membrane.
This surface is mostly glycan free, and antibodies binding to it
would be required to approach from ‘‘below.’’ Thus, unlike
RBD, where neutralizing antibodies appear to have diverse
approach angles, the presence of only a single-NTD site of
vulnerability may relate to the requirement to approach
from above.
In addition to satisfying requirements stemming from the
restricted approach angle, the higher relative prevalence of
NTD-supersite-directed antibodies is likely to stem from
increased immunogenicity due to both the lower relative glycan
density of the supersite and the flexible nature of the N3 hairpin
and N5 loop primary recognition regions, as well as their ability to
assume distinct conformations that allow for recognition by
diverse antibodies. In the case of the multi-donor VH1-24 anti-
body class, which arises from the most prevalent VH gene uti-
lized (Figure S1A), two additional NTD-directed neutralizing class
members have recently been identified: FC05 and CM25 (Voss
et al., 2020; Wang et al., 2021). We found VH1-24 to be the
most negatively charged human VH gene (Figure S5B). Such
negative electrostatic potential complements the highly electro-
positive nature of the NTD supersite that we observe here (Fig-
ure 6D). Thus, multiple factors, including epitope glycosylation
and flexibility, restrictions on approach angle, and paratope
charge complementarity, can contribute to the prevalence of an-
tibodies targeting the NTD supersite.
Although the approach to the spike from above observed for
all NTD-directed neutralizing antibodies is consistent with a
neutralization mechanism based on steric hindrance of spike
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interaction with ACE2 receptor at the cell membrane, there is
currently no evidence for competition betweenNTD-directed an-
tibodies and ACE2 (Liu et al., 2020a). A plausible alternative
model would be for antibody recognition of the NTD supersite
to impede spike function in mediating fusion of virus and host
cell membranes. Indeed, protease-resistance analysis of
MERS spike in complex with MERS NTD-directed neutralizing
antibody 7d10 showed that 7d10 binding prevented increased
protease sensitivity associated with the prefusion-to-postfusion
transition (Zhou et al., 2019). A conformational stabilization
mechanism could also explain how an antibody that binds only
one subunit per spike trimer could achieve effective neutraliza-
tion. Further studies will be required to understand mechanisms
of neutralization for antibodies that recognize the NTD supersite.
With respect to vaccine implications, our results clearly iden-
tify the NTD site of vulnerability most likely to elicit neutralizing
antibodies. There are many ways that this information can be
incorporated into vaccine design, including the inclusion of
NTD along with RBD in vaccine formulations, the multivalent
display of the NTD supersite on nanoparticle immunogens, and
epitope-focusing through the creation of scaffolds displaying
the N3 b-hairpin and other regions of recognized by NTD-
directed neutralizing antibodies.
With respect to the therapeutic potential of NTD-directed an-
tibodies, these target a site that is remote from those targeting
RBD sites and thus should provide complementary neutraliza-
tion to RBD-directed antibodies and require distinct escape
pathways. The fact that all, or a great majority, of NTD-neutral-
izing antibodies target a single site, however, suggests there
may be little utility to utilizing combinations of NTD-directed
neutralizing antibodies.
Finally, new mutant SARS-CoV-2 strains, particularly those
emerged in the UK and South Africa (strains B.1.1.7 and
B.1.351, respectively), are concerning due to increased
transmissibility, and these strains escape most NTD-directed
neutralizing antibodies. B.1.1.7 includes NTD deletion mutations
D69-70 and D144, and strain B.1.351 includes NTD mutations
D242-244 and R246I. Consistent with our findings, the mutated
positions including 144, 242-244, and 246 are all within the
NTD supersite. While the deletion at 69-70 is outside of the
supersite, it forms part of the hairpin N2 loop of NTD; its deletion
could significantly impact the conformation of theNTD supersite.
Notably, only three residues were shared among the eight NTD-
directed neutralizing antibody epitopes analyzed here: Y144,
R246, and L249 (Table S5). Interestingly, two of these three res-
idues are the exact residues mutated in emerging variants of
concern (D144 and R246I), and L249 is likely affected by D242-
244. Thus, the flipside of a single supersite is that variation of
the supersite may induce resistance against most of the anti-
bodies targeting the site—and be selected for among emerging
variants.
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Deposited data
Crystallographic structure of neutralizing
antibody 2-51 in complex with SARS-CoV-2
spike N-terminal domain (NTD)
This study PDB: 7L2C
Cryo-EM structure of NTD-directed
neutralizing antibody 1-87 in complex with
prefusion SARS-CoV-2 spike glycoprotein
This study PDB: 7L2D
EMDB: EMD-23125
Cryo-EM structure of NTD-directed
neutralizing antibody 4-18 in complex with
prefusion SARS-CoV-2 spike glycoprotein
This study PDB: 7L2E
EMDB: EMD-23126
Cryo-EM structure of NTD-directed
neutralizing antibody 5-24 in complex with
prefusion SARS-CoV-2 spike glycoprotein
This study PDB: 7L2F
EMDB: EMD-23127
Cryo-EM structure of NTD-directed
neutralizing antibody 4-8 in complex with
prefusion SARS-CoV-2 spike glycoprotein
This study PDB: 7LQV
EMDB: EMD-23489
Cryo-EM structure of NTD-directed
neutralizing antibody 2-17 in complex with
prefusion SARS-CoV-2 spike glycoprotein
This study PDB: 7LQW
EMDB: EMD-23490
Cryo-EM map of NTD-directed neutralizing
antibody 1-68 in complex with prefusion
SARS-CoV-2 spike glycoprotein
This study EMDB: EMD-23150
Cryo-EM map of NTD-directed neutralizing
antibody 2-51 in complex with prefusion
SARS-CoV-2 spike glycoprotein
This study EMDB: EMD-23151
Software and algorithms
AIMLESS Evans and Murshudov, 2013 https://www.mrc-lmb.cam.ac.uk/harry/
pre/aimless.html
CCP4 Winn et al., 2011 https://www.ccp4.ac.uk
Coot Emsley and Cowtan, 2004 https://www2.mrc-lmb.cam.ac.uk/
personal/pemsley/coot
cryoSPARC Punjani et al., 2017 https://cryosparc.com
Leginon Suloway et al., 2005 https://sbgrid.org/software/titles/leginon
Molprobity Davis et al., 2004 http://molprobity.biochem.duke.edu
Phaser McCoy, 2007 https://www.phenix-online.org/
documentation/reference/phaser.html
(Continued on next page)
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RESOURCE AVAILABILITY
Lead contact
Further information and requests for resources and reagents should be directed to andwill be fulfilled by the Lead Contact, Lawrence
Shapiro (lss8@columbia.edu).
Materials availability
Expression plasmids generated in this study for expressing SARS-CoV-2 proteins and antibodymutants will be shared upon request.
Data and code availability
The cryo-EM structures and the crystallographic structure are in the process of being deposited to the Electron Microscopy Data
Bank (EMDB) and the Protein Data Bank (RCSB PDB).
Cryo-EM structural models and maps of NTD-directed antibodies in complex with SARS-CoV-2 spike have been deposited in the
PDB and EMDB for antibodies 1-87 (PDB:7L2D, EMDB: EMD-23125), 2-17 (PDB: 7LQW, EMDB: EMD-23490), 4-8 (PDB: 7LQV,
EMDB: EMD-23489), 4-18 (PDB:7L2E, EMDB: EMD-23126) and 5-24 (PDB: 7L2F, EMDB: EMD-23127); cryo-EM maps have been
deposited for antibodies 1-68 (EMDB: EMD-23150) and 2-51 (EMDB: EMD-231251). The crystallographic structure of antibody 2-
51 in complex with SARS-CoV-2 spike NTD has been deposited in the PDB with accession code 7L2C.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell lines
FreeStyle 293-F (cat# R79007), Expi293F cells (cat# A14635) were from Thermo Fisher Scientific. HEK293S GnTI- (cat# CRL-3022),
HEK293T/17 (cat# CRL-11268), I1 mouse hybridoma (cat# CRL-2700) and Vero E6 cells (cat# CRL-1586) were from ATCC.
FreeStyle 293-F cells and were cultured in serum-free FreeStyle 293 Expression Medium (GIBCO, cat# 12338026) at 37C, 10%
CO2, 115 rpm. HEK293S GnTI- cells were cultured in FreeStyle 293 Expression Medium at 37
C, 10% CO2, 115 rpm. Expi293F cells
were cultured in Expi293 Expression Medium (GIBCO, cat# A14635) at 37C, 8%CO2, 125 rpm. HEK293T/17 cells and Vero E6 cells
were cultured in 10% Fetal Bovine Serum (FBS, GIBCO cat# 16140071) supplemented Dulbecco’s Modified Eagle Medium (DMEM,
ATCC cat# 30-2002) at 37C, 5% CO2. Cell lines were not specifically authenticated.
Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
Phenix Adams et al., 2010 https://www.phenix-online.org




SAbPred Dunbar et al., 2016 http://opig.stats.ox.ac.uk/webapps/
newsabdab/sabpred
UCSF Chimera Pettersen et al., 2004 https://www.cgl.ucsf.edu/chimera/
UCSF Chimera X Pettersen et al., 2021 https://www.cgl.ucsf.edu/chimerax/
XDS Kabsch, 2010 https://xds.mr.mpg.de/
GraphPad Prism Software GraphPad Prism Software, Inc. N/A
PDBePISA Krissinel and Henrick, 2007 https://www.ebi.ac.uk/pdbe/pisa/
Scrubber 2.0 BioLogic Software http://www.biologic.com.au/scrubber.html
The PyMol Molecular Graphics
System, v1.8.6
Schrödinger, LLC https://pymol.org/2/
IgBLAST-1.16 Ye et al., 2013 https://www.ncbi.nlm.nih.gov/igblast/
IMGT Schramm et al., 2016 http://www.imgt.org/
MUSCLE v3.8.31 Edgar, 2004 https://www.drive5.com/muscle/manual/
install.html
SONAR v2.0 Schramm et al., 2016 https://github.com/scharch/sonar/
Python v3.8.3 https://www.python.org/
The R Project for Statistical Computing https://www.r-project.org/
R bio3d package Grant et al., 2006 http://thegrantlab.org/bio3d/
MAFFT Katoh et al., 2002 https://mafft.cbrc.jp/alignment/software/
FreeSASA v2.0.3 Mitternacht, 2016 https://freesasa.github.io/
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METHOD DETAILS
Protein samples expression and purification
The SARS-CoV-2 S2P and HexaPro spike variant constructs were produced as described in Wrapp et al., 2020b and in Hsieh et al.,
2020 respectively. They were expressed in Human Embryonic Kidney (HEK) Freestyle 293-F cells (Invitrogen) in suspension culture
using serum-free media (Invitrogen) and transfected into HEK293 cells using polyethyleneimine (Polysciences). Cell growths were
harvested four days after transfection, and the secreted proteins were purified from supernatant by nickel affinity chromatography
using Ni-NTA IMAC Sepharose 6 Fast Flow resin (GE Healthcare) followed by size exclusion chromatography on a Superdex 200
column (GE Healthcare) in 10 mM Tris, 150 mM NaCl, pH 7.4.
The N-terminal domain of SARS-CoV-2 spike (NTD, residues 1-330) was cloned into the pVRC-8400 mammalian expression
plasmid, with a C-terminal 6X-His-tag cleavable by HRV-3C protease. The NTD construct was transiently transfected into
HEK293 GnTI- cells suspension culture in serum-free media using polyethyleneimine. Four days after transfection, the secreted pro-
tein was purified using Ni-NTA IMAC Sepharose 6 Fast Flow resin followed by size exclusion chromatography on a Superdex 200
column in 10 mM Tris, 150 mM NaCl, pH 7.4. Fractions containing NTD were combined and 1% (w/w) HRV-3C protease (Thermo
fisher) was added to remove the C-terminal His-tag, followed by incubation for 24 h at 4C. Inverse IMAC using Ni-NTA resin was
then performed to purify NTD from the His-tag and residual uncleaved protein. Enzymatic deglycosylation of NTD was carried out
by adding 2.5 mL Endo Hf (NEB) per 20 mg of NTD and incubating for 24 h at 25C; a second round of SEC was performed to remove
excess EndoHf and to exchange buffer in 10mMTris, 150mMNaCl, pH 7.4. Protein purity was analyzed by SDS-PAGE at every step.
NTD-directed monoclonal antibodies 1-68, 1-87, 2-17, 2-51, 4-8, 4-18 and 5-24 were expressed and purified as described in (Liu
et al., 2020a). Fabs fragmentswere produced by digestion of IgGswith immobilized papain at 37C for 3 h in 50mMphosphate buffer,
120 mM NaCl, 30 mM cysteine, 1 mM EDTA, pH 7. The resulting Fabs were either purified from Fc by affinity chromatography on
protein A (1-68, 1-87, 2-17, 2-51 and 4-8) or used as Fab/Fc mixture (4-18 and 5-24). Fab purity was analyzed by SDS-PAGE; all
Fabs were buffer-exchanged into 10 mM Tris, 150 mM, pH 7.4 for crystallization and cryo-EM experiments.
Antibody mutagenesis
For each antibody, variable genes were optimized for human cell expression and synthesized by GenScript. VH and VLwere inserted
separately into plasmids (gWiz or pcDNA3.4) that encoding the constant region for heavy chain and light chain. Monoclonal anti-
bodies were expressed in Expi293F (ThermoFisher, A14527) by co-transfection heavy chain and light chain expressing plasmids us-
ing polyethylenimine (PEI, Linear, MV25,000, Polysciences, Inc. Cat. No. 23966) and culture in 37C degree shaker at 125 rpm and
8% CO2. Supernatants were collected on day 5, antibodies were purified by rProtein A Sepharose (GE, 17-1279-01) affinity
chromatography.
Antibody gene mutations were introduced by QuikChange II site directed mutagenesis kit (Agilent, Cat. No. 200524).
Antibody Fab binding affinity measurement by surface plasmon resonance
SPR binding assays for Fabs were performed using a Biacore T200 biosensor, equipped with a Series S CM5 chip, in a running buffer
of 10 mM HEPES pH 7.4, 150 mM NaCl, 0.1 mg/mL BSA and 0.01% (v/v) Tween-20 at 25C.
HexaPro Spike was captured through its C-terminal his-tag over an anti-his antibody surface. These surfaces were generated us-
ing the His-capture kit (Cytiva, MA) according to the instructions of themanufacturer, resulting in approximately 10,000 RU of anti-his
antibody over each surface. HexaPro was captured over a single flow cell at a capture level of 500-800RU with Fabs with higher KDs
(2-17 and 4-18) requiring higher capture levels. An anti-his antibody surface was used as a reference flow cell to remove bulk shift
changes from the binding signal.
Fabs were tested using a three-fold dilution series ranging from 2.96-240 nM, except for Fabs 4-18 and 2-17, which were analyzed
at concentrations of 8.88-720 nM. The association and dissociation rates were each monitored for 120 s and 600 s respectively, at
50 mL/min. The bound HexaPro/Fab complex was regenerated from the anti-his antibody surface using a 10 s pulse of 15 mMH3PO4
at a flow rate of 100 mL/min, followed by a 60 s buffer wash at the same flow rate. Each Fab was tested in order of increasing protein
concentration, in duplicate. Blank buffer cycles were performed by injecting running buffer instead of Fab to remove systematic noise
from the binding signal. The data was processed and fit to 1:1 single cycle model using the Scrubber 2.0 (BioLogic Software). For
each parameter reported, the number in brackets represents the error of the fit in the last significant figure.
Full IgG binding affinity measurements by surface plasmon resonance
Themammalian expression vector that encodes the ectodomain of the SARS-CoV-2 S trimer for full IgG binding affinity measurement
was kindly provided byDr. JasonMcLellan (Wrapp et al., 2020b). SARS-CoV-2 S trimer expression vector was transiently transfected
into Expi293 cells using 1 mg/mL of polyethylenimine (Polysciences). Five days post transfection, the S trimer was purified using
Strep-Tactin XT Resin (Zymo Research).
The binding affinities of full IgG antibodies to SARS-CoV-2 spike protein were determined using surface plasmon resonance (SPR)
and a BIAcore T200 instrument (GE Healthcare) at 25C. The anti-his antibody was first immobilized onto two different flow cells of a
CM5 sensorchip (BR100030, Cytiva) surface using the His Capture Kit (28995056, Cytiva) according to the manufacturer’s protocol.
The His-tagged SARS-CoV-2 spike protein was then injected and captured on flow cells 2. Flow cells 1 was used as the negative
control. A three-fold dilution series of antibodies with concentrations ranging from 300 nM to 1.2 nM were injected over the sensor
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surface for 30 s at a flow rate of 10 mL/minute. The dissociation wasmonitored for 300 s and the surface was regenerated with 10mM
Glycine pH 1.5 (BR100354, Cytiva). The running and sample buffer is 10 mMHEPES pH 7.4, 150 mMNaCl, 3 mM EDTA, 0.05% P-20
(HBS-EP+ buffer, BR100826, Cytiva). The resulting data were fit to a 1:1 binding model using Biacore Evaluation Software and were
plotted using Graphpad.
Pseudoviruses neutralization assays
Recombinant Indiana VSV (rVSV) expressing SARS-CoV-2 spikes were generated as previously described. HEK293T cells were
grown to 80% confluency before transfection with pCMV3-SARS-CoV-2-spike (kindly provided by Dr. Peihui Wang, Shandong Uni-
versity, China) using FuGENE 6 (Promega). Cells were cultured overnight at 37C with 5% CO2. The next day, medium was removed
and VSV-G pseudo-typed DG-luciferase (G*DG-luciferase, Kerafast) was used to infect the cells in DMEM at a MOI of 3 for 1 h before
washing the cells with 1X DPBS three times. DMEM supplemented with anti-VSV-G antibody (I1, mouse hybridoma supernatant from
CRL-2700; ATCC) was added to the infected cells and they were cultured overnight as described above. The next day, the super-
natant was harvested and clarified by centrifugation at 300 g for 10 min and aliquots stored at 80C.
Neutralization assays were performed by incubating pseudoviruses with serial dilutions antibodies, and scored by the reduction in
luciferase gene expression. In brief, Vero E6 cells were seeded in a 96-well plate at a concentration of 2 3 104 cells per well. Pseu-
doviruses were incubated the next day with serial dilutions of the test samples in triplicate for 30 min at 37C. The mixture was added
to cultured cells and incubated for an additional 24 h. The luminescence wasmeasured by Britelite plus Reporter Gene Assay System
(PerkinElmer). IC50 was defined as the dilution at which the relative light units were reduced by 50% compared with the virus control
wells (virus + cells) after subtraction of the background in the control groups with cells only. The IC50 values were calculated using
non-linear regression in GraphPad Prism.
Authentic SARS-CoV-2 microplate neutralization
An end-point dilution assay in a 96-well plate format was performed to measure the neutralization activity of purified mAbs. In brief,
each antibody was serially diluted (5-fold dilutions) starting at 50 mg/mL. Triplicates of each mAb dilution were incubated with SARS-
CoV-2 at an MOI of 0.1 in EMEM with 7.5% inactivated fetal calf serum (FCS) for 1 h at 37C. Post incubation, the virus-antibody
mixture was transferred onto a monolayer of Vero E6 cells grown overnight. The cells were incubated with the mixture for 70 h. Cyto-
pathic effect (CPE) of viral infection was visually scored for each well in a blinded fashion by two independent observers. The results
were then converted into percentage neutralization at a given mAb concentration, and the averages ± SEMwere plotted using a five-
parameter dose-response curve in GraphPad Prism v8.0.
Antibody gene assignments and genetic analyses
The 17 SARS-COV-2 neutralizing antibodies were collected from seven publications. We annotated these antibodies using IgBLAST-
1.16.0 with the default parameters (Ye et al., 2013). For antibodies which have cDNA sequences deposited, the V and J genes were
assigned using SONAR version 2.0 (https://github.com/scharch/sonar/) with germline gene database from IMGT (Lefranc, 2008;
Schramm et al., 2016). For each antibody, the N-addition, D gene, and P-addition regions were annotated by IMGT V-QUEST (Bro-
chet et al., 2008). To identify somatic hypermutations, each antibody sequence was aligned to the assigned germline gene using
MUSCLE v3.8.31 (Edgar, 2004). Somatic hypermutations were identified from the alignment. In addition, the analysis of single cell
antibody repertoire sequencing data of SARS-CoV-2 patient 2 from (Liu et al., 2020a), showed that 29 of the 38 unique transcripts
assigned to IGLV2-14*01 share nucleotide mutations G156T and T165G. These mutations lead to amino acid mutations E50D and
N53K. Both nucleotide mutations are also observed in 82 of 90 unique IGLV2-14 transcripts from patient 1 of the same study.
Because these transcripts having different VJ recombination and paired with different heavy chain genes, the chances that the
two convergent mutations are the results of somatic hypermutation are very low. Thus, we suspect that both donors contain a
new IGLV2-14 gene allele (IGLV2-14*0X), which was deposited to European Nucleotide Archive (ENA) with project accession
numbers: PRJEB31020. Light chain of 1-87 was assigned to the IGLV2-14*0X allele.
Cryo-EM samples preparation
Samples for cryo-EM grids preparation were produced by mixing purified SARS-CoV-2 S2P spike (final trimer concentration of
0.33 mg/mL) with NTD-directed Fabs in a 1:9 molar ratio, followed by incubation on ice for 1 h. The final buffer for 1-87, 4-18 and
5-24 complexes was 10 mM sodium acetate, 150 mM NaCl, pH 4.5; the final buffer for 1-68, 2-17, 2-51 and 4-8 complexes was
10 mM sodium acetate, 150 mM NaCl, pH 5.5. n-Dodecyl b-D-maltoside (DDM) at a final concentration of 0.005% (w/v) was added
to themixtures to prevent aggregation during vitrification. Cryo-EM grids were prepared by applying 2 mL of sample to a freshly glow-
discharged carbon-coated copper grid (CF 1.2/1.3 300mesh); the sample was vitrified in liquid ethane using a Vitrobot Mark IV with a
wait time of 30 s and a blot time of 3 s.
Cryo-EM data collection, processing and structure refinement
Cryo-EM data were collected using the Leginon software (Suloway et al., 2005) installed on a Titan Krios electron microscope oper-
ating at 300 kV, equipped with a Gatan K3-BioQuantum direct detection device. The total dose was fractionated for 3 s over 60 raw
frames or 2 s over 40 raw frames. Motion correction, CTF estimation, particle extraction, 2D classification, ab initiomodel generation,
3D refinements and local resolution estimation for all datasets were carried out in cryoSPARC 2.15 (Punjani et al., 2017); particles
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were picked using Topaz (Bepler et al., 2019). Symmetry expansion and focused classification in RELION 3.1 (Scheres, 2012) was
used for S2P spike complex with 2-51. The particle orientation distributionwas assessed by angular distribution plots for all EM struc-
tures. Whenever a preferred orientation issue was identified, we calculated the sphericity values and the Fourier shell correlation
(FSC) curves using the 3D FSC Processing Server (Tan et al., 2017).The interface between NTD and the Fab was locally refined
by using a mask that included NTD and the variable domains of the Fab; symmetry-expanded particles in C3 were used in the local
refinement for S2P spike complexes with 4-18 and 5-24. The 4-8 interface was locally refined following particle subtraction without
symmetry expansion, since it lacked C3 symmetry, using a mask over the same region. Particle subtraction did not improve the den-
sity in the local refinement of the 2-17 interface and was therefore not used in the final map refinement. The density at the interface
was well-defined for S2P spike complexes with 1-87, 4-8, 4-18 and 5-24, providing structural details of antibody binding to NTD. The
2-17 interface density allowed for fitting of the main chain but did not provide enough detail to confidently fit side chains, which were
left out of the model in that region.
SARS CoV-2 S2P spike density was modeled using PDB entry 6VXX (Walls et al., 2020), as initial template. The RBDs and were
initially modeled using PDB entry 7BZ5 (Wu et al., 2020); the NTDs were initially modeled using PDB entry 6ZGE (Wrobel et al.,
2020). The initial models for all Fab variable regions were obtained using the SAbPred server (Dunbar et al., 2016).
Automated and manual model building were iteratively performed using real space refinement in Phenix (Adams et al., 2004) and
Coot (Emsley and Cowtan, 2004) respectively. Geometry validation and structure quality assessment were performed using EM-
Ringer (Barad et al., 2015) and Molprobity (Davis et al., 2004). Map-fitting cross correlation (Fit-in-Map tool) and figures preparation
were carried out using PyMOL and UCSF Chimera (Pettersen et al., 2004) and Chimera X (Pettersen et al., 2021). A summary of the
cryo-EM data collection, reconstruction and refinement statistics is shown in Table S1.
X-ray crystallography sample preparation, data collection, structure solution and refinement
Purified SARS-CoV-2 spike N-terminal domain (NTD) and 2-51 Fab were mixed at a 1:1 molar ratio and incubated at 4C for 1 h; the
Fab-NTD complex was purified by SEC on a Superdex 200 column in buffer 10 mM Tris, 150 mM NaCl, pH 7.4. Fractions containing
the complex were combined and concentrated to a total protein concentration of 7.5 mg/mL for crystal screening by the sitting drop
vapor diffusion method at 25C. Diffracting crystals of NTD in complex with 2-51 Fab grew in 0.16 M calcium acetate, 0.08 M sodium
cacodylate, 14.4% PEG 8000, 20% glycerol, pH 6.5. For data collection, crystals were cryo-protected by briefly soaking in reservoir
solution supplemented with 35% (v/v) glycerol before flash-cooling in liquid nitrogen. X-ray diffraction data was collected to 3.44 Å
resolution at 100 K from a single flash-cooled crystal on beamline 24ID-C at the Advanced Photon Source (APS) at Argonne National
Laboratory. Diffraction data were processed with XDS (Kabsch, 2010) and scaled using AIMLESS (Evans andMurshudov, 2013) from
the CCP4 software suite (Winn et al., 2011). Molecular replacement was performed with Phaser (McCoy, 2007) using the structure of
NTD in complex with 4A8 (extracted from the whole spike-Fab structure fromPDB entry 7C2L) as searchmodel. Structure refinement
was performed with a 3.65 Å high-resolution cutoff using Phenix refine (Adams et al., 2010) and PDB-redo (Joosten et al., 2014) alter-
nated with manual model building using Coot. The Molprobity server was used for geometry validation and structure quality assess-
ment. A summary of the X-ray crystallography data collection and refinement statistics is shown in Table S2.
Calculation of antibody angle of approach
The angles of antibody approach to the NTD of SARS-CoV-2 spike were calculated with UCSF Chimera (Pettersen et al., 2004). To
define the latitudinal and longitudinal access of an antibody to the viral spike, we first defined two reference axes: the 3-fold axis of the
spike trimer and a line perpendicular to the 3-fold axis and passing through the Ca atom of Trp104 located in the hydrophobic core of
the NTD. We then defined the axis of antibody as the long axis of the Fab. The latitudinal access, which describes the freedom be-
tween the viral and host cell membranes, was defined as the angle between the antibody axis and the 3-fold axis; the longitudinal
access, which describes the freedom within the plane of the membrane, was defined as the angle between the antibody axis and
the other reference axis. The angles between two axes were calculated with the built-in function of UCSF Chimera, and expressed
in 0-to-180-degree scale for the latitudinal angles and 0-to-360-degree scale counter-clockwise to show the longitudinal angles. To
compare the relative orientations of antibody heavy and light chains, we used a vector going from the center of heavy chain variable
domain to that of the light chain variable domain.
Glycan analysis
To estimate the effect of glycan shield on protein surface residue, we used an in-house algorithm, GLYCO, to quantify the number of
glycan atoms associated with each residue. Briefly, the number of glycan atoms per protein surface residue was counted within 34 Å
radius distance cutoff, while the glycans do not provide the shielding effect were excluded in the calculation. This analysis was per-
formed on each trajectory of molecular dynamics simulation (Casalino et al., 2020) to average the glycan atom counts for each
residue.
Interface definition and net charge computation
The residues of each antibody paratope and epitope were obtained by running PDBePISA (Krissinel and Henrick, 2007), with the
default parameters. Cryo-EM structures were of sufficient resolution to define all epitopes, except for 1-68 and 2-17. The epitope
of 1-68 was obtained by docking the structure of the homolog antibody 1-87 in complex with NTD in the locally refined EM map
of 1-68:NTD and real-space refinement was used to orient the residues of 1-68 that differed from 1-87. The missing side chains
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of 2-17were added by CHARMM-GUI (Jo et al., 2008) and the structure was combinedwith NTD to produce amodel for the complex;
the NTD structure was obtained by template-based Swiss modeling (Waterhouse et al., 2018). The hydrophobic interaction residues
among antibodies were defined by the buried surface area (BSA) that large than 20 Å2. The antigen contact region for germline genes
were adopt from (Sela-Culang et al., 2013), which includes additional interactions not accounted for in the CDRs. The number of
charged residues were counted and the summation of their charges was used to quantify the net charge of selected residues.
Ca distance calculation
The Ca distances per residue between superimposed ligand-free and antibody-bound NTD were calculated by Python 3.8. The 8
NTD-antibody complexes (NTD-5-24, NTD-4-8, NTD-2-17, NTD-4-18, NTD-1-87, NTD-4A8, NTD-2-51, NTD-1-68) were used as
antibody bound structures, and the averaged Ca distances per residue of 8 complexes were analyzed.
RMSD calculation
The root mean square deviation (RMSD) of antibody epitopes was calculated by PyMOL 2.4 between two superimposed NTDs –
ligand-free and antibody-bound structures. The identical ligand-free and antibody-bound NTDs described in Ca distance analysis
were used in the calculation. Onlymatching atomswith the same name and number in both epitopes were included in the calculation.
The epitope residues of antibodies were obtained by running FreeSASA (Mitternacht, 2016) with probe radius 1.4 Å. The residues with
non-zero surface area difference between NTD and NTD-antibody complex structures were selected as protein epitope residues to
the corresponding antibodies.
Sequence entropy of betacoronavirus spike
Human coronavirus reference amino acid sequences of OC43 (UniProt ID: P36334), HKU1 (UniProt ID: Q5MQD0), SARS (UniProt ID:
P59594), and MERS (UniProt ID: W5ZZF5), as well as the initial SARS-CoV-2 (GenBank: QHO60594.1) sequence reported in Wash-
ington state were aligned using MAFFT software with default parameters (Katoh et al., 2002). Subsequently, we used the R bio3d
package’s function Conserv with default parameters to estimate sequence conservation at all alignment position
QUANTIFICATION AND STATISTICAL ANALYSIS
The statistical analyses for the pseudovirus and authentic virus neutralization assessments were performed using GraphPad Prism
for calculation ofmean value and SEM for each data point (see Figures S1 and S6). The SPR data were fitted using Biacore Evaluation
Software (see Figure S6), and Scrubber (see Table S6). Cryo-EM data were processed and analyzed using cryoSPARC and Relion
(see Figure S3). Cryo-EM and crystallographic structural statistics were analyzed using Phenix, Molprobity, EMringer and Chimera
(see Tables S1 and S2). Statistical details of experiments are described in Method Details or Figure Legends.
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4.6 Structural basis for accommodation of emerging B.1.351 and B.1.1.7 variants by two
potent SARS-CoV-2 neutralizing antibodies
This final subchapter focuses on antibodies that can neutralize emerging variants of concern,
a crucial finding for the continued development of effective monoclonal antibody therapies and
vaccines. Some of these variants, such as B.1.351, avoid neutralization by the most common and
potent antibodies elicited by the original SARS-CoV-2 strain [240].
The two antibodies in this study, 1-57 and 2-7, both target the RBD but using two different
epitopes that are rare in the human antibody response. These epitopes sit slightly outside of the
ACE2 binding motif, the target of many of the most common and potent RBD-directed antibodies
and the location of many RBD mutations found in numerous lineages.
Our work suggests that many variants evolved to bind to ACE2 more tightly, allowing anti-
bodies like those we described, which bind further from the ACE2 binding site, to maintain their
ability to neutralize. The large amount of structural data available for RBD-directed antibodies
enabled us to correlate the frequency with which a certain reside on the RBD mutates in avail-
able SARS-CoV-2 sequences and how frequently it is targeted by antibodies for which there are
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Cerutti et al. report the structural
characterization of two potent
neutralizing antibodies, 1–57 and 2–7,
bound to the SARS-CoV-2 spike. The
cryo-EM structures elucidate distinct
mechanisms to accommodate the RBD
mutations observed in the B.1.1.7 and
B.1.351 variants. Both antibodies
represent low-frequency immune
responses and their use as therapeutics
is suggested.
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SUMMARY
Emerging SARS-CoV-2 strains, B.1.1.7 and B.1.351, from the UK and South Africa, respectively, show
decreased neutralization by monoclonal antibodies and convalescent or vaccinee sera raised against the
original wild-type virus, and are thus of clinical concern. However, the neutralization potency of two anti-
bodies, 1–57 and 2–7, which target the receptor-binding domain (RBD) of the spike, was unaffected by these
emerging strains. Here, we report cryo-EM structures of 1–57 and 2–7 in complex with spike, revealing each
of these antibodies to utilize a distinct mechanism to bypass or accommodate RBDmutations. Notably, each
antibody represented an immune response with recognition distinct from those of frequent antibody classes.
Moreover, many epitope residues recognized by 1–57 and 2–7 were outside hotspots of evolutionary pres-
sure for ACE2 binding and neutralizing antibody escape. We suggest the therapeutic use of antibodies,
such as 1–57 and 2–7, which target less prevalent epitopes, could ameliorate issues of monoclonal antibody
escape.
INTRODUCTION
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
2), the causative agent for coronavirus disease 2019 (COVID-
19), emerged in 2019, rapidly establishing an ongoing worldwide
pandemic with over 100 million infected and over 2 million dead
at the time of writing (Callaway et al., 2020; Cucinotta and Vanelli,
2020; Dong et al., 2020). The possible emergence of mutant
strains of SARS-CoV-2 with improved transmissibility, virulence,
or ability to evade human immunity has been a major concern
(Baric, 2020). The SARS-CoV-2 lineage known as B.1.1.7
emerged in September 2020 in South East England, quickly
becoming the dominant variant in the UK, and subsequently
spreading to over 50 countries, potentially due to enhanced
transmissibility (Rambaut et al., 2020). The B.1.1.7 strain con-
tains the early spike mutation D614G, now common to most
SARS-CoV-2 lineages, as well as eight additional spike muta-
tions, including two deletions (69-70del and 144del) in the N-ter-
minal domain (NTD), a single mutation (N501Y) in receptor-bind-
ing domain (RBD) and (A570D) in SD1, two mutations (P681H
and T716I) near the furin cleavage site, and two mutations in
S2 (S982A and D1118H). Another emerging lineage, SARS-
CoV-2 B.1.351, appeared late in 2020 in Eastern Cape, South Af-
rica (Tegally et al., 2020), and also became dominant locally,
again raising the possibility of increased transmissibility.
B.1.351 contains nine spike mutations in addition to D614G,
including a cluster of mutations (e.g., 242-244del and R246I) in
NTD, one mutation (A701V) near the furin cleavage site, and
three mutations (K417N, E484K, and N501Y) in RBD.
Recent studies have shown that some of these new variants
impede the function of some SARS-CoV-2 neutralizing anti-
bodies, with most NTD-directed neutralizing antibodies showing
a near complete loss of potency against either the B.1.351 or
B.1.1.7 strains (Wang et al., 2021b; Wibmer et al., 2021). With
respect to RBD-directed antibodies, however, while the most
prevalent classes of multi-donor RBD-directed antibodies, orig-
inating from the VH3-53/66 and VH1-2 genes (Banach et al.,
2021; Rapp et al., 2021; Yuan et al., 2020), are generally inhibited
bymutations in RBD (K417N and N501Y for VH3-53/66 class an-
tibodies and E484K for VH1-2 class antibodies) (Wang et al.,
2021b). Fortunately, many RBD-directed antibodies not from
these frequent classes retain their activity.
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In a companion manuscript (Wang et al., 2021b), we screened
monoclonal antibodies and found two super potent RBD-
directed antibodies, 1–57 and 2–7 (0.008 and 0.003 mg/mL of
live virus neutralization at half-maximal inhibitory concentrations
for 1–57 and 2–7, respectively), whose binding competed with
that of the ACE2 receptor (Liu et al., 2020), but whose neutraliza-
tion was unaffected by the emerging B.1.351 and B.1.1.7 strains
(Wang et al., 2021b). To understand how these antibodies
accommodate the mutations present in B.1.351 and B.1.1.7
strains, we determined their cryoelectron microscopy (cryo-
EM) structures in complex with spike. We used the 52 currently
known complex structures of RBD-directed neutralizing anti-
body to create a residue-level map of antibody recognition fre-
quency. This analysis suggested mutations in RBD to emerge
under evolutionary pressure from both antibody escape and
binding to the ACE2 receptor on host cells. We suggest that
neutralizing antibodies, such as 1–57 and 2–7, that target epi-
topes with few selection hotspots may result in less viral escape
and lead to more effective therapeutic strategies.
RESULTS
Antibody 1–57 utilizes a hydrophilic pocket to
accommodate mutation E484K in emerging strains
From complexes of SARS-CoV-2 spike—stabilized by 2P muta-
tions (Wrapp et al., 2020)—with the antigen-binding fragment
(Fab) of antibody 1–57,we collected single-particle data on a Titan
Krios microscope, yielding a cryo-EM reconstruction to an overall
resolution of 3.42 Å (Figures 1A, S1, and S2; Table S1). A single
conformational state with three Fabs per trimer, each bound to
an RBD in the ‘‘down’’ conformation, was identified. Recognition
of RBD by 1–57 was dominated by the heavy chain, which buried
533.7 Å2 surface area, with a smaller 223.3 Å2 contribution by the
light chain. The 21 amino acid longCDRH3 formed a b hairpin sta-
bilized by a disulfide bond between Cys100a and Cys100f (Kabat
numbering scheme [WuandKabat, 1970]) provided theprimary in-
teractions with RBD, with additional contributions from CDR L1
and L2 (Figure 1C, left panel). CDRH3 formedmainly hydrophobic
contactswithRBD residuesTyr351, Leu452,Phe490, andLeu492.
The light chain contributed to RBD recognition mainly through
hydrogen bonds formed between the hydroxyl groups of Ser30,
Tyr32, and Ser53 in CDR L1 and L2, and residues Gln493,
Ser494, and Gln498 in RBD, respectively (Figure 1C, right panel).
Antibody 1–57 also displayed a small quaternary interaction, as
Asn100c on the tip of CDR H3 hydrogen bonds with both Thr470
in a neighboring RBD and glycanN165 in a neighboring NTD (Fig-
ure 1C, middle panel).
With respect to the three RBD mutations in the UK and South
Africa strains, only residue E484K of the South African strain
was near the binding site of 1–57 (Figure 1B). Despite its proximity
to the epitope, however, Glu484 did not interact significantly with
1–57, as the amino acids in the immediate vicinity—Val100e from
the heavy chain, and Ser29 and Ser93 from the light chain—were
too distant (Figure 1D, left panel). Structural modeling of the
E484K mutation showed that a Lys residue was geometrically
compatible with 1–57 binding; modeling of K484 with a high-fre-
quency rotamer showed that the distance between the amino
group of K484 and the side chain of Ser29 was compatible with
a hydrogen bond (2.81 Å) (Figure 1D, right panel).
Structural basis of antibody 2–7 accommodation of
mutation N501Y in emerging strains
Cryo-EM analysis of the Fab from antibody 2–7 in complex with
SARS-CoV-2 spike produced a reconstruction with three Fabs
bound to a single spike, and was refined to an overall resolution
of 3.72 Å (Figures 2A, S1, and S3; Table S1). Only one conforma-
tion was observed, with Fabs bound to two RBDs in the ‘‘up’’
conformation and one in the ‘‘down’’ conformation. Due to
extensive conformational heterogeneity, the up RBDs could
not be resolved to high resolution, thus the down RBD was the
focus of structural analysis.
Recognition of RBD by antibody 2–7 was dominated by inter-
actions proximal to the RBD loops formed by residues 438–451
and 495–502 (Figure 2C, left panel). CDR H2 formed an exten-
sive network of hydrogen bonds and salt bridges (Figure 2C,
middle panel). RBD residue Lys444 formed salt bridges with
Fab heavy chain residues Asp56 and Asp54. In addition, CDR
H2 residues Asp54, Tyr52, and Arg58 formed hydrogen bonds
with RBD residues Asn450, the backbone amine of Val445, and
the backbone carbonyl of Gly447, respectively. Val445 at the
apex of loop 438–451 was at the center of a hydrophobic
pocket, which included Pro499 on RBD that accommodated
several residues on the heavy chain (Trp47, Leu50, Tyr52,
and Ile97) and one on the light chain (Tyr91). Light chain residue
Tyr32 also formed a hydrogen bond with the RBD via residue
N440 (Figure 2C, right panel).
With respect to the three mutated positions in the UK and
South Africa variants, antibody 2–7 bound near only N501, but
the side chain of N501 pointed away from the antibody (Figures
2B and 2D). While some conformational change of the 495–502
loop would be expected in the context of the N501Y mutation,
this loop contributed only 225 Å2 out of 736 Å2 and contained
few residues that form significant interactions with the Fab.
Genetic and epitope similarities to other SARS-CoV-2
neutralizing antibodies
The heavy chain of 1–57 derived from the VH3-72*01 gene with a
CDR H3 of 21 amino acids, and the light chain was from KV3-
20*01, with a 9 residue CDR L3 (Figure S1). Antibody 2–7 utilized
VH2-5*02 with an 11 amino acid CDRH3, and LV2-14*01 with a 9
residue CDR L3. Both antibodies thus utilized heavy chain genes
with relatively low frequencies in SARS-CoV-2-specific neutral-
izing antibody repertoire (Rapp et al., 2021), suggesting that an-
tibodies with genetic features similar to 1–57 and 2–7 may not
appear frequently in human response to SARS-CoV-2.
To assess the neutralization mechanism for antibodies 1–57
and 2–7 we compared the structure of the ACE2:RBD complex
(Lan et al., 2020) with the structures of 1–57 and 2–7 aligned
on RBD: the structural superposition shows that binding of these
two antibodies is not compatible with receptor binding, as major
clashes would result (Figure S4A). In addition, we performed
ACE2 competition ELISA assays for both antibodies binding to
SARS-CoV-2 spike, which confirmed that binding of ACE2 is
progressively depleted as the concentration of 1–57 and 2–7 in-
creases (Figure S4B).
To understand whether the binding orientations of anti-
bodies 2–7 and 1–57 were common among RBD-directed an-
tibodies, we superposed structures of RBDs from the 52
RBD-directed antibody complex structures deposited in the
ll
Article
2 Structure 29, 1–9, July 1, 2021
Please cite this article in press as: Cerutti et al., Structural basis for accommodation of emerging B.1.351 and B.1.1.7 variants by two potent SARS-
CoV-2 neutralizing antibodies, Structure (2021), https://doi.org/10.1016/j.str.2021.05.014
PDB and measured root-mean-square deviations (RMSDs)
between antibodies. Overall, clustering of the 52 antibodies
using pairwise RMSD showed that antibodies 1–57 and 2–7
did not cluster with the most frequent VH3-53 and VH1-2
antibody classes (Figure 3A). The binding orientation of anti-
body 1–57 was similar to antibodies P2B-2F6 and CV07-270
(Figure S4C). Antibody 2–7 was grouped with REGN10987
(Figure S4D), which was a component of a SARS-CoV-2 ther-
apeutic cocktail (Hansen et al., 2020). However, these anti-
bodies utilize paratopes different from 1–57 and 2–7 for
RBD recognition, probably because each antibody has a
unique genetic origin.
During in vivo viral infection, epitopes frequently targeted by
the antibody may impose strong selection pressure for viral
Figure 1. Antibody 1–57 utilizes a hydrophilic pocket to accommodate mutation E484K in emerging strains
(A) Cryo-EM reconstruction for spike complex with antibody 1–57 from two orthogonal views; a single conformation with all RBDs down is observed. NTD is
shown in orange, RBD in green, glycans in red, antibody heavy chain in blue, and light chain in gray.
(B) Domain level view of 1–57 in complex with RBD, with the emerging mutants highlighted in red.
(C) Details of antibody 1–57 recognition of RBD showing the overall interface (left panel), recognition by CDRH3 (middle panel), and recognition by CDR L1 and L2
(right panel). CDR H1, H2, H3 are colored in shades of blue; CDR L1, L2, and L3 are colored in shades of gray. E484 is highlighted in bright red (right panel).
Nitrogen atoms are colored in blue, oxygen atoms in red; hydrogen bonds (distance <3.2 Å) are represented as dashed lines.
(D) Expanded view of the E484 environment at the interface with 1–57 (left panel) and modeling of K484 (right panel) suggest a mechanism of antibody 1–57
accommodation of the E484K mutation; colored as in (B).
See also Table S1 and Figure S2.
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escape. We used the 52 neutralizing antibodies in the PDB to es-
timate the frequencies of the epitopes of 1–57 and 2–7 being
recognized by assuming that these antibodies recapitulate in vivo
recognition frequencies of RBD epitopes. In brief, for each anti-
body, we identified epitope residues and calculated the fre-
quency of each RBD residue being recognized by antibody.
The analysis revealed that the epitope residues of 1–57 and 2–
7 showed lower antibody recognition frequencies (about 11.2
and 19.8 antibodies per residue on average for 2–7 and 1–57,
respectively) compared with those targeted by the prevalent
antibody classes (about 27.4 and 25.9 antibodies per residue
on average for VH1-2 and VH3-53 class, respectively, Figure 3B),
suggesting that 1–57 and 2–7 epitopes are relatively less-tar-
geted antigenic sites.
Figure 2. Structural basis of antibody 2–7 accommodation of mutation N501Y in emerging strains
(A) Cryo-EM reconstruction for spike complex with antibody 2–7 from two orthogonal views; a single conformation with one RBD down and two RBDs up is
observed. NTD is shown in orange, RBD in green, glycans in red, antibody heavy chain in magenta, and light chain in gray.
(B) Domain level view of 2–7 in complex with RBD, with the emerging mutants highlighted in red.
(C) Details of antibody 2–7 recognition of RBD showing the overall interface (left panel), recognition by CDR H2 (middle panel), and recognition by CDR L1 and L3
(right panel). CDR H1, H2, and H3 are colored in shades of magenta; CDR L1, L2, and L3 are colored in shades of gray. N501 is highlighted in bright red
(right panel).
(D) Expanded view of the N501 environment at the interface with 2–7 (left panel) and modeling of Y501 (right panel) suggest a mechanism of antibody 2–7 ac-
commodation of the N501Y mutation; colored as in (B).
See also Table S1 and Figure S3.
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Antibody escape mutations may result from ACE2
binding and antibody escape selection pressure
Analysis of RBD mutations observed in circulating SARS-CoV-2
sequences revealed many emerging mutations (Figure 4A). To
understand whether the emerging mutations affect antibodies
1–57 and 2–7 recognition, we analyzed structural locations of
the top 10 most frequent RBD mutations. We found that, while
antibodies 1–57 and 2–7 are not affected by the three mutations
observed in the UK and South Africa strains, several RBD muta-
tions may affect antibodies 1–57 and 2–7. For example, muta-
tions at position 452 and 494werewithin the antibody 1–57 bind-
ing footprint (Figure 4B). Mutations at position 439 may affect 2–
Figure 3. Antibodies 2–7 and 1–57 exemplify rare responses, suggesting thatmutations against these antibodies have low selection pressure
(A) Analysis of 52 known RBD-directed neutralizing antibodies indicates that 2–7 and 1–57 approach RBD with angles distinct from prevalent antibody classes.
(B) Per residue frequency recognized by the 52 antibodies. VH1-2 and VH3-53 antibody classes recognize RBD residues with high targeting frequency; 1–57 and
2–7 recognize RBD residues with low targeting frequencies.
See also Figure S4.
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7 binding. However, further experiments will be required to
assess such effects.
Studies have proposed that many SARS-CoV-2 escape muta-
tions are selected by neutralizing antibodies (Baum et al., 2020;
Ku et al., 2021). However, it is unclear whether the observed anti-
body-resistant mutations are all the results of antibody selection.
To shed light on this, we calculated correlations between posi-
tional mutation frequency and antibody recognition frequency
by assuming that the estimated per RBD residue targeting fre-
quency reflects the in vivo frequency of antibody recognition
and that the most frequently targeted RBD residues may undergo
strong selection pressure to mutate. To our surprise, we only
observed a very weak correlation (Figure 4C, r = 0.23, p = 0.1),
albeit that some of the most frequently targeted residues do
have higher mutation frequencies. Because RBD is always under
selection pressure from ACE2 binding for entry (Starr et al., 2020),
we next examined whether the emerging RBD mutations were
selected by enhancing ACE2 binding. We calculated the correla-
tion between the frequencies of RBD mutations and their normal-
ized effects on ACE2 binding affinity obtained from deep muta-
tional scanning data (Starr et al., 2020), which showed a
significant correlation (Figure 4D, Pearson’s r = 0.34, p = 0.015).
The correlation coefficient could be further increased significantly
when removing two ‘‘outlier’’ mutations, K417N and F486L, both
of which reduce ACE2 binding affinity significantly (Figure 4D).
Further analysis of the antibody escape mutations showed that
the frequent antibody escape mutations we observed may arise
from selection advantage for both ACE2 binding and antibody
escape. For example, the most frequent N501Y could improve
the binding affinity of ACE2 as well as impair recognition of the
most frequent VH3-53 class antibodies (Wang et al., 2021b).
The E484K mutation—detected in B.1.351 and recently emerging
Figure 4. Prevalent emerging mutations
appear to arise at epitopes of prevalent
neutralizing response, suggesting that resis-
tance mutants might arise less frequently to
rare responses, such as antibodies 1–57 and
2–7
(A) Most frequent mutations and positions observed
in circulating SARS-CoV-2 strains.
(B) Location of prevalent RBD mutations and anti-
body footprints.
(C) Correlation between per residue antibody
recognition frequency and the top 50 RBD position
mutations.
(D) Correlation between mutation effect on ACE2
binding and its frequency. The blue dashed line, R
value, and p value represent the fit after removing
the two ‘‘outliers,’’ K417N and F486L mutations.
See also Figure S4.
strains P.1 and P.2 (Faria et al., 2021)—im-
pairs recognition of numerous antibodies
(Wang et al., 2021a) and also weakly im-
proves ACE2 binding affinity. However, the
frequentmutation K417N resulted in escape
of the prevalent VH3-53-derived antibody
class (Wang et al., 2021b), and may be
selected predominantly by antibody pres-
sure. Despite the ability of 1–57 and 2–7 to still potently neutralize
emerging strains that carry N501Y, K417N, and E484Kmutations,
we observed that individual mutations at 452, 494, 477, and 439
(Figure 4B)—which may affect 1–57 and 2–7 recognition—do
not or only weakly enhance ACE2 binding (Bayarri-Olmos et al.,
2021; Lopez et al., 2021; Starr et al., 2020; Thomson et al.,
2020; Tian et al., 2021; Zahradnı́k et al., 2021) (Figure S4E).
Thus, these mutations may undergo weak selection pressure for
enhancing ACE2 binding affinity.
Our analysis suggests that potent antibodies 2–7 and 1–57
may not put much selection pressure on circulating strains,
thus resistance mutants to these two antibodies are less likely
to arise. Overall, due to the diversity of emerging strains, different
antibody cocktails become more and more important, and 2–7
and 1–57 are decent candidates for therapeutic development.
DISCUSSION
The emergence of mutant SARS-CoV-2 strains and their impact
on the function of neutralizing antibodies has become a major
concern. The B.1.1.7 (UK) and B.1.351 (South Africa) variants
containmutations that evade themost frequently elicited classes
of RBD-directed neutralizing antibodies from the VH1-2
(B.1.351) and VH3-53/66 classes (B.1.1.7) (Ku et al., 2021;
Wang et al., 2021b). Both antibody classes recognize predomi-
nantly the RBM, which is mutated convergently in many
emerging viral lineages (e.g., K417T, E484K, and N501Y in
both B.1.351 and B.1.1.28 [Brazil]). In this study, we report the
structures and accommodation mechanisms for two potent
SARS-CoV-2 neutralizing antibodies, 1–57 and 2–7, which are
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Quantifying epitope-targeting frequency is important for un-
derstanding mechanisms of antibody-induced viral escape.
Despite an algorithm having been developed to estimate linear
epitope-targeting frequency by serum antibodies in a high-
throughput way (Shrock et al., 2020), it is still difficult to measure
the epitope-targeting frequency of antibodies recognizing three-
dimensional epitopes. Methods, such as competition ELISA, can
only reveal frequencies of targeted epitope regions with no res-
idue-level information. Here, we use a method to roughly esti-
mate residue-level frequencies for antibody recognition of RBD
based on the 52 currently known atomic-level structures of
neutralizing antibody-RBD complexes. These antibodies, identi-
fied in separate studies of infected donors from around the world
(Barnes et al., 2020; Hansen et al., 2020; Lv et al., 2020; Pinto
et al., 2020) were generally chosen for study due to their neutral-
ization potency. Overall, these studies identified antibodies
mainly targeting RBD (Brouwer et al., 2020; Shi et al., 2020; Tor-
torici et al., 2020; Wu et al., 2020), with some NTD-directed neu-
tralizers (Cerutti et al., 2021; Chi et al., 2020), with antibodies of
the same class often identified in multiple studies. The residue-
level antibody-interaction frequencies we present for RBD are
likely to represent a reasonable estimate of relative frequencies,
but only for themost potent andmost frequent classes. Thus, the
calculated residue-level antibody-interaction frequency may not
reflect epitope-targeting frequencies of weakly neutralizing or
non-neutralizing antibodies, which are a significant portion of
antibody response to SARS-CoV-2 (Liu et al., 2020; Robbiani
et al., 2020). It is also unclear whether weakly neutralizing or
non-neutralizing antibodies impose selection pressure on RBD
epitopes. Therefore, the weak correlation between antibody-
interaction frequency and mutation frequency could be due to
multiple confounding factors not included. Nonetheless, many
of the identified antibody-interaction hotspots are within or close
to the ACE2 binding site. Linear-peptide epitopes around these
hotspots are also recognized by numerous serum antibodies
(Shrock et al., 2020), confirming that the hotspots we identified
are frequently targeted.
The study of mechanisms of mutant accommodation by anti-
bodies 1–57 and 2–7 shed insights on effective therapeutic stra-
tegies. Studies have shown that persistent SARS-CoV-2 infec-
tion can last for months in immunocompromised human
individuals (Avanzato et al., 2020; Choi et al., 2020). During
such a long acute infection period, the arms race between the
immune system and virus results in many viral mutations to be
accumulated in the spike to escape antibody neutralization.
Because the human neutralizing antibody response frequently
and convergently targets the ACE2 receptor-binding region on
RBD, there is strong positive selection pressure tomutate this re-
gion. In the meantime, our results showed that the most frequent
mutations tend to enhance ACE2 binding, suggesting additional
selection pressure underlying SARS-CoV-2 evolution. Because
most RBD mutations are detrimental to ACE2 binding (Starr
et al., 2020), the virus may have a limited mutation space for
escaping antibody neutralization. This may explain the rapid
spread of convergent RBD mutations in different emerging
SARS-CoV-2 lineages (e.g., E484K mutation in Brazilian P.1,
SA B.1.351, and US B.1.526 lineages) (Sabino et al., 2021;
West et al., 2021). For therapeutics, antibodies that can either
tolerate mutations in the ACE2-binding region or recognize epi-
topes outside this region are critical for protection. Here, 1–57
and 2–7 bind epitopes that are not predominantly focused on
the ACE2-binding region and also accommodate RBD muta-
tions. A residue-level interaction frequency analysis of RBD inter-
action with all currently known RBD-directed neutralizing anti-
bodies of structure revealed them to represent relatively low-
frequency antibody response, which may not form strong selec-
tion pressure on the epitope regions. Therapeutics developed
from such neutralizing antibodies could lead to persistent pro-
tection for a longer period of time.
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STAR+METHODS
KEY RESOURCES TABLE
REAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
1-57 Liu et al., 2020 N/A
2-7 Liu et al., 2020 N/A
Chemicals, peptides, and recombinant proteins
SARS-CoV-2 spike protein Wrapp et al., 2020 N/A
Polyethylenimine Polysciences Cat# 24765-2
Freestyle 293 Expression Media Thermo Scientific Cat# 12338-026
Expi293 Expression Media Thermo Scientific Cat# A14635
Opti-MEM Reduced Serum Media Thermo Scientific Cat# 31985-070
IMAC Sepharose 6 Fast Flow GE Healthcare Cat# 17092109
Tris Base Thermo Scientific Cat# BP152-5
Sodium Chloride Thermo Scientific Cat# S271-10
Imidazole ACROS Cat# 301870025
HEPES Sigma Cat# H3375
Critical commercial assays
FuGENE 6 Promega Cat# E2691
Strep-Tactin XT Superflow 50% Zymo research Cat# P2004-1-5
Spin Miniprep Kit Qiagen Cat# 27106
Hispeed Plasmid Maxi Kit Qiagen Cat# 12663
HisTrap Fast Flow GE Healthcare Cat# 17-0921-09
Ni-NTA Agarose Thermo Scientific Cat# R90115
Pierce Fab Preparation Kit Thermo Scientific Cat# 44985
Superdex 200 Increase 10/300 GL Cytiva Cat# 28990945
Deposited data
Cryo-EM structure of neutralizing antibody
1-57 in complex with prefusion SARS-CoV-
2 spike glycoprotein
This paper PDB: 7LS9
Cryo-EM map of neutralizing antibody 1-57
in complex with prefusion SARS-CoV-2
spike glycoprotein
This paper EMDB: EMD-23506
Cryo-EM structure of the SARS-CoV-2
spike glycoprotein bound to Fab 2-7
This paper PDB: 7LSS
Cryo-EM map of the SARS-CoV-2 spike
glycoprotein bound to Fab 2-7
This paper EMDB: EMD-23507
Experimental models: Cell lines
FreeStyle 293-F Thermo Scientific Cat# R79007
Expi293F Cells Thermo Scientific Cat# A14635
Recombinant DNA
pCMV3-SARS-CoV-2-spike Dr. Peihui Wang, Shandong
University, China
N/A
gWiz-blank Aldevron Cat# 5009
Software and algorithms
Coot Emsley and Cowtan, 2004 https://www2.mrc-lmb.cam.ac.uk/
personal/pemsley/coot
cryoSPARC Punjani et al., 2017 https://cryosparc.com
Leginon Suloway et al., 2005 https://sbgrid.org/software/titles/leginon
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RESOURCE AVAILABILITY
Lead contact
Further information and requests for resources and reagents should be directed to and will be fulfilled by Lawrence Shapiro
(lss8@columbia.edu).
Materials availability
This study did not generate new unique reagents.
Data and code availability
The cryo-EM structures have been deposited to the ElectronMicroscopy Data Bank (EMDB) and the Protein Data Bank (RCSB PDB).
Cryo-EM structural models and maps for antibodies 1-57 and 2-7 in complex with SARS-CoV-2 spike have been deposited in the
PDB and EMDB with accession codes PDB 7LS9, EMD-23506, and PDB 7LSS, EMD-23507, respectively.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell lines
FreeStyle 293-F (cat# R79007), Expi293F cells (cat# A14635) were from Thermo Fisher Scientific. FreeStyle 293-F cells and were
cultured in serum-free FreeStyle 293 Expression Medium (GIBCO, cat# 12338026) at 37C, 10% CO2, 115 rpm. Expi293F cells
were cultured in Expi293 Expression Medium (GIBCO, cat# A14635) at 37C, 8% CO2, 125 rpm. Cell lines were not specifically
authenticated; cell lines were of female origin.
METHOD DETAILS
SARS-CoV-2 spike expression and purification
SARS-CoV-2 S2P spike was produced as described in (Wrapp et al., 2020). Protein expression was carried out in Human Embryonic
Kidney (HEK) 293 Freestyle cells (Invitrogen) in suspension culture using serum-free media (Invitrogen) by transient transfection using
polyethyleneimine (Polysciences). Cell growths were harvested four days after transfection, and the secreted protein was purified
from supernatant by nickel affinity chromatography using Ni-NTA IMAC Sepharose 6 Fast Flow resin (GE Healthcare) followed by
size exclusion chromatography on a Superdex 200 column (GE Healthcare) in 10 mM Tris, 150 mM NaCl, pH 7.4.
Production of 1-57 and 2-7 Fab
Monoclonal antibody 1-57 was expressed and purified as Fab: VHCH1 with a C-terminal His-tag (His8) and LC were constructed
separately into the gWiz expression vector, and then co-transfected and expressed in Expi293. Five days after transfection, super-
natants were harvested and 1-57 Fab was purified by nickel affinity chromatography using Ni-NTA agarose (Invitrogen cat# R90115).
Continued
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Molprobity Davis et al., 2004 http://molprobity.biochem.duke.edu
Phenix Adams et al., 2004 https://www.phenix-online.org




SAbPred Dunbar et al., 2016 http://opig.stats.ox.ac.uk/webapps/
newsabdab/sabpred
UCSF Chimera Pettersen et al., 2004 https://www.cgl.ucsf.edu/chimera/
UCSF Chimera X Pettersen et al., 2021 https://www.cgl.ucsf.edu/chimerax/
GraphPad Prism Software GraphPad Prism Software, Inc. N/A
PDBePISA Krissinel and Henrick, 2007 https://www.ebi.ac.uk/pdbe/pisa/
The PyMol Molecular Graphics
System, v1.8.6
Schrödinger, LLC https://pymol.org/2/
IgBLAST-1.16 Ye et al., 2013 https://www.ncbi.nlm.nih.gov/igblast/
IMGT IMGT http://www.imgt.org/
Python v3.8.3 Python https://www.python.org/
The R Project for Statistical Computing R Core Team https://www.r-project.org/
R bio3d package Grant et al., 2006 http://thegrantlab.org/bio3d/
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Monoclonal antibody 2-7 was expressed and purified as described in (Liu et al., 2020). Fab fragment was produced by digestion of
IgG with immobilized papain at 37C for 3 hrs in 50 mM phosphate buffer, 120 mM NaCl, 30 mM cysteine, 1 mM EDTA, pH 7. The
resulting Fab was purified from Fc by affinity chromatography on protein A.
Fab purity was analyzed by SDS-PAGE; all Fabs were buffer-exchanged into 10 mM Tris, 150 mM, pH 7.4 for cryo-EM
experiments.
Cryo-EM samples preparation
The final sample for EM analysis of the 1-57 in complex with SARS-CoV-2 S2P spike was produced by mixing the Fab and spike in a
1:9 molar ratio, with a final trimer concentration of 0.33 mg/mL, followed by incubation on ice for 1 hr. The final buffer was 10 mM
sodium acetate, 150 mM NaCl, 0.005% (w/v) n-Dodecyl b-D-maltoside, pH 4.5. Cryo-EM grids were prepared by applying 2 mL of
sample to a freshly glow-discharged carbon-coated copper grid (CF 1.2/1.3 300mesh); the sample was vitrified in liquid ethane using
a Vitrobot Mark IV with a wait time of 30 s and a blot time of 3 s.
The final sample for EM analysis of Fab 2-7 in complex with SARS-CoV-2 S2P spike was produced bymixing the Fab and spike in a
1:9 molar ratio, with a final trimer concentration of 0.66 mg/mL, followed by incubation on ice for 1 hr. The final puffer was 10 mM
sodium acetate, 150 mM NaCl, 0.005% (w/v) n-Dodecyl b-D-maltoside, pH 5.5. Cryo-EM grids were prepared by applying 2 mL of
sample to a freshly plasma-cleaned carbon-coated copper grid (CF 1.2/1.3 300 mesh); the sample was vitrified in liquid ethane using
a Leica EMGP with a wait time of 15 s and a blot time of 1.5 s.
Cryo-EM data collection, processing and structure refinement
For 1-57, cryo-EM data were collected using the Leginon software (Suloway et al., 2005) installed on a Titan Krios electron micro-
scope operating at 300 kV, equipped with a Gatan K3-BioQuantum direct detection device. The total dose was fractionated for
3 s over 60 raw frames. Motion correction, CTF estimation, particle extraction, 2D classification, ab initio model generation, 3D re-
finements and local resolution estimation for all datasets were carried out in cryoSPARC 2.15 (Punjani et al., 2017); particles were
picked using Topaz (Bepler et al., 2019). The final 3D reconstruction was obtained using non-uniform refinement with C3 symmetry.
SARS CoV-2 S2P spike density was modeled using PDB entry 7L2E (Cerutti et al., 2021), as initial template. The initial model for
1-57 Fab variable region was obtained using the SAbPred server (Dunbar et al., 2016).
For 2-7, cryo-EM data were collected as described for 1-57, except that the total electron flux was fractionated over 2 s with 40
total frames. Data processing was also performed as described above. The final reconstruction was obtained using non-uniform
refinement with C1 symmetry, followed by local refinement of the ‘down’ RBD and Fab. The SARS-CoV-2 S2P spike density was
modeled using PDB entry 6XEY (Liu et al. 2020) as an initial template. A homology model for the 2-7 Fab variable region was obtained
using Schrodinger Release 2020-2: BioLuminate (Zhu et al., 2014).
Automated and manual model building were iteratively performed using real space refinement in Phenix (Adams et al., 2004) and
Coot (Emsley and Cowtan, 2004) respectively. For 2-7, ISOLDE v1.1 (Croll, 2018) was also used to interactively refine the structure.
Half maps were provided to Resolve Cryo-EM tool in Phenix to support manual model building. Geometry validation and structure
quality assessment were performed using EMRinger (Barad et al., 2015) and Molprobity (Davis et al., 2004). Map-fitting cross cor-
relation (Fit-in-Map tool) and figures preparation were carried out using PyMOL and UCSF Chimera (Pettersen et al., 2004) and
Chimera X (Pettersen et al., 2021). A summary of the cryo-EM data collection, reconstruction and refinement statistics is shown in
Table S1.
Clustering of published RBD-directed antibodies
Information of published SARS-CoV-2 neutralizing antibodies were obtained from CoV-AbDab database (Raybould et al., 2021), the
structure for each antibody was download from PBD. For each pair of antibodies, the RBDs were superimposed and the RMSD of Ca
between antibody variable domains were calculated. The heavy and light chain sequence alignment were performed using the online
muscle program included in bio3d package (Grant et al., 2006). RMSD of Cawere then calculated based on the sequence alignment
by an in-house python script, clustering of the RMSD matrix was performed by hclust package in R.
Calculation of antibody targeting frequency for RBD
The epitope RBD-directed antibodies were determined by PISA with the default parameters (Krissinel and Henrick, 2007), the RBD
residues with non-zero BSA value were considering as epitope residue. For each residue on RBD, the number of contact antibodies
was counted as the frequency of antibody recognition. The antibody targeting frequency was set as b factor of RBD and displayed by
Pymol 2.3.2 (DeLano, 2002).
CALCULATION OF POSITIONAL MUTATION FREQUENCY AND CORRELATIONS
The positional mutation frequency were calculated based on the SARS-CoV2 spike sequences deposited in GISAID at Jan 23rd, 2021
(Elbe and Buckland-Merrett, 2017). Briefly, spike sequences were aligned pairwise with Wuhan-Hu-01 strain as reference, the mu-
tation frequency for each position were calculated as the total mutations divided by total number of deposited sequences, the low
quality ‘X’ residue were not counted asmutations. Normalized effects on ACE2 binding affinity for eachmutation on RBDwere down-
load from the source data (Starr et al., 2020). The r value and p value for correlations were calculated by cor.test function in R 4.0.3.
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ACE2 competition ELISA assay
For the ACE2 competition ELISA, 100 ng of ACE2 protein (Abcam) was immobilized overnight on plates at 4C. The unbound ACE2
waswashed away by PBST (0.5%Tween-20 in PBS) and then the plates were blocked. After washing, 50 mL dilution buffer containing
100 ng of S trimer was added into each well, followed by additional 50 mL of serially diluted competitor antibodies and incubation at
37C for 1 h. The ELISA plates were washed 4 times with PBST and then 100 mL of 2000-fold diluted anti-strep-HRP (Millipore Sigma)
was added into each well for another 1 h at 37C. The plates were then washed and developed with TMB (3,3’,5,5’-tetramethylben-
zidine) and absorbance was read at 450 nm after stopping the reaction. For all the competition ELISA experiments, the relative bind-
ing of ACE2 to the S trimer in the presence of competitors was normalized by comparing to competitor-free controls.
QUANTIFICATION AND STATISTICAL ANALYSIS
The statistical analyses for the pseudovirus neutralization assessments were performed using GraphPad Prism. Cryo-EM data
were processed and analyzed using cryoSPARC. Cryo-EM and crystallographic structural statistics were analyzed using Phenix,
Molprobity, EMringer and Chimera. The correlations were performed in R. Statistical details of experiments are described in method
details or figure legends.
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4.7 Future Perspectives
The emergence of new SARS-CoV-2 variants [241, 242, 243] continues to drive structural work
on neutralizing antibodies. Structures of several antibodies bound to mutated spikes have been
solved, primarily targeting the RBD [244, 245, 246, 247]. Common deletions in the NTD centered
around the antigenic supersite seem to abrogate neutralization, and the E484K mutation in the
RBD found in many SARS-CoV-2 lineages adversely effects neutralization by many RBD-directed
antibodies [240]. Sequencing efforts to track such mutations must be expanded in order to quickly
adjust which therapeutic antibodies are being used in a given region. Cryo-EM reconstructions may
help guide development of novel therapeutic antibodies that neutralize emerging variants while
maintaining their high potency.
Before the COVID-19 pandemic, betacoronaviruses were responsible for outbreaks of severe
acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) in China and
Saudi Arabia, respectively [248, 249], and have the worrying potential to cause future pandemics.
Development of pan-coronavirus vaccines may prevent such occurrences, as well as combat emerg-
ing SARS-CoV-2 variants [134]. To do so, candidate vaccines must elicit antibodies that recognize
common structural motifs on diverse betacoronavius spike proteins. Cryo-EM reconstructions of
neutralizing antibodies in complex with various spike proteins may reveal such motifs, providing
valuable information for epitope-based vaccine design strategies that prime the human immune
system to recognize these structurally conserved regions. Insight into such an approach can be pro-
vided from work on human immunodeficiency virus (HIV) vaccine development, where structural
biology has interrogated broadly-neutralizing antibodies (bNAbs) bound to the envelope glycopro-
tein [250]. These studies have revealed sites of vulnerability in the HIV spike, including regions
essential to viral entry which seem to be conserved between strains and, as revealed by cryo-EM,
exposed in the pre-fusion conformation. Antibodies directed to such regions have provided the
basis for epitope-based vaccine strategies [251] as well as strategies designed to illicit specific
antibody lineages [252]. Sequence alignment of betacoronavirus RBDs [134] reveals significant
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diversity between ACE2-binding motifs, but higher conservation on other surfaces of the RBD.
Vaccines that expose these motifs, e.g. by using cryo-EM to assess the effect of glycosylation on
potential biasing of the RBD towards a conformation that exposes conserved surfaces [253], may
illicit antibodies that can neutralize multiple betacoronaviruses, or at least multiple SARS-CoV-2
variants.
While the neutralization mechanism for antibodies that bind to the RBD seems straightforward,
antibodies that bind but do not neutralize the virus have been reported [254, 255]. Structures of
additional non-neutralizing antibodies in complex with the spike may yield useful insight into how
neutralizing antibodies work. These antibodies dominate the human immune response [218] and
thus may be putting some selective pressure on the spike that could explain the emergence of new
variants, however the mechanism by which this could happen are unclear.
Some antibodies, such as 2-15 [236], induce disassembly of the spike in solution, an obser-
vation potentially related to its extraordinarily high potency. This disassembly in solution may
indicate a premature transition to the post-fusion state of spikes on the viral surface. Given the
lack of transmembrane domains and artificial trimerization domains present in spike constructs,
these rearrangements may result in protein that simply appears disassembled. One possible direc-
tion of future research is to study the spike protein on intact SARS-CoV-2 or pseudovirus virions,
the latter of which can be based on lentivirus or vesicular stomatitis virus (VSV). This kind of
in situ cryo-EM has been performed for intact SARS-CoV-2 virions where post-fusion spike is
clearly visible [256, 257]. Incubating virions with antibody 2-15 F(ab) or IgG and quantifying
its effect on spike structure in its native biophysical environment may yield insight into its high
potency. Understanding the molecular basis for this high potency may facilitate the development
of highly potent synthetic antibodies that can be used as treatments against emerging variants. In
situ cryo-EM could also be used to study ACE2-mediated fusion, particularly visualizing the dif-
ferences between monomeric and dimeric ACE2, the latter of which is found in cells [258] though
structural studies have been limited to the former.
Though much attention has been paid to ACE2-mediated fusion, a number of other possible
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receptors have been identified, including AXL [259], cell surface heparan sulfate [260], known
binder of furin-cleaved substrates neurophilin-1 [261, 262], and L-SIGN/DC-SIGN [263, 264, 265,
266] which are carbohydrate-binding receptors involved in the innate immune response. These
additional receptors may explain the tissue tropism of SARS-CoV-2 and 3D reconstructions of




The cryo-EM resolution revolution is now well under way. The first truly atomic resolution
structures ofmolecules as single particles in their native hydrated states have been solved.
Intermembrane proteins, like the important drug targets G-protein coupled receptors, are now
routinely being resolved to sub-3Å resolution. SPA continues to reveal the details of the assembly
of large nucleoprotein complexes such as the ribosome. As was demonstrated here, a veritable
flood of structures of neutralizing antibodies targeting the SARS-CoV-2 spike were produced only
months after the onset of the global COVID-19 pandemic.
As the mutually beneficial relationship between technological development and need for
biological insight continues, cryo-EM structure determination will become more and more
accessible for a wider range of molecules. However, routine structure determination by SPA is not
the only promise of cryo-EM. Advancements in tomography, from high resolution sub-tomogram
averaging to the carving of windows into cells and tissue, promise to reveal structural details in
ever-more physiological environments. Both techniques have been essential to my work as a
graduate student, and I am happy to have played some small part in advancing cryo-EM
methodology and contributing to the knowledge it affords.
If I can conclude with one final thought, it is that proteins are complex, dynamic machines
constantly interacting with their extraordinarily, perhaps unimaginably, complex environments.
Cryo-EM may help us understand those complexities better by letting us do as Richard Feynman
suggested and “just look at the thing!”
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[59] B. Turoňová, F. K. M. Schur, W. Wan, and J. A. G. Briggs, “Efficient 3d-ctf correction
for cryo-electron tomography using novactf improves subtomogram averaging resolution
to 3.4å,” Journal of Structural Biology, vol. 199, no. 3, pp. 187–195, 2017.
[60] B. A. Himes and P. Zhang, “Emclarity: Software for high-resolution cryo-electron tomog-
raphy and subtomogram averaging,” Nature Methods, vol. 15, no. 11, pp. 955–961, 2018.
[61] D. Tegunov, L. Xue, C. Dienemann, P. Cramer, and J. Mahamid, “Multi-particle cryo-
em refinement with m visualizes ribosome-antibiotic complex at 3.5å in cells,” Nature
Methods, vol. 18, no. 2, pp. 186–193, 2021.
[62] M. Gruska, O. Medalia, W. Baumeister, and A. Leis, “Electron tomography of vitreous
sections from cultured mammalian cells,” Journal of Structural Biology, vol. 161, no. 3,
pp. 384–392, 2008.
[63] E. Villa, M. Schaffer, J. M. Plitzko, and W. Baumeister, “Opening windows into the cell:
Focused-ion-beam milling for cryo-electron tomography,” Current Opinion in Structural
Biology, vol. 23, no. 5, pp. 771–777, 2013.
[64] P. M. Frederik and D. H. W. Hubert, “Cryoelectron microscopy of liposomes,” in Methods
in Enzymology. Academic Press, 2005, vol. 391, pp. 431–448, ISBN: 0076-6879.
[65] R. Grimm, H. Singh, R. Rachel, D. Typke, W. Zillig, and W. Baumeister, “Electron tomog-
raphy of ice-embedded prokaryotic cells,” Biophysical Journal, vol. 74, no. 2, pp. 1031–
1042, 1998.
[66] W. J. Rice, A. Cheng, A. J. Noble, E. T. Eng, L. Y. Kim, B. Carragher, and C. S. Potter,
“Routine determination of ice thickness for cryo-em grids,” Journal of Structural Biology,
vol. 204, no. 1, pp. 38–44, 2018.
[67] M. J. Peet, R. Henderson, and C. J. Russo, “The energy dependence of contrast and damage
in electron cryomicroscopy of biological molecules,” Ultramicroscopy, vol. 203, pp. 125–
131, 2019.
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Appendix A: Other collaborative projects
In addition to the work described thus far, I have had the pleasure of working on a number of
other projects in collaboration with my colleagues. Some of these are related to my interest in cell
adhesion, while others are cryo-EM methods development projects that have been used extensively
throughout the previous chapters. This appendix contains the names, authors, and abstracts for
those projects in chronological order.
1. Routine single particle cryoEM sample and grid characterization by tomography
2. Mechanotransduction by PCDH15 relies on a novel cis-dimeric architecture
3. Positive-unlabeled convolutional neural networks for particle picking in cryo-electron mi-
crographs
4. Cryo-EM structures of SARS-CoV-2 spike without and with ACE2 reveal a pH-dependent




Routine single particle cryoEM sample and grid characterization by tomography
Alex J Noble1, Venkata P Dandey1#, Hui Wei1#, Julia Brasch1,2, Jillian Chase3,4, Priyamvada
Acharya1,5, Yong Zi Tan1,2, Zhening Zhang1, Laura Y Kim1, Giovanna Scapin1,6, Micah Rapp1,2,
Edward T Eng1, William J Rice1, Anchi Cheng1, Carl J Negro1, Lawrence Shapiro2, Peter D
Kwong5, David Jeruzalmi3,4,7,8, Amedee des Georges3,4,8,9, Clinton S Potter1,2, Bridget Carragher1,2*
1National Resource for Automated Molecular Microscopy, Simons Electron Microscopy Center,
New York Structural Biology Center, New York, United States;
2Department of Biochemistry and Molecular Biophysics, Columbia University, New York, United
States;
3Department of Chemistry and Biochemistry, City College of New York, New York, United States;
4Program in Biochemistry, The Graduate Center of the City University of New York, New York,
United States;
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Single particle cryo-electron microscopy (cryoEM) is often performed under the assumption that
particles are not adsorbed to the air-water interfaces and in thin, vitreous ice. In this study, we
performed fiducial-less tomography on over 50 different cryoEM grid/sample preparations to de-
termine the particle distribution within the ice and the overall geometry of the ice in grid holes.
Surprisingly, by studying particles in holes in 3D from over 1000 tomograms, we have determined
that the vast majority of particles (approximately 90water interface. The implications of this ob-
servation are wide-ranging, with potential ramifications regarding protein denaturation, conforma-
tional change, and preferred orientation. We also show that fiducial-less cryo-electron tomography
on single particle grids may be used to determine ice thickness, optimal single particle collection





Mechanotransduction by PCDH15 relies on a novel cis-dimeric architecture
Gilman Dionne1,2, Xufeng Qiu3, Micah Rapp1,2,4, Xiaoping Liang3, Bo Zhao3, Guihong Peng3,
Phinikoula S. Katsamba1,2,5, Goran Ahlsen1,2,5, Rotem Rubinstein1,5,6, Clinton S. Potter1,4, Brid-
get Carragher1,4, Barry Honig1,2,5,6,7*, Ulrich Muller3*, Lawrence Shapiro1,2,6,8*
1Department of Biochemistry and Molecular Biophysics, Columbia University, New York, NY
10032, USA;
2Zuckerman Mind Brain Behavior Institute, Columbia University, New York, NY 10027, USA;
3The Solomon H. Snyder Department of Neuroscience, Johns Hopkins University School of Medicine,
Baltimore, MD 21205, USA;
4National Resource for Automated Molecular Microscopy, Simons Electron Microscopy Center,
New York Structural Biology Center, New York, NY 10027, USA 5Howard Hughes Medical Insti-
tute, Columbia University, New York, NY 10032, USA;
6Department of Systems Biology, Columbia University, New York, NY 10032, USA;
7Department of Medicine, Columbia University, New York, NY 10032, USA;
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(L.S.)
The tip link, a filament formed by protocadherin 15 (PCDH15) and cadherin 23, conveys mechan-
ical force from sound waves and head movement to open hair-cell mechanotransduction chan-
nels. Tip-link cadherins are thought to have acquired structural features critical for their role
in mechanotransduction. Here, we biophysically and structurally characterize the unusual cis-
homodimeric architecture of PCDH15. We show that PCDH15 molecules form double-helical
210
assemblies through cis-dimerization interfaces in the extracellular cadherin EC2-EC3 domain re-
gion and in a unique membrane-proximal domain. Electron microscopy studies visualize the cis-
dimeric PCDH15 assembly and reveal the PCDH15 extracellular domain as a parallel double helix
with cis cross-bridges at the two locations we defined. The helical configuration suggests the po-
tential for elasticity through helix winding and unwinding. Functional studies in hair cells show
that mutations that perturb PCDH15 dimerization contacts affect mechanotransduction. Together,
these data reveal the cis-dimeric architecture of PCDH15 and show that dimerization is critical for
sensing mechanical stimuli.
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Nature Methods 16:1153-1160 (2019)
https://doi.org/10.1038/s41592-019-0575-8
Positive-unlabeled convolutional neural networks for particle picking in cryo-electron
micrographs
Tristan Bepler1,2, Andrew Morin2,3, Micah Rapp4,5, Julia Brasch4,5, Lawrence Shapiro4, Alex J.
Noble5*, Bonnie Berger2,3*
1Computational and Systems Biology, MIT, Cambridge, MA, USA.
2Computer Science and Artificial Intelligence Laboratory, MIT, Cambridge, MA, USA.
3Department of Mathematics, MIT, Cambridge, MA, USA.
4Department of Biochemistry and Molecular Biophysics, Mortimer B. Zuckerman Mind Brain Be-
havior Institute, Columbia University, New York, NY, USA.
5National Resource for Automated Molecular Microscopy, Simons Electron Microscopy Center,
New York Structural Biology Center, New York, NY, USA.
*For correspondence: anoble@nysbc.org (A.N.), bab@mit.edu (B.B.)
Cryo-electron microscopy is a popular method for the determination of protein structures; how-
ever, identifying a sufficient number of particles for analysis can take months of manual effort.
Current computational approaches find many false positives and require ad hoc postprocessing,
especially for unusually shaped particles. To address these shortcomings, we develop Topaz, an ef-
ficient and accurate particle-picking pipeline using neural networks trained with a general-purpose
positiveunlabeled learning method. This framework enables particle detection models to be trained
with few sparsely labeled particles and no labeled negatives. Topaz retrieves many more real par-
ticles than conventional picking methods while maintaining low false-positive rates, is capable of
picking challenging unusually shaped proteins (for example, small, non-globular and asymmetric
particles), produces more representative particle sets and does not require post hoc curation. We
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demonstrate the performance of Topaz on two difficult datasets and three conventional datasets.
Topaz is modular, standalone, free and open source (http://topaz.csail.mit.edu).
213
Cell Host & Microbe 9-28(6):867-879 (2020)
https://doi.org/10.1016/j.chom.2020.11.004
Cryo-EM structures of SARS-CoV-2 spike without and with ACE2 reveal a pH-dependent
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The SARS-CoV-2 spike employs mobile receptor-binding domains (RBDs) to engage the human
ACE2 receptor and to facilitate virus entry, which can occur through low-pH-endosomal path-
ways. To understand how ACE2 binding and low pH affect spike conformation, we determined
cryo-electron microscopy structures-at serological and endosomal pH-delineating spike recogni-
tion of up to three ACE2 molecules. RBDs freely adopted "up" conformations required for ACE2
interaction, primarily through RBD movement combined with smaller alterations in neighboring
domains. In the absence of ACE2, single-RBD-up conformations dominated at pH 5.5, resolv-
ing into a solitary all-down conformation at lower pH. Notably, a pH-dependent refolding region
(residues 824-858) at the spike-interdomain interface displayed dramatic structural rearrangements
and mediated RBD positioning through coordinated movements of the entire trimer apex. These
structures provide a foundation for understanding prefusion-spike mechanics governing endosomal
entry; we suggest that the low pH all-down conformation potentially facilitates immune evasion
from RBD-up binding antibody.
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